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ABSTRACT

The ErbB-2 gene is amplified and the resulting protein product overexpressed in 1530% of breast tumors, and associated with aggressive behavior and poor overall survival.
Currently, there are two FDA approved therapies targeting ErbB-2 for the treatment of
ErbB-2 positive breast cancer: trastuzumab, a humanized monoclonal antibody is directed
against the extracellular domain of ErbB-2 and lapatinib, a dual EGFR/ErbB-2 tyrosine
kinase inhibitor. Unfortunately, anti-ErbB-2 therapy resistance remains a major problem
in metastatic breast cancer. Our data suggested that gene amplification or overexpression
of ErbB-2 inhibits Notch-1 transcriptional activity and trastuzumab or lapatinib increased
Notch-1 transcriptional activity. Furthermore, Notch-1 is a breast oncogene and a novel
target for the treatment of trastuzumab resistant ErbB-2 positive breast cancer in vitro.
The Notch-1 receptor is overexpressed with its ligand Jagged-1 in breast cancers with
the poorest overall survival. We showed that ErbB-2 inhibition activates Notch-1 which
results in a compensatory increase in Notch-1-mediated proliferation. However, we do
not yet know the mechanism by which ErbB-2 overexpression suppresses Notch-1
activity and whether inhibition of Notch-1 would reverse resistance to trastuzumab in
vivo. Our results demonstrated that trastuzumab or lapatinib treatment of SKBr3 cells
increased the cell surface protein expression of Jagged-1 by flow cytometry and cell
surface biotinylation. Moreover, confocal studies indicated that Jagged-1 and Notch-1
co-localized possibly in early endosomal antigen-1 (EEA-1) positive vesicles. However,
xviii

upon treatment with trastuzumab, Jagged-1 and Notch-1 don’t co-localize. Jagged-1 is
present at the plasma membrane and Notch-1 is distributed throughout the cell. In SKBr3
and MCF-7/HER-2 breast cancer cells, ErbB-2 stabilizes the protein levels of Jagged-1.
We demonstrated for the first time that Jagged-1 inhibits Notch in cis.

More

interestingly, ErbB-2 prevents Jagged-1-mediated trans-activation of Notch signaling by
limiting the association of Jagged-1 and Mib-1 and subsequent ubiquitylation of Jagged1.

Moreover, Mib-1 is the E3 ubiquitin ligase required for lapatinib-mediated

ubiquitylation of Jagged-1 and induction of Notch activity.

Additionally, ErbB-2

promotes an association between Jagged-1 and PKCα. Further, PKCα inhibits Notch
transcriptional activity. Importantly combined inhibition of Jagged-1 by siRNA and
ErbB-2 by trastuzumab significantly growth arrested SKBr3, BT474 HS, and BT474 HR
cells in G1 phase of the cell cycle and induced cell death in vitro. Combined inhibition of
Notch and ErbB-2 signaling pathways could decrease recurrence rates for ErbB-2
positive breast tumors and may be beneficial in the treatment of recurrent trastuzumabresistant disease. Our studies will elucidate the mechanism by which ErbB-2 and Notch
pathways crosstalk in ErbB-2 positive breast cancer cells. Mechanisms underlying transactivation and cis-inhibition of Notch by its ligand even though not well characterized yet
are critical processes regulating Notch activity. These findings will provide a mechanism
and functional relevance of Jagged-1–Notch interactions in ErbB-2 positive breast cancer
cells. Furthermore, these studies will identify Jagged-1 as a novel and better therapeutic
target for the treatment of ErbB-2 positive breast cancer. Finally, these studies will
provide a preclinical proof of concept for future clinical trials using combination of
xix

trastuzumab or lapatinib and a Notch pathway inhibitor (GSI or Jagged-1 targeted
therapy) for the treatment of ErbB-2 positive breast cancer.

xx

CHAPTER I
INTRODUCTION

1. Anatomy of the Human Breast
In women, the breast organ develops after birth but grows rapidly at puberty to
produce tree-like structures referred to as terminal end buds. The tree-like structures are
composed of an inner layer of luminal cells surrounded by an outer layer of basal or
myoepithelial cells. The luminal cells (comprising of ductal and alveolar epithelial cells)
differentiate further into milk producing cells and the basal cells facilitate the movement
of the milk from the alveolar epithelial cells into the ducts to be ejected from the nipples.
Interestingly, during each menstrual cycle and pregnancy, the breast epithelium expands
in number and subsequently regresses. Upon weaning, the tree-like structures referred to
as terminal end buds regresses to their pre-pregnant stage through a process known as
involution. These repeated cycles of expansion and regression of the breast epithelial
cells suggest the existence of adult breast stem cells. In mice, the breast organ is called a
mammary gland and normal mammary stem cells are able to reconstitute an entire
functional gland at the single-cell level, displaying regenerative potential (Shackleton et
al., 2006; Stingl et al., 2006). Moreover, the mouse mammary gland has been reported to
be enriched in multi-potent progenitor cells (Alvi et al., 2003; Welm et al., 2002)
1
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whereas, in human breast tissue, bi-potent cells capable of generating both luminal and
myoepithelial cells in vitro have been identified (Dontu et al., 2004; Gudjonsson et al.,
2002; Stingl et al., 2001). Multiple steps during normal development and pregnancy
could be susceptible to mutations, which, in turn, transform normal breast epithelial cells
to a malignant phenotype.
2. Breast Cancer
Breast cancer continues to be the second leading cause of cancer-related deaths
among women. Breast cancer accounts for 22.9% of all cancers in women worldwide.
Although the mortality rate due to breast cancer has decreased in western populations due
to early detection, the American Cancer Society estimated that 229,060 (226,870 women,
2,190 men) new breast cancer cases would be identified in the United States in 2012 with
an estimated death rate of 39,920 (39,510 women, 410 men).
Until recently, for many years it was believed that the majority of the cells in a tumor
have the potential to extensively proliferate and the treatment should eliminate all the
proliferating cells and cure the disease. However, recent studies have suggested that the
ability of tumors to proliferate relies on a small subpopulation of cells which exhibit stem
cell-like properties. This limited subpopulation of cells was termed as cancer stem (CS)
cells or tumor initiating cells. Emerging evidence suggests that breast cancer also arise
from a small sub-population of cells termed as breast cancer stem (BCS) cells identified
by CD44+/CD24- cell surface markers. CD44+/CD24- BCS cells show tumor-initiating
properties, invasive features, and are resistant to most targeted and cytotoxic agents
(Farnie and Clarke, 2007).

3

3. An Introduction to Breast Cancer Subtypes
Breast cancer is a heterogenous disease exhibiting considerable diversity both
biologically and clinically. Based on gene expression profiling and clinical outcomes,
Sorlie and Perou described five distinct subtypes: luminal A, luminal B, ErbB-2, normal
breast-like and basal-like (Sorlie et al., 2001; Sorlie et al., 2003). The most important
determinants of these subtypes are the presence or absence of expression of the estrogen
receptor alpha (ER) or the progesterone receptor (PR), or the amplification of the
Epidermal Growth Factor Receptor-2 or ErbB-2 proto-oncogene. Despite the ability of
these subtypes to predict outcome, patient response to targeted therapy remains variable.
The heterogeneity was also reflected by differences in histological staining of sections of
patient samples: keratin 5 and 17 positive tumors (basal-epithelial origin), and keratin 8
and18 positive tumors (luminal origin) (Perou et al., 2000).

Further classifications are

continuing to emerge such as the molecular apocrine and claudin-low breast cancer
subtypes. Although divided into different categories, sometimes the classification of
breast cancer subtypes tends to overlap with their gene expression profile.
3.1. Basal-like, triple negative breast cancers
Most triple negative breast tumors are classified as basal-like because the tumor
cells arise from the basal or myoepithelial cells of the breast (Jones et al., 2004). The
triple negative breast cancer subtype acquires its name because of the lack of expression
of ER, PR, and ErbB-2 in tumor cells (Sorlie et al., 2001). The triple negative subtype
makes up approximately 15-20% of all breast cancer cases. The tumors express basal
markers such as cytokeratin 5 and 17 (Perou et al., 2000). These tumors are highly

4

proliferative, very aggressive in nature, have high histological grade, and high rates of
metastasis (Nielsen et al., 2004). Approximately 85% tend to harbor TP53 mutations
(Sorlie et al., 2001; Weigelt et al., 2009) and up to 60% overexpress the Epidermal
Growth Factor Receptor-1 (EGFR) or HER-1 (Nielsen et al., 2004; Reis-Filho et al.,
2006). Women diagnosed with triple negative breast cancer have lower overall survival
than those who present with luminal type tumors. Furthermore, the majority of the
patients with triple negative breast cancer never make their five year survival mark.
Currently, there is no known targeted therapy available for the treatment of triple
negative breast cancer.

The standard of care is a combination of cytotoxic drugs

including cyclophosphamide, doxorubicin, and fluorouracil (Hortobagyi, 1998). Thus,
there is an immediate need to identify novel targets to treat these patients and increase
their survival.
3.2. Luminal A breast cancers
The luminal A subtype is the most common form of breast cancer accounting for
approximately 60-70% of all breast cancers. This subtype of breast cancer originates
from the epithelial cells within the lumen of the breast. The luminal A subtype exhibit
distinct characteristic gene expression profile which is summarized as follows: positive
for the expression of luminal markers – ERα and PR; negative for the overexpression or
gene amplification of ErbB-2 (Sorlie et al., 2001); lack expression of basal markers such
as cytokeratin 5/6; express GATA3 (Chou et al., 2010; Usary et al., 2004), show TP53
mutation in 13% of the cases (Langerod et al., 2007), and low expression of a
proliferation marker (Ki-67).

Luminal A breast tumors usually present with a low

histological grade and are responsive to anti-estrogen therapy, have lower risk of

5

recurrence, and have overall good prognosis (Langerod et al., 2007). Currently, premenopausal women diagnosed with this subtype of breast cancer are treated with the
Selective Estrogen Receptor Modulator (Tamoxifen). However, post-menopausal women
diagnosed with ER+ breast cancer are treated preferably with an aromatase inhibitor
(Letrozole, anastrozole, or Exemestane) or Tamoxifen (Swaby and Jordan, 2008). The
major differences in the two targeted agents are that Tamoxifen is a competitive inhibitor
of ER and an aromatase inhibitor blocks the synthesis of 17-estradiol from the
androgen, androstenedione. Although luminal A breast cancer have the longest survival
rates when compared to other subtypes, intrinsic and/or acquired resistance to antiestrogen therapy is still a major problem showing a 63% rate of recurrence (Peppercorn
et al., 2008).
3.3. Luminal B breast cancers
Like luminal A, the luminal B subtype makes up 55% of breast cancers and
originates from luminal epithelial cells of the breast. However, the luminal B gene
expression profile differs from the luminal A and is characterized as follows: positive for
the expression of hormone receptors, ERα and/or PR, and ErbB-2 (Sorlie et al., 2001);
lack expression of basal markers such as cytokeratin 5/6; express GATA3 (Usary et al.,
2004), and have a 40% – 70% rate of TP53 mutation (Langerod et al., 2007; Peppercorn
et al., 2008). These tumors are more aggressive in nature than luminal A tumors, have
high expression of proliferation-associated genes and high histological grade.

Non-

metastatic luminal B breast cancer patients have overall good survival due to the
availability of a combination treatment strategy targeting ER using an anti-estrogen and
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ErbB-2 using anti-ErbB-2 therapy (Amar et al., 2009; Bedard et al., 2009; Dean-Colomb
and Esteva, 2008). Unfortunately, despite the available treatment options, intrinsic or
acquired resistance to anti-estrogen or anti-ErbB-2 therapy remains problematic as
evidenced by a 81% rate of recurrence (Peppercorn et al., 2008).
3.4. Normal-like breast cancers
Normal-like breast cancer, although not well-characterized, is known to be ER
positive or negative, PR status undetermined, and ErbB-2 negative. The expression of
basal markers leads one to believe that it arises from the basal-like subtype. The grade,
presence of TP53 mutations, and expression of proliferative markers such as Ki-67 are
low. Interestingly, normal-like breast tumors have been shown to consistently cluster
with fibroadenoma and normal breast samples. These normal-like breast tumors contain
genes normally associated with adipose tissue (Peppercorn et al., 2008).
3.5. Claudin-low breast cancers
Claudin-low breast cancer show reduced expression of genes associated with tight
junctions and cell-cell adhesion. This subtype lacks expression of ER, PR, or ErbB-2
suggesting a possible link with the triple negative subtype. Like the triple negative
subtype, the claudin-low subtype has high histological grade and high levels of genes
responsible for proliferation. The TP53 mutation status is unknown. However, what
differentiates this subtype from the triple negative is that they appear as ‘cancer stem celllike’ based on their gene expression profile (Hennessy et al., 2009). Investigations into
this subtype may prove to be advantageous and interesting to the field of breast cancer
stem cell research.
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3.6. Molecular apocrine breast cancers
Molecular apocrine tumors represent 8–14% of breast cancers.

Molecular

apocrine breast cancer is believed to be ErbB-2 positive, ER and PR negative, and
androgen receptor (AR) positive. Although, what distinguishes it from the other ErbB-2+
and ER- tumors is the presence of an androgen receptor (AR) and its subsequent target
genes (Farmer et al., 2005).

In addition, relative levels of genes responsible for

proliferation are high. High level of AR expression may serve as a novel target for the
treatment of this type of breast cancer.
4. ErbB-2 Positive Breast Cancer
The ErbB-2 or HER-2 protein is a member of the ErbB family of type I
transmembrane receptor tyrosine kinases (RTKs), which includes ErbB-1 or HER-1,
ErbB-3 or HER-3, and ErbB-4 or HER-4.

The ErbB family members contain an

extracellular ligand-binding domain, a transmembrane domain, and an intracellular
tyrosine kinase domain (Figure 1) (Citri et al., 2003). The crystal structure of the
extracellular domain of ErbB receptors identified four subdomains that are critical for
ligand binding in the case of ErbB-1, ErbB-3, and ErbB-4 (cysteine-free subdomains I:
L1 and subdomain III: L2), and receptor dimerization (cysteine-rich subdomains II: S1
and IV: S2). Protrusion of the S1 dimerization loop is critical for ErbB family homo- and
hetero-dimerization and subsequent receptor activation. In the absence of ligand, the S1
and S2 subdomains of ErbB-1, ErbB-3, and ErbB-4 receptors interact with each other to
achieve an “inactive” conformation.
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However, binding of a ligand to the L1 and L2 subdomains of the ErbB receptors
rearranges the conformation of the extracellular domain, leading to protrusion of the S1
dimerization loop. The crystal structure of ErbB-2 revealed that its L1 and L2
subdomains interact and are already in a “ligand bound” conformation, allowing
protrusion of the S1 dimerization loop even in the absence of ligand binding (Citri et al.,
2003). Heterodimerization between a ligand-bound ErbB-3 and ErbB-2 receptors is
mediated primarily by the S1 dimerization loop and secondarily by the S2 subdomain.
Additionally, interactions between the transmembrane and tyrosine kinase domains may
also play a role in stabilizing the heterodimer. Binding of ligands to the extracellular
region of ErbB-1, ErbB-3, or ErbB-4 induces homodimerization or heterodimerization of
receptors followed by cis-phosphorylation and trans-phosphorylation of several tyrosine
residues within the C-terminal region of the receptor or its dimer partner, respectively.
These phosphorylated tyrosine residues, in turn, serve as docking sites for a number of
src homology (SH2) domain containing adaptors and signal transducers (i.e. Grb-2
through, Shc, and the regulatory subunit of the phosphoinositide 3-kinase (PI3-K), p85)
(Citri et al., 2003; Linggi and Carpenter, 2006; Wieduwilt and Moasser, 2008; Yarden
and Sliwkowski, 2001).

ErbB RTK dimerization is required for activation and

subsequent downstream signaling, mediated primarily by the PI3-K and mitogenactivated protein kinase (MAPK) pathways that mediate cell survival, proliferation, and
the transforming effects of these receptors (Figure 2).
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ErbB-2 is the preferred dimer partner for ErbB-1, ErbB-3, or ErbB-4 in breast cancer
as it is the most stable RTK protein when overexpressed. The ErbB family of RTKs,
except ErbB-2, is activated by growth factor binding to the EGF repeats of the N-terminal
extracellular domain. ErbB-1 family of growth factors includes EGF, TGF-, AREG,
and ampiregullin. ErbB-3 or ErbB-4 bind the Heregulin (HRG) family of growth factors
which comprise HRG-1, -2, -3, and -4.

The choice of which ErbB receptor will

heterodimerize with ErbB-2 is primarily determined by the availability and/or abundance
of growth factors. Each unique heterodimer has a predicted signaling potency based on
the partners. For example, the ErbB-2–ErbB-3 heterodimer has the most transforming
ability based on the high numbers of tyrosines that can be phosphorylated (Yarden and
Sliwkowski, 2001). ErbB-2 mediated trans-phosphorylation of ErbB-3 recruits at least 8
p85 regulatory subunits of PI-3K, which in turn potentially forms 8 active PI-3Kinases to
activate protein kinase B (AKT) survival pathway (Alimandi et al., 1995; Lee-Hoeflich et
al., 2008; Ritter et al., 2007; Wallasch et al., 1995; Yakes et al., 2002).
ErbB-2 positive breast cancers, which account for 20–30% of all breast cancers,
contain gene amplification of ErbB-2 on chromosome 17q12 which results in protein
overexpression. ErbB-2 gene amplification can be determined by fluorescence in situ
hybridization

(FISH)

and

protein

overexpression

can

be

detected

by

immunohistochemistry (IHC), respectively (Press et al., 2008). ErbB-2 positive breast
cancers have an aggressive phenotype, (Slamon et al., 1987; Slamon et al., 1989), high
expression of proliferation-associated genes compared to luminal A tumors (Peppercorn
et al., 2008), high histological grade and harbor a 71% rate of TP53 mutations
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(Peppercorn et al., 2008; Weigelt et al., 2009). ErbB-2 positive tumors are associated
with early relapse, high risk of recurrence, and more likely to involve metastasis to the
axillary lymph nodes before diagnosis (Sorlie et al., 2001). Currently, there are two FDA
approved therapies targeting ErbB-2 for the treatment of ErbB-2 positive breast cancer:
trastuzumab, a recombinant, humanized, monoclonal antibody directed against the
extracellular juxtadomain of ErbB-2 (Carter et al., 1992) and lapatinib, a small molecule
dual EGFR/ErbB-2 tyrosine kinase inhibitor (Chen et al., 1997; Geyer et al., 2006;
McArthur, 2009). The therapeutic effect of trastuzumab is possibly due to number of
mechanisms including inhibition of receptor-receptor interaction, endocytic-mediated
receptor down-regulation, blocking cleavage of the extracellular domain of the receptor,
activation of antibody-dependent cell-mediated cytotoxicity, and induction of p27
mediated G1 cell cycle arrest (Hudis, 2007). In the treatment of ErbB-2 positive breast
cancer, trastuzumab showed significant efficacy in the adjuvant settings with an overall
response rate (ORR) of 26%, which increased to about 90% when combined with
chemotherapeutic agents (Amar et al., 2009; Bedard et al., 2009; Dean-Colomb and
Esteva, 2008; Hall and Cameron, 2009). However, despite its proven efficacy and
dramatic effects on survival, 20–50% of women with ErbB-2–positive, metastatic breast
cancer exhibit intrinsic resistance, indicating that they do not respond to trastuzumab
(Cobleigh et al., 1999; Vogel et al., 2002). Furthermore, 10–15% of the women treated
with trastuzumab plus chemotherapy in the adjuvant setting developed acquired
resistance within the first year, which means that they initially responded to trastuzumab,
but became resistant during treatment (Amar et al., 2009; Romond et al., 2005). In ErbB2 positive breast cancer, lapatinib is a potent inhibitor of ErbB-2’s activity and strongly
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inhibits downstream PI-3K–AKT and MAPK signaling pathways. Lapatinib, a dual
EGFR/ErbB-2 tyrosine kinase inhibitor, is approved for the treatment of ErbB-2 positive
breast cancer that has advanced during or after trastuzumab treatment (Chen et al., 1997;
Geyer et al., 2006; McArthur, 2009). Recently, it was shown that in patients with
metastatic breast cancer, treatment with lapatinib induced apoptosis (Spector et al., 2005).
Further, in a neoadjuvant study, lapatinib showed significant inhibition of cell
proliferation in patients with newly diagnosed ErbB-2 positive breast cancer (Dave et al.,
2011). Even though patients treated with lapatinib showed significant clinical benefit, it
is clear that a fraction of the patients will become resistant. This suggests that tumors
harbor intrinsic or acquired mechanisms of resistance to anti-ErbB-2 targeted therapies.
T-DM1 (trastuzumab-DM1) consists of trastuzumab conjugated to a derivative of
maytansine (an inhibitor of microtubule polymerization) via a non-cleavable linker. TDM1 increased clinical response rate by 25% when used as a single agent in patients with
metatstatic disease and who has progressed after trastuzumab-, lapatinib-, taxanes-, and
anthrcyclines-based therapy (Burris et al., 2011; Krop et al., 2010). The clinical benefits
exhibited by T-DM1 in lapatinib resistant xenografts were due to inhibition of
downstream signaling and induction of an ADCC response. Thus, understanding the
mechanisms responsible for resistance to ErbB-2 targeted therapies is critical to identify
novel targets to prevent and/or reverse the resistant phenotype that is responsible for
disease progression and the majority of deaths.

14

5. Potential Mechanisms Responsible for Resistance to Trastuzumab
Extensive efforts have been made to understand the exact mechanism of intrinsic or
acquired resistance to anti-ErbB-2 targeted inhibitors using cell culture models,
preclinical models, and in some cases, patient-derived tumor samples. Identification of
signaling pathways that are responsible for resistance has allowed and will allow for the
development of novel therapeutic agents (Table 1). Each of the novel agents, either alone
or when combined with trastuzumab or lapatinib, could potentially open new horizons
that may help to replace trastuzumab or lapatinib or increase the efficacy of anti-ErbB-2
therapy to prevent and/or reverse resistance.
Resistance to anti-ErbB-2 therapy occurs at three levels: 1. resistance that involves
ErbB-2 gene mutations; 2. resistance that involves activation of parallel and/or bypass
signaling pathways; and 3. resistance that arises from alterations in the apoptotic pathway
in tumor cells.
5.1. ErbB-2 Mutations
Mutations in the tyrosine kinase domain or the juxtamembrane region of ErbB-2
could result in decreased affinity of drug binding and resistance to ErbB-2 directed
inhibitors. Mutations in the kinase domain decrease the affinity of the TKI to bind to the
kinase domain and thus decrease the therapeutic efficacy of TKIs. However, mutations in
the kinase domain do not alter the affinity of trastuzumab to bind to the juxtamembrane
region of ErbB-2. In contrast, mutations in the juxtamembrane region decrease binding of
trastuzumab but retain kinase activity and thus the ErbB-2 RTK is susceptible to TKI
activity. Kinase domain mutations in ErbB-2 have been observed in patients with lung
cancer, CML and gastrointestinal stromal tumors treated with an EGFR TKI or a c-ABL
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TKI, imatinib, respectively (Anido et al., 2006; Engelman et al., 2006; Gorre et al., 2001;
Kobayashi et al., 2005; Kosaka et al., 2006; Pao et al., 2005; Tamborini et al., 2004).
Moreover, patients harboring a truncated form of ErbB-2 (p95HER2), which lacks the
entire N-terminal extracellular region including the trastuzumab binding region, are
resistant to trastuzumab but retain sensitivity to lapatinib (Anido et al., 2006).
Furthermore, D16 ErbB-2, a splice variant that retains the trastuzumab binding epitope
but stabilizes ErbB-2 homodimers, has been identified to cause resistance to trastuzumab
in breast cancer cell lines (Castiglioni et al., 2006; Mitra et al., 2009). A small number of
point mutations or small insertions in the ErbB-2 gene have been identified in non-smallcell lung, gastric, colorectal, head and neck, and ErbB-2 overexpressing human breast
cancers (Mounawar et al., 2007; Shigematsu et al., 2005; Stephens et al., 2004;
Willmore-Payne et al., 2006a, b).
Another emerging mechanism that could possibly contribute to trastuzumab
resistance is altered interaction between ErbB-2 and trastuzumab by co-expression of
another protein that binds to ErbB-2. For example, Mucin-4 (MUC4), a membraneassociated proteoglycan, is up-regulated during acquired trastuzumab resistance (Nagy et
al., 2005). MUC4 directly interacts with ErbB-2 via an EGF-like domain, masking the
trastuzumab binding site on ErbB-2 (Carraway et al., 2001; Price-Schiavi et al., 2002).
MUC4 activates ErbB-2, but does not affect the expression of ErbB-2 (Carraway et al.,
2001; Price-Schiavi et al., 2002). Knockdown of MUC4 increased trastuzumab binding
and sensitized the resistant JIMT-1 breast cancer cells to trastuzumab (Nagy et al., 2005).
Studies have also shown that MUC1, another family member, interacts with ErbB-2 (Li
et al., 2003), initiates heterodimerization and induces downstream signaling that
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promotes survival and proliferation (Hikita et al., 2008; Mahanta et al., 2008). Thus,
novel agents targeting expression and/or function of MUC family members in
combination with trastuzumab might prove to be advantageous in the treatment of
resistant breast tumors.
5.2. Activation of compensatory signal transduction pathways
5.2.1. Role for receptor tyrosine kinases
ErbB family members have some redundant functions but are also unique as
they can form homodimers and amplify diverse signaling pathways.

Trastuzumab

inhibits ErbB-2 phosphorylation but it rarely blocks the heterodimerization of ErbB-2
with other ErbB family members. Therefore, signaling initiated by other ErbB family
members can trans-activate ErbB-2 and drive proliferation and survival, thus bypassing
the anti-proliferative effects of lapatinib or trastuzumab. Recently, elevated ErbB-1 or
ErbB-3 expression has been reported when ErbB-2–overexpressing breast cancer cells
(T47D, UACC812, UACC893, MDA-MB-453, MDA-MB-361) were treated with
trastuzumab for long durations (Narayan et al., 2009). This suggests that alternate ErbB
family dimers, such as ErbB-1/ErbB-1 homodimers or ErbB-1/ErbB-3 heterodimers,
could possibly rescue the inhibitory effects of trastuzumab. Moreover, in ErbB-2–
overexpressing MCF-10A and BT474 cells, TGF-β has been shown to activate ErbB-3
and, subsequently, the PI3-K pathway by activating ADAM17. This result in an increase
in ErbB ligand shedding and decreased sensitivity to trastuzumab (Wang et al., 2008). A
gene signature of TGF-β activity, derived from breast cancer cells expressing a
constitutively active mutant form of the TGF-β type I receptor, correlates with resistance
to trastuzumab and poor clinical outcome in patients (Wang et al., 2008). Interestingly,
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from ErbB-1 and ErbB-3 receptor knockdown studies, ErbB-3 has been shown to play a
crucial role over ErbB-1 in ErbB-2 positive breast cancer (Lee-Hoeflich et al., 2008) and
ErbB-3 signals preferably by heterodimerizing with ErbB-2 (Hynes and Lane, 2005).
Therefore, the promising approach to treat trastuzumab resistance would be to design
monoclonal antibodies that can target dimerization among the ErbB family members.
Pertuzumab, another humanized, monoclonal antibody against ErbB-2, prevents
heterodimerization of ErbB-2 with ErbB-3 and has shown a 6-month clinical benefit
when used in combination with trastuzumab in patients who had progressed after
trastuzumab-based therapy (Franklin et al., 2004; Nahta et al., 2005). Also, multi-targeted
tyrosine kinase inhibitors, including ErbB-1/ErbB-2–specific inhibitors lapatinib,
neratinib, and BIBW 2992, have shown significant efficacy in trastuzumab-resistant
disease (Allen et al., 2002; Rusnak et al., 2001).
Crosstalk with other RTKs has also been implicated as a means to bypass
trastuzumab action. Insulin-like growth factor-1 receptor (IGF-1R) is another type I
transmembrane receptor tyrosine kinase that is activated by IGF-1 and a related growth
factor, IGF-2 (Lu et al., 2001). Up-regulation of IGF-1R or an increase in levels of IGF1R/ErbB-2 heterodimers and subsequent trans-phosphorylation can strongly activate the
PI3-K – AKT pathway and contribute to trastuzumab resistance (Lu et al., 2001; Nahta et
al., 2005).

In a neo-adjuvant study of trastuzumab plus chemotherapy, high level

expression of IGF-1R correlated with a poor clinical outcome (Harris et al., 2007).
Interestingly, IGF-1R has been found to form a heterotrimeric complex with ErbB-2 and
ErbB-3 (Huang et al., 2010). IGF-1R blockade mediated by IGF-binding protein 3,
neutralizing antibody, or a TKI resensitized SKBR3 cells to trastuzumab (Nahta et al.,
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2005).

These results suggest a possible role for the IGF-1R signaling pathway in

trastuzumab resistance, and that IGF-1R inhibitors in combination with trastuzumab may
help to improve the efficacy of trastuzumab. CP-751871, a monoclonal neutralizing
antibody, and NVP-AEW541, an IGF-1R tyrosine kinase inhibitor, should be tested
either in combination or sequentially with trastuzumab in women with ErbB-2 positive,
metastatic breast cancer. Recently, targeting IGF-1R with metformin was also shown to
overcome resistance to trastuzumab (Liu et al., 2011a).
Importantly, the c-Met (mesenchymal-epithelial transition factor) receptor is
another type I transmembrane tyrosine kinase receptor that is activated by binding to its
ligand, hepatocyte growth factor (HGF) (Bottaro et al., 1991). c-Met and HGF are often
overexpressed in breast cancer, including a subset of ErbB-2 positive breast cancer
(Edakuni et al., 2001; Kang et al., 2003; Lindemann et al., 2007; Nagy et al., 1996;
Yamashita et al., 1994). The aberrant expression of c-Met correlates with decreased
overall survival and poor patient prognosis (Camp et al., 1999; Ghoussoub et al., 1998).
Further, over-expression of c-Met and its ligand, HGF, were reported in ErbB-2 positive
breast cancer patients who did not respond to trastuzumab plus chemotherapy (Shattuck
et al., 2008). Activated c-Met has been shown to dampen the growth-inhibitory effects of
trastuzumab and promote survival of ErbB-2 overexpressing BT474 and SKBR3 breast
cancer cells. The proliferative effects exhibited by activated c-Met are mediated through
inhibition of a cyclin dependent kinase inhibitor (p27Kip1) expression (Shattuck et al.,
2008). Therefore, inhibition of c-Met resensitized BT474 and SKBR3 cells to
trastuzumab (Shattuck et al., 2008). Consistent with this finding is that trastuzumab
treatment rapidly increases expression of c-Met in ErbB-2 overexpressing breast cancer

19

cells (Shattuck et al., 2008). This is important, as simultaneous overexpression of both cMet and ErbB-2 has been shown to collaborate to promote cellular invasion, suggesting
that tumors expressing both receptors may present with aggressive behavior. Thus, it is
certainly possible to predict that a subset of women with co-overexpression of ErbB-2
and c-Met might benefit from a combined therapy targeting both ErbB-2 and c-Met
receptors.
Overexpression of the EphA2 receptor was found to predict for reduced disease
free survival in a cohort of patients with ErbB-2 positive breast cancer. Trastuzumab
resistant, ErbB-2 positive breast cancer cells showed increased activation of EphA2, and
treatment with an EphA2 neutralizing antibody restored trastuzumab sensitivity (Zhuang
et al., 2010).
Moreover, co-expression of erythropoietin receptor and ErbB-2 was noted in
ErbB-2 positive breast cancer cells and primary tumors.

In these cell lines, concurrent

treatment with recombinant human erythropoietin conferred trastuzumab resistance. This
was mediated via Jak2 and c-Src signaling, leading to inactivation of PTEN, a tumor
suppressor and negative regulator of AKT. Finally, in patients with ErbB-2 positive
metastatic breast cancer, the concurrent treatment of erythropoietin and trastuzumab
correlated with a shorter overall survival compared to patients who did not receive
erythropoietin (Liang et al., 2010).
Finally, in a model of acquired resistance to lapatinib, the AXL receptor
tyrosine kinase was found up-regulated. The phosphorylated tyrosines in the C-terminal
region of AXL recruited the p85 regulatory subunit of PI3-K to activate PI3-K and
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bypass the effects of either lapatinib or trastuzumab. A kinase inhibitor targeting AXL
activity restored sensitivity to ErbB-2 antagonists (Liu et al., 2009).
5.2.2. Role for intracellular kinases
Activating mutations in the components of the PI3-K–AKT pathway are
frequent and can confer resistance to ErbB-2 inhibitors. These include gain-of-function
mutations in the p110 catalytic subunit of PI3-K, AKT1, the p85 regulatory subunit of
PI3-K or amplification of AKT2. In addition, loss-of-function mutations have been
identified in tumor suppressors such as PTEN (Bachman et al., 2004; Bellacosa et al.,
1995; Campbell et al., 2004; Carpten et al., 2007; Gewinner et al., 2009; Li et al., 1997;
Saal et al., 2005).
PI3-K activating mutants and consequently, constitutive AKT kinase activity
has also been shown to promote growth and proliferation of breast tumors (Yakes et al.,
2002). Concurrently, loss or decreased expression of PTEN has been reported in ErbB2+ breast tumors and is associated with poor response to ErbB-2–targeted therapy (Berns
et al., 2007; Esteva et al., 2010; Nagata et al., 2004). PTEN is a lipid phosphatase that
dephosphorylates phosphatidylinositol (3,4,5)-triphosphate (PIP3) to PIP2 and thus
negatively regulates the AKT pathway. In addition, human breast cancer cell lines
containing endogenous mutations in PI3-K are intrinsically resistant to trastuzumab
(Ginestier et al., 2007; O'Brien et al., 2010). Human breast cancer cell lines in which
activating PI3-K mutations are ectopically expressed exhibit an attenuated response to
lapatinib (Eichhorn et al., 2008). ErbB-2 overexpressing BT474 breast cancer cells that
have heightened PI3-K/AKT signaling and reduced PTEN expression were shown to be
sensitive to PI3-K or Mammalian target of rapamycin (mTOR) inhibitors, and these
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inhibitors were able to reverse trastuzumab resistance both in vitro and in vivo (Chan et
al., 2005; Nagata et al., 2004). Furthermore, combinations of trastuzumab plus PI3-K
inhibitor XL147, or trastuzumab or lapatinib plus the dual PI3-K-mTOR inhibitor
BEZ235, inhibit growth of PI3-K mutant xenografts resistant to anti-ErbB-2 therapies
(Chakrabarty et al., 2010; Eichhorn et al., 2008; Serra et al., 2008). In a model of
trastuzumab resistance caused by PTEN loss, targeting mTOR or AKT was able to at
least partially overcome resistance (Lu et al., 2007). These results suggest that loss or low
expression of PTEN and subsequent high AKT kinase activity serve as predictors of
trastuzumab response, and those inhibitors of the PI3-K/AKT/mTOR signaling pathway
need to be explored in combination with trastuzumab to prevent possible trastuzumab
resistance. For example, in a phase II study, the combination of the everolimus, a
TORC1 inhibitor, with trastuzumab and chemotherapy showed a partial response rate of
19% in patients with ErbB-2 positive metastatic breast cancer that had progressed on
trastuzumab plus taxanes.
Up-regulation of the non-receptor tyrosine kinase, Src (SFK) activity, has been
reported in several trastuzumab and lapatinib resistant cell lines. Src kinase mediated
anti-ErbB-2 therapy resistance may be partly through activation of erythropoietin
receptor. EpoR activates Src via Jak2. Activated Src associates with ErbB-2, where it is
proposed to phosphorylate and inhibit PTEN. The inhibition of PTEN, in turn, upregulates PI3-K, providing a viable mechanism for attenuation of trastuzumab action
(Liang et al., 2010). Combination of SFK inhibitor (dasatinib) and lapatinib partially
blocked PI3-K activation in the resistant cells and restored sensitivity to lapatinib in
BT474 xenografts (Rexer et al., 2011). Combinatory treatment strategy including Src
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inhibitor and trastuzumab overcame trastuzumab resistance conferred by the D16 ErbB-2
splice variant (Mitra et al., 2009; Zhang et al., 2011).

Finally, the activation of EphA2

seen after chronic trastuzumab treatment and onset of trastuzumab resistance is also
mediated through Src (Zhuang et al., 2010).
5.3. Defects in apoptosis and cell cycle control
ErbB-2 is the oncogenic driver promoting survival and proliferation signals. In
these breast tumors, inhibiting ErbB-2 activity induces growth arrest and apoptosis.
Therefore, alterations in the normal apoptotic machinery acquired during the course of
trastuzumab treatment, in turn can cause resistance to ErbB-2-targeted therapies. In a
recent report, levels of the pro-apoptotic BH3-only Bcl-2 family member BIM were
shown to be predictive of response to a TKI in an ErbB-2 addicted breast cancer.
Although lapatinib potently inhibited ErbB-2 activity in all ErbB-2 positive breast cancer
cells, only the cell lines expressing high levels of BIM underwent apoptosis (Faber et al.,
2011; Tanizaki et al., 2011).
Survivin is a member of the inhibitor of apoptosis (IAP) protein family, which
inhibits the activity of caspases, necessary effectors of programmed cell death. ErbB-2
positive breast cancer cells resistant to lapatinib showed up-regulation of ERα, which, in
turn induced FoxO3a mediated transcription of survivin (Xia et al., 2006). Elevated
levels of survivin and the anti-apoptotic Mcl-1 proteins were found in trastuzumab
resistant cells. Treatment with a general kinase inhibitor that reduces levels of survivin
and Mcl-1 inhibited the growth and survival of the ErbB-2 positive breast cancer cells
(Valabrega et al., 2011).

Knockdown of survivin in combination with trastuzumab

restored sensitivity to trastuzumab (Oliveras-Ferraros et al., 2011). Furthermore, PI3-K
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signaling regulates survivin expression in ErbB-2 gene amplified breast cancer cells.
Thus, inhibition of ErbB-2 – PI3-K pathway reduces survivin expression and induces
apoptosis in ErbB-2 overexpressing breast cancer cells (Faber et al., 2009; Tanizaki et al.,
2011).
Trastuzumab induces a G1 cell cycle arrest and eventually apoptosis within the
breast tumor by enhancing the association of p27Kip1 with cyclin E/Cdk2 complexes. This
association increases the half-life of p27Kip1 and prevents the phosphorylation of p27Kip1
by Cdk2 and subsequent ubiquitin-dependent degradation (Le et al., 2003; Nahta et al.,
2004). Thus, altered control of cell cycle progression in response to trastuzumab may
play a critical role in resistance. Decreased p27Kip1 levels and amplification of Cdk2 have
been reported in trastuzumab resistant breast cancer (Nahta et al., 2004; Scaltriti et al.,
2011).

In a cohort of patients with ErbB-2 positive breast cancers treated with

trastuzumab, amplification of cyclin E was associated with decreased response to
trastuzumab.
xenografts.

Further, Cdk2 inhibitors reduced growth of trastuzumab resistant
Depletion of p27Kip1 using either antisense or siRNA with a resulting

increase in Cdk2 activity prevented trastuzumab induced growth inhibition in ErbB-2
positive SKBR3 breast cancer cells. Conversely, overexpression of p27 Kip1 or preventing
p27Kip1 degradation using a proteasome inhibitor MG132 resensitized resistant cells
derived from the SKBR3 cell line to trastuzumab. These results suggest that low level
expression of p27Kip1 and increased Cdk2 activity are also critical trastuzumab resistant
markers. Additionally, modulation of p27Kip1 levels appears to be a common downstream
mechanism for several of the resistance pathways described previously, including IGF1R and c-MET (Lu et al., 2001; Nahta et al., 2005; Shattuck et al., 2008).
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6. Conclusion
Several mechanisms of resistance to both trastuzumab and lapatinib have been
identified in preclinical and clinical settings. Emerging preclinical and clinical data
suggest the use of combinations of therapies targeting the ErbB-2 signaling network at
multiple points. However, there is little to no consideration of crosstalk between ErbB-2
and other oncogenic pathways that may play a role in development and maintenance of
ErbB-2 positive breast cancer and resistance phenotype. Thus, open ended molecular
approaches must be utilized to identify biomarkers and/or effectors of resistance to antiErbB-2 therapies.
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Targeted Therapies
Lapatinib, Neratinib or Afatinib
Pertuzumab
T-DM1
Perifosine
MUC4, MUC1 monoclonal
antibody
Dasatinib
Everolimus,
Temsirolimus
Sirolimus
AP23573
CP-751871
NVP-AEW541
IMC-A12
EphA2 antibody
AXL inhibitor

Target
ErbB-2 and ErbB-1
ErbB-2
ErbB-2
AKT
MUC4

Mechanism
TKI
Dimerization inhibitor
Neutralizing antibody - microtubule inhibitor
fusion
Plasma membrane translocation inhibitor
Neutralizing antibody

Src
mTOR
mTOR
mTOR
mTOR
IGF-1R
IGF-1R
IGF-1R
EphA2
AXL receptor

TKI
TKI
TKI
TKI
TKI
Monoclonal antibody
TKI
Monoclonal antibody
Neutralizing antibody
TKI

Table 1: Novel therapeutic strategies to overcome trastuzumab resistance in
combination with anti-ErbB-2 therapies.

26

NOTCH: A LITERATURE REVIEW
The molecular profile of ErbB-2 positive breast cancer has identified several crosstalk
mechanisms as described previously that limit the effectiveness of ErbB-2 directed
therapy. The tumor cells acquires bypass signaling through other receptor or intracellular
signaling pathways which is then responsible for the proliferation, survival, resistance to
apoptosis and/or metastasis. Oncogenic pathways that increase proliferation and prevent
apoptosis have emerged as potential targets for the treatment of breast cancer. For
example, Notch signaling has been presented as a novel biomarker of trastuzumab
resistance. Activated Notch in response to ErbB-2 inhibitors could promote a survival
advantage and contribute to resistance. Thus, a thorough investigation of the role of
Notch signaling in ErbB-2 positive breast cancer and trastuzumab resistance would
provide an evidential rationale of whether targeting the Notch pathway either alone or in
combination with therapies targeting ErbB-2 will be effective in overcoming or
preventing resistance.
1. Introduction
The Notch pathway was identified early in the twentieth century through a genetic
mutation screen in Drosophila melanogaster. Affected flies demonstrated a “notched”
wing margin that was passed on from parent to progeny (Morgan et al., 1917). Since the
identification of the Notch gene, continuous work on understanding Notch signaling has
been done which eventually led to the discovery of the Notch pathway. We now know
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that Notch signaling plays critical roles during development and cancer in a variety of
organisms. These include stem cell maintenance, cell proliferation, survival, apoptosis,
and differentiation.
2. Notch Function
The development of the breast in humans and the mammary gland in mice is
governed by a variety of signaling pathways involved in cell fate determination and
differentiation. Notch signaling plays diverse and essential roles in the regulation of cellfate decisions during mammary gland development. Cell fate decisions occur through
ligand – receptor interactions; Receptor activation leads to the specific fate of a cell,
whereas receptor inhibition leads to an alternate fate. Notch also acts as a regulator of
cell survival and proliferation in a context-dependent manner (Artavanis-Tsakonas et al.,
1995; Greenwald, 2012; Politi et al., 2004). Recently, it has been demonstrated that
pathways such as Notch which regulate development during embryonic life and adult
stem cells, can be reactivated in malignancies (Nickoloff et al., 2003; Radtke and Raj,
2003) and support the tumor initiating cells (Song and Miele, 2007).
2.1. Notch receptors
The Notch heterodimer is comprised of three domains: extracellular,
transmembrane, and intracellular (Figure 3). The N-terminal extracellular portion (NEC)
of Notch receptors contains the ligand binding domain, which comprises of 29-36 tandem
epidermal growth factor (EGF) – like repeats.

Productive interactions with ligands to

receptors presented in trans require EGF repeats 11-12. In contrast, cis-inhibition of
Notch receptors by ligands expressed in the same cell requires EGF repeats 24-29. Notch
integrates cis-trans activities to regulate and determine cell fate specifications. From
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each extracellular domain extend six cysteine residues which form three intra-domain
disulfide bridges. Following the extracellular domain is the transmembrane domain (NTM)
which comprises two components: the unique negative regulatory region (NRR)
composed of three cysteine-rich Lin-12/Notch repeats (LNR) which prevent ligandindependent interactions, and the heterodimerization domain which maintains the Notch
receptor in an inactivated state. In the absence of ligand, the second cleavage site (S2) is
buried within the NRR thus preventing receptor activation in the absence of ligands. The
transmembrane portion (NTM) contains the S3 cleavage site for the γ-secretase complex.
Finally, the C-terminal region of the Notch receptor is the intracellular domain (NTM)
which extends from the inner cell membrane into the cytoplasm. The NTM comprises
four components: a RAM domain (RBP-JK associated molecule; interacts with the DNAbinding protein CSL), seven cdc10/ankyrin repeats (ANK domain; associated with CSL
to help recruit the co-activator Mastermind), two nuclear localization sequences (NLS)
flanking the ANK domain, followed by a transcription activation domain (TAD) and a
proline/glutamic acid/serine/threonine-rich PEST domain (regulates the stability of
NICD). Lastly, Notch-1 and Notch-2 contain transcription activation domains (TAD)
and cytokine response elements (NCR), whereas Notch-3 only contains a NCR region
(Kopan and Ilagan, 2009). All these elements together are critical to the productive
activation of Notch signaling.
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Figure 3: Canonical Regulators of Notch Signaling Pathway
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2.2. Notch ligands
In vertebrates, there are five type I, membrane spanning Notch ligands, Delta-like
1, 3, and 4 and Jagged-1 and 2 (Figure 3). The Notch ligands bind and activate the Notch
receptor presented on the surface of an adjacent cell. Ligands of Notch receptors are
composed of a large extracellular region and a 100-150 residue cytoplasmic tail. Notch
ligands are characterized by three structural motifs in their extracellular domain: an Nterminal DSL (Delta/Serrate/LAG-2) motif, specialized tandem EGF repeats called the
DOS domain, and EGF-like repeats. Both the DSL and DOS domains are involved in
receptor binding, with the DSL domain involved in both trans- and cis- interactions with
the Notch receptor. The Jagged ligands are longer than the Delta-like ligands and the
length is determined by the 6-16 EGF-like repeats in the extracellular domain.

A

cysteine-rich area is located at the end of the EGF-like repeats. Notch ligands can be
divided into two groups based on the presence (Jagged) or absence (Delta) of a cysteinerich domain and the presence (Jagged-1, -2, and Delta-like 1) or absence (Delta-like 3
and 4) of a DOS domain (Cordle et al., 2008; D'Souza et al., 2008; Komatsu et al., 2008).
The intracellular domain (C-terminal) of each ligand has a shorter cytoplasmic tail than
the extracellular domain and contains a PDZ (PSD95/Dlg1/ZO1)-binding motif which
aids in intracellular protein-protein interactions. Popovic et al has identified several
residues in the intracellular region of Jagged-1 (T1197, S1207, S1210, Y1216) as
potential targets for protein kinases and to play a role in the modulation of protein-protein
interactions (Popovic et al., 2011).
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In Drosophila, both Delta-like (Delta) and Jagged (Serrate) ligands can be
proteolytically cleaved by metalloproteinases and cause extracellular domain shedding
(Klueg et al., 1998; Sun and Artavanis-Tsakonas, 1997). Although, cleaved or soluble
DSL ligands can activate Notch signaling, they are less active than membrane bound
ligands. Soluble ligands may require clustering or attachment to extracellular matrix or
cell surface to efficiently activate Notch signaling. In fact, endocytosis deficient prefixed
Delta-expressing cells can activate Notch target genes (Itoh et al., 2003; Parks et al.,
2000). Perhaps the pulling force required for Notch activation is generated by cell
detachment or Notch endocytosis upon ligand–receptor interaction. This mechanism may
account for the signaling activity of naturally occurring soluble DSL ligands identified
for C. elegans (Chen and Greenwald, 2004; Komatsu et al., 2008). Alternatively, ligand
shedding could represent a mechanism for down-regulation of activated ligand (Kopan
and Ilagan, 2009; Weinmaster, 1997).
3. An Overview of Canonical Notch Signaling Pathway
Notch signaling is an evolutionary conserved signaling pathway (Figure 4) that has
emerged as a target for the treatment of breast cancer. There are four mammalian Notch
receptors (Notch-1, -2, -3, and -4) (Blaumueller and Artavanis-Tsakonas, 1997) with five
associated ligands (Delta-like 1, 3, and 4 and Jagged-1 and -2) (Dunwoodie et al., 1997;
Lindsell et al., 1995; Shawber et al., 1996). Notch ligands and receptors are type I cell
surface proteins (Blaumueller and Artavanis-Tsakonas, 1997). Notch receptor-ligand
interactions promote the expansion one cell fate at the expense of another and the specific
outcome is often context-dependent (Callahan and Raafat, 2001). Notch is synthesized as
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a single, relatively large (>300 kDa) polypeptide in the endoplasmic reticulum. The
newly translated Notch receptor proteins are then glycosylated. Addition of O-linked
fucose to the EGF-like repeats is mediated by the enzymes O-fucosyl transferase I (O-fut)
and Rumi, which is the first step in the production of a mature receptor. Glycosylated
Notch receptors undergo a series of proteolytic cleavages by the PC5/furin, tumor
necrosis factor-α-converting enzyme (TACE/ADAM 10/17) and γ-secretase complex
(comprised of presenilin-1/2, nicastrin, Pen-2, and Aph-1).

After the initial addition of

O-linked fucose, the Notch pro-protein is chaperoned by the GTPase Rab-protein 6
through the secretory pathway to the trans-Golgi network. In the trans-Golgi, the first
cleavage (S1) is mediated by PC5/furin-like convertase, which leads to production of a
mature receptor. Enzymatic activity of O-fucose-specific β1,3-N acetylglucosaminyltransferases Fringe (Lunatic, Manic, or Radical) then extends the O-fucose modification
on Notch receptors, thereby altering the ability of specific ligands to activate Notch.
EC

Mature Notch receptors are composed of an extracellular subunit (N ) and
transmembrane subunit (N

TM

) held together by calcium cation mediated non-covalent

interactions. Notch heterodimers are then trafficked to the cell surface where it relies on
the ability of a ligand to bring about receptor proteolysis (Kopan and Ilagan, 2009). At
the surface, Notch receptors are activated by binding to a ligand expressed on an adjacent
cell. Ligand binding generates a mechanical force to promote a conformation change in
the bound Notch receptor. This conformational change dissociates N

EC

TM

and N

subunits

and the released NEC domain is then trans-endocytosed by the ligand-expressing cell,
exposing the second cleavage site (S2) in the Notch receptor. The second cleavage (S2)
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is facilitated by TACE, which generates the membrane-anchored Notch extracellular
truncation (NEXT) fragment, a substrate for the γ-secretase complex (Brou et al., 2000).
The third and fourth cleavages (S3 and S4) are mediated by the γ-secretase complex
(Kopan and Ilagan, 2004), which releases the active Notch intracellular domain (NICD)
into the cytoplasm (Saxena et al., 2001). This final step can be pharmacologically
inhibited by -secretase inhibitors (GSIs), which prevent the release of NICD, thus
inhibiting Notch-mediated transcription and cell growth. GSIs are currently in clinical
trials for the treatment of breast cancer and other solid tumors (Pannuti et al., 2010).
GSIs currently undergoing clinical trials are listed in Table 2.

NIC can subsequently

enter the nucleus because of the presence of nuclear localization signals located within it
(Lieber et al., 1993; Stifani et al., 1992).

NICD forms an active transcriptional complex

by displacing the corepressor proteins and histone deacetylases (HDACs) complex (Hsieh
et al., 1999) and recruiting the protein mastermind-like 1 (MAML) (Wu et al., 2000) and
histone acetyltransferases to the CSL (CBF-1/RBPjκ/Su(H)/Lag-1) complex. A few
Notch target genes have been identified, including Hes (Hairy enhance of split) family
(Iso et al., 2003), Hey (Hairy/enhancer of spit related with YRPW motif), nuclear factorkappa B (NFκB) (Cheng et al., 2001), vascular growth factor receptor (VEGF) , PI-3K –
AKT - mammalian target of rapamycin (mTOR) (Gutierrez and Look, 2007; Palomero et
al., 2007), cyclin D1 (Ronchini and Capobianco, 2001), c-myc (Weng et al., 2006), IGF1R (Eliasz et al., 2010), p21, p27, etc, all of which have been well documented for their
roles in tumor development and progression.
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Co-A

35

3.1. Notch signaling in mammary gland development
Murine mammary gland development is governed by a variety of signaling
pathways involved in cell fate determination and differentiation. Notch signaling plays
diverse and essential roles in the regulation of cell-fate decisions during mammary gland
development. Cell fate decisions occur through ligand – receptor interactions; Receptor
activation leads to the specific fate of a cell, whereas receptor inhibition leads to an
alternate fate. Notch also acts as a regulator of cell survival and proliferation in a
context-dependent manner (Artavanis-Tsakonas et al., 1995; Greenwald, 2012; Politi et
al., 2004). Recently, it has been demonstrated that pathways such as Notch which
regulate development during embryonic life and adult stem cells, can be reactivated in
malignancies (Nickoloff et al., 2003; Radtke and Raj, 2003) and support the tumor
initiating cells (Song and Miele, 2007).
A role for Notch in the normal mammary gland development has been highlighted in
several key experiments. The Notch receptors, their ligands, and target genes play a
critical role during different stages of mammary gland development. Among the Notch
genes, mRNA levels of Notch-3, Jag-1, DLL3, and Hey-2 were highest during different
stages of mammary gland development (Raafat et al., 2011). In addition, luminal cell
commitment is defined by activation of Notch-3 and suppression of Notch-4 (Bouras et
al., 2008; Raouf et al., 2008). Loss of the RBP-J in mammary progenitors disrupted
luminal cell fate specification during pregnancy associated alveolar development (Buono
et al., 2006). In vivo, transgenic mice expressing a constitutively active form of Notch-4
in the mammary gland fail to regulate branching morphogenesis of mammary epithelial
cells, and subsequently develop mammary tumors (Soriano et al., 2000; Uyttendaele et
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al., 1998). The Wicha group has demonstrated that Notch signaling plays a critical role
in regulation of self-renewal and lineage specific differentiation of both adult stem cells
and progenitor cells during normal mammary gland development (Dontu et al., 2004).
This finding supports a role for Notch in normal breast development, and suggests that
alterations in Notch signaling components might play a significant role in breast-cancer
development by deregulating the self-renewal properties of normal mammary stem cells.
Thus, identification and proper understanding of the role of Notch signaling in mammary
cell fate decisions, will be of crucial interest for understanding breast cancer diversity
and, ultimately, improving treatment options and breast cancer outcome.
3.2. Notch signaling in breast cancer
Emerging evidence suggests that the Notch signaling network is frequently
deregulated in human malignancies including lung, colon, head and neck, breast,
pancreas and renal carcinoma, acute myeloid leukemia, Hodgkin’s and large cell
lymphoma (Wang et al., 2010). Most notably, deregulated Notch signaling has been
frequently found in breast tumors, suggesting that Notch is a potent breast oncogene
(Stylianou et al., 2006).

Constitutive activation of Notch-1 through chromosomal

translocation occurs in more than 50% of T-cell acute lymphoblastic leukemias (T-ALL)
patients (Ellisen et al., 1991; Weng et al., 2004). As evidenced from literature, there is no
known activating mutation or amplification of Notch gene reported in breast cancer.
Rather, aberrant Notch activation occurs through transcriptional and post-translational
regulation of core Notch pathway components which will be discussed in detail in
chapter II (Lee et al., 2007; Stylianou et al., 2006).
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The first evidence of aberrant Notch signaling in breast cancer comes from the
murine mammary gland studies. The role of Notch-1, -3 or -4 in the development of
mouse mammary tumors was established by using MMTV/neu transgenic mice. This
data suggests that Notch-1, -3 or -4 has transforming potentials in vivo (Dievart et al.,
1999; Gallahan and Callahan, 1997; Gallahan et al., 1987; Hu et al., 2006).
Furthermore, both Notch-1 and Notch-4 genes were identified as a novel target for
MMTV provirus insertional activation. MMTV insertion in the Notch-1 and Notch-4
locus induced the overexpression of mutant active form of Notch (NICD) protein that can
transform HC11 mouse mammary epithelial cells in vitro (Dievart et al., 1999; Gallahan
and Callahan, 1997; Gallahan et al., 1987). Transgenic expression of Notch-4/INT-3
RNA species encoding Notch-4 NICD (an active form) in non-malignant human
mammary epithelial cell line MCF-10A enabled these cells to grow in soft agar suggested
Notch-4 can transform MCF-10A cells (Imatani and Callahan, 2000). Furthermore, Wnt
driven oncogenesis occurs through a Notch-dependent mechanism in human breast
epithelial cells (Ayyanan et al., 2006). In addition, Notch-1 was found to be a mediator
of oncogenic Ras (Weijzen et al., 2002). High level co-expression of Notch-1 and Jag-1
generates synergistic effect on overall survival of breast cancer patients (Dickson et al.,
2007; Reedijk et al., 2005).
In addition, Notch-1 and Notch-3 NICD proteins correlated with increased
transcription of its target genes in most breast cancer cell lines (Yamaguchi et al., 2008).
In a recent report, knockdown of Notch-3 in breast cancer cells decreased osteoblast- and
transforming growth factor (TGF)-β1 induced colony formations. Moreover, osteolytic
lesions were significantly reduced following Notch-3 knockdown (Zhang et al., 2010).
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These results suggest Notch-3 knockdown may stand as a novel mechanism for
decreasing breast cancer derived bone metastasis.
Activated Notch-2 in normal mammary epithelial cells in vivo has not been reported.
However, unlike other Notch members, Notch-2 expression correlated with better
survival in patients with breast cancer (Parr et al., 2004). These data suggests that Notch2 activation corresponds to well-differentiated and benign tumor states. Constitutively
active form of Notch-2 NICD in the human adenocarcinoma line MDA-MB-231
increased apoptosis in vitro (O'Neill et al., 2007). These results demonstrated that Notch2 signaling is a potent inhibitory signal in human breast cancer carcinogenesis.
3.3. Activation of Notch signaling in breast cancer stem (BCS) cells
Analogous to normal stem/progenitor cells, a role for Notch in BCS cells has been
postulated, since Notch signaling pathway has key functions in the development of
normal breast as well as breast cancer. Up-regulated Notch expression is found in BCS
cells (Farnie and Clarke, 2007). BCS cells contain undifferentiated cells that exhibit
tumor-initiating properties and invasive features (Farnie and Clarke, 2007). Active form
of Notch-1 impairs mammary stem/progenitor cells and BCS cells self-renewal properties
through cyclin-D1 (Ling et al., 2010) and ErbB-2 (Magnifico et al., 2009) dependent
pathways, respectively.

Moreover, Notch-1 has been demonstrated to interact with

erythropoietin to maintain self-renewing capacity of BCS cells (Phillips et al., 2007).
Notch-1 (luminal cells) (Raouf et al., 2008) and Notch-4 (basal cells and BCS-enriched
population) (Harrison et al., 2010) are differentially expressed within normal breast
epithelium suggesting that Notch-1 and Notch-4 may have different roles in maintenance
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of BCS cells. Harrison et al found that inhibition of Notch-4 caused a significantly
greater inhibition in mammosphere formation compared to affecting Notch-1 activity by
γ-secretase which only partially inhibits mammosphere formation (Harrison et al., 2010).
These findings can be recapitulated in vivo where Notch-4 activation, but not Notch-1,
was not sufficient to generate mammary carcinogenesis in mice (Gallahan and Callahan,
1987). Notch-3 is critical for luminal cell commitment in vitro suggesting a possible role
in BCS cells (Raouf et al., 2008).
3.4. Role of Notch in novel crosstalk mechanisms in breast cancer
In human breast cancers, the oncogenic effect of Notch activation is partly due to
its crosstalk with other signaling pathways. For example, receptor tyrosine kinases
(RTKs), developmental pathways (Wnt and HedgeHog), janus kinase/signal transducers
and

activators

of

transcription

(Jak/STAT),

transforming

growth

factor-

β/Decapentaplegic (TGF-β), platelet-derived growth factor (PDGF/PDGFR), vascular
endothelial growth factor (VEGF), phosphatidylinositol 3-kinase (PI-3K/Akt), Ras,
mTOR, NF-κB, HIF, cytokines IL-6, IL-1, and leptin plus ER signaling as well as
microRNAs (Guo et al., 2011) have been described. Here we are going to focus on
crosstalk between Notch signaling and the most critical pathways (ErbB-2, ER, and
PEA3) necessary for breast cancer development, progression, tumor recurrence, and the
resistance phenotype.

Elucidating the cross-talk between Notch and other pathways

critical for breast cancer development is necessary to determine patients that would
benefit from Notch inhibitors, agents to be combined with Notch inhibitors, and
biomarkers that are indicative of Notch activity.
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The existence of Notch-1 and ErbB-2 crosstalk in breast cancer has been established
by our research group and many others since. We have shown that Notch-1 signaling is
decreased in ErbB-2 gene amplified (BT-474 and SKBr3) and overexpressing (MCF7/ErbB-2) breast cancer cells (Osipo et al., 2008). However, trastuzumab or a small
molecule tyrosine kinase inhibitor similar to lapatinib reactivated Notch-1 (Osipo et al.,
2008). More importantly, a GSI or specific down-regulation of Notch-1 by RNA
interference increased the sensitivity of ErbB-2 positive breast cancer cells to
trastuzumab mediated growth inhibition, indicating that Notch-1 signaling might
contribute to trastuzumab resistance in vitro (Osipo et al., 2008). In contrast, Chen et al
observed RBPJkappa binding sites in the ErbB-2 promoter and that RBPJkappa/Notch
stimulated transcription from ErbB-2 promoter (Chen et al., 1997). Yamaguchi et al
indicated that Notch-3 rather than Notch-1 signaling plays an important role in the
proliferation of ErbB-2 negative breast tumor cells (Yamaguchi et al., 2008). Finally,
Magnifico et al demonstrated that ErbB-2 overexpressing breast cancer stem cells display
activated Notch-1 signaling.

Moreover, Notch-1 siRNA or a γ-secretase inhibitor

resulted in down-regulation of ErbB-2 expression and decrease in mammosphere
formation (Magnifico et al., 2009). These studies together suggest critical interactions
between Notch and ErbB-2 pathways, both of which are involved in the progression of
breast cancer and regulation of breast cancer stem cells.
Recently, Clementz et al demonstrated for the first time that PEA3, an Ets family
transcription factor, is a transcriptional activator of Notch-1 and Notch-4 in triple
negative breast cancer (Clementz et al., 2011). While, PEA3 recruitment on the Notch-1
promoter was independent of AP-1 activity, PEA3 recruitment to the Notch-4 promoter
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was dependent on AP-1 activity: positively regulated by c-JUN and Fra-1 and negatively
regulated by c-Fos (Clementz et al., 2011). Finally, the findings from this study showed
that down regulation of PEA3 using siRNA strongly inhibited triple negative breast
cancer growth in vitro and in vivo (Clementz et al., 2011). Taken together, the results
from this study demonstrated that combination therapy targeting PEA3 and Notch
pathways might provide a new therapeutic strategy for triple-negative and possibly other
aggressive breast cancer subtypes where PEA3 activates Notch transcription.
One of the most critical pathways necessary for survival of breast cancer cells is the
ERα pathway. Rizzo et al demonstrated that Notch-1, Notch-4, and Jagged-1 were
expressed at variable levels in ductal and lobular carcinomas (Rizzo et al., 2008a). In
addition, a panel of breast cancer cell lines tested showed an inverse correlation between
ERα or ErbB-2 and Notch activity. Specifically, triple negative MDA-MB-231 breast
cancer cells exhibited the highest Notch activity, whereas, ERα positive MCF-7 and
T47D:A18 breast cancer cells suppressed Notch activity (Rizzo et al., 2008a). Moreover,
either tamoxifen or raloxifene blocked this effect, reactivating Notch (Rizzo et al.,
2008a). In vivo, γ-secretase inhibitor treatment arrested the growth of ERα negative
MDA-MB-231 tumors and, in combination with tamoxifen, caused regression of ERα
positive T47D:A18 tumors (Rizzo et al., 2008a). Together, these data indicated that
combination therapy targeting ERα and Notch pathways may be effective in the treatment
of ERα positive breast cancers and that targeting Notch pathway alone may be effective
in the treatment of ERα negative breast cancers. Moreover, Soares et al demonstrated a
novel crosstalk between estrogen and Notch signaling in breast cancer and endothelial
cells (Soares et al., 2004). In particular, the investigators demonstrated that estrogen
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promoted a significant increase in Notch-1 and Jagged-1 gene expression in
ER+/PR+/ErbB-2- breast cancer cells, MCF-7 and endothelial cells (Soares et al., 2004).
In another report, Notch gene expression, together with HIF-1α, was up-regulated by
estrogen (Soares et al., 2004).

Overall, the crosstalk between Notch and the ER

signaling pathway plays a significant role in the development and progression of human
breast cancer and angiogenesis.

CHAPTER II
REGULATION OF LIGAND – INDUCED NOTCH SIGNALING

Although simple at first glance, the complexity involved in the regulation of Notch
activity is significant (Fortini, 2009; Fortini and Bilder, 2009; Kopan and Ilagan, 2009;
Takeuchi and Haltiwanger, 2010). In particular, glycosylation of the NEC is necessary for
proper folding and trafficking of the signaling competent Notch receptor to the plasma
membrane. Glycosylation also modulates Notch interactions with ligands: glycosylation
of Notch by glycosyltransferase Fringe increases its affinity for Delta ligands but reduces
its affinity for Jagged ligands.

Also, ubiquitylation of the Notch ligands by the

evolutionary conserved E3 ligases Neuralized (Neur) and Mindbomb-1 (Mib-1) is
required for Notch receptor activation. Similarly, the amount of Notch at the cell surface
as well as the formation of NICD is also affected by Notch endocytosis and trafficking to
endosomes. Several endocytic routes, including Notch removal from the membrane and
control of NICD turnover have been proposed to avoid spurious, excessive or sustained
activation. Here, we review the functional significance and molecular mechanisms of
ligand mediated regulation of Notch activity because co-overexpression of Jagged-1 and
Notch in primary breast cancer is associated with poorest overall survival (Reedijk et al.,
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2005) and high Jagged-1 expression is associated with the basal phenotype and
recurrence in lymph node negative breast cancer (Reedijk et al., 2008).
1. Regulation of DSL Ligand Expression
DSL ligand expression could be controlled at the levels of transcription and cell
surface ligand expression. Notch signaling can regulate gene expression of both the
receptor and the ligand. Moreover, signaling from transforming growth factor-β (TGF-β)
(Niimi et al., 2007; Zavadil et al., 2004), vascular endothelial growth factor (Hainaud et
al., 2006; Lawson et al., 2002; Patel et al., 2005; Ridgway et al., 2006), EGFR/MAP
kinase (Izrailit et al., 2013), steroid hormones (Soares et al., 2004), NF-κB activation
(Bash et al., 1999), and Toll-like receptor (TLR) activation (Foldi et al., 2010) also
enhances DSL ligand expression.
2. Regulation of DSL Ligand Activity
Mechanisms that limit Notch signaling to one of the two adjacent cells are important
to the Notch biology and determination of the correct cell fate during development.
Notch signaling mediates such function through a process of “lateral inhibition”, a
transcriptional feedback mechanism. While cells that receive the Notch signal induce
developmental programs distinct from those sending the signal, the specific outcome is
often context-dependent.

The lateral inhibition mechanism is strengthened by two

activities presented by Notch ligands: trans-activation of Notch in neighboring cells, and
cis-inhibition of Notch in its own cell. If ligand and receptor are expressed on the same
cell, then ligand-receptor interaction results in cis-inhibition of cell fate in that cell. If
ligand and receptor are expressed on adjacent cells, then ligand-receptor interaction
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results in trans-activation of Notch signaling in Notch receptor expressing cell. However,
it remains unclear how Notch integrates these two activities and how the resulting system
facilitate cell fate specifications. Lateral inhibition explains how small differences in the
expression levels of Notch and DSL ligands can direct cell fate decisions for the initially
equivalent cells. Initially equivalent cells are defined as both expressing similar amounts
of Notch receptor, its ligand, and target genes of the E(Spl)/HES family. E(spl)/HES
proteins inhibit activity of the achaete-scute complex (AS-C) genes, which has been
shown to exhibit differential effects on expression of Notch and its ligands. Thus, a small
stoichiometric difference in the expression levels of Notch and DSL ligands will drive the
two interacting cells to function as either the signal-sending cell (up-regulating AS-C and
Delta, down-regulating Notch and HES) or signal receiving cell (up-regulating Notch and
HES, down-regulating AS-C and Delta) (Campos-Ortega, 1993; Fortini, 2009). These
data suggests that a stable regulatory feedback loop between Notch and Delta is under a
transcriptional control involving E(spl)/HES and the AS-C. In addition to the transactivation of Notch, lateral signaling is also reinforced by cis-interactions between ligand
and Notch expressed on the same cell. Whether cis-interactions between Notch receptor
and its ligand occur at the cell surface or within the endosomes is not clear yet. The
lateral inhibition mechanism explained here is a foundation of the Notch signaling and
provides better understanding of Notch mediated cell fate specification events.
Several lines of evidence indicate that the endocytosis of DSL ligands within the
ligand expressing cell is essential for trans-activation of Notch receptor on the signal
receiving cell. It is clear that endocytosis and membrane trafficking regulate ligand and
receptor availability at the cell surface and ligand induced Notch activation. Genetic
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mosaic studies with the conditional Drosophila shibire mutant published in 1997 showed
that dynamin-dependent endocytosis is required in both Notch signaling and receiving
cells (Seugnet et al., 1997). Further evidence for DSL ligand endocytosis comes from
antibody uptake assays performed in Drosophila tissue (Le Borgne and Schweisguth,
2003a, b). In vertebrates, DSL ligands defective in endocytosis (Delta proteins that lack
the intracellular domain or with specific intracellular domain mutations) accumulate at
the cell surface and are unable to activate Notch (Parks et al., 2000). Moreover, DSL
ligands are detected predominantly in endocytic vesicles in Drosophila, zebrafish and
mammalian cells, suggesting that Delta is indeed internalized from the cell surface (Itoh
et al., 2003; Kramer and Phistry, 1996). A specialized endocytic pathway mediated by E3
ubiquitin ligases Neur and Mib-1 (ubiquitylate DSL ligands) and epsin liquid facets
(clathrin associated sorting protein), has been identified to promote Notch ligand removal
from the cell surface and potentiate ligand signaling activity in a non-autonomous fashion
(Figure 5) (Bingham et al., 2003; Itoh et al., 2003; Le Borgne et al., 2005; Le Borgne and
Schweisguth, 2003a, b; Pavlopoulos et al., 2001; Wang and Struhl, 2004). In addition,
the ligand expressing cells also require proteins that function in clarthrin-mediated
endocytosis such as clathrin, dynamin, auxilin, and Eps15 for DSL ligand to signal
effectively. These studies suggests that the productive Notch signaling relies on the
ability of ligand to be ubiquitylated (Neuralized and Mindbomb) and routed to an
endocytic pathway (epsin liquid facets) to generate the physical force needed to pull the
NEC, exposing the ADAM cleavage site and bring about receptor proteolysis.
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Figure 5: Mib/Neur and Epsin Dependent Ligand Endocytosis and Notch Activation
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The observation that the endocytosis of DSL ligand removes the ligand from the cell
surface where it interacts and activates its receptor is seemingly paradoxical. Several
models have been proposed to understand the role for ligand ubiquitination and
endocytosis in activation of Notch signaling (Figure 5) and will be discussed in depth
below.
2.1. E3 ubiquitin ligases – Neuralized and Mindbomb
2.1.1. Role for Mib and Neur in Notch activation
Mindbomb (Mib) and Neuralized (Neur), E3 ubiquitin ligases of the RING finger
family, are known as being key regulators of ligand signaling activity. Loss of Neur and
Mib results in phenotypes that are consistent with loss of Notch signaling. Additionally,
in the Neur or Mib mutant cells, Notch ligands accumulated on the cell surface and were
defective in activating Notch signaling (De Renzis et al., 2006; Deblandre et al., 2001;
Lai et al., 2001; Le Borgne and Schweisguth, 2003b; Pavlopoulos et al., 2001). Neur has
been previously reported to promote ligand degradation.

However, Mib mediated

ubiquitylation promoted ligand endocytosis but did not appear to promote ligand
degradation (Deblandre et al., 2001; Lai et al., 2001). This finding indicates that the
ubiquitylation of Delta by Neur may have a dual antagonistic role in promoting (signal
sending cells) and inhibiting (signal receiving cells) ligand signaling activity. In signal
receiving cells, Neur induced ubiquitylation of Delta promotes ligand endocytosis and
subsequent degradation, thus removing cis-inhibiting ligand and allowing Notch to bind
ligand in trans on adjacent cells (Deblandre et al., 2001; Lai et al., 2001). However, in
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signal sending cells, Neur mediated ubiquitylation of ligand is not necessary for cisinhibition of receptor, as evidenced from Neur deficient cells being able to inhibit Notch
in adjacent cells, but can cis-inhibit Notch receptor (Glittenberg et al., 2006; Miller et al.,
2009). However, overexpression of Neur suppresses cis-inhibition, possibly by removing
ligand from the cell surface, leaving open the possibility that Neur may regulate Notch
activation in receiving cells by modulating the amount of ligand available to cis-inhibit
receptor (Glittenberg et al., 2006). Studies from both flies and frogs identified the Notch
ligand Delta as a substrate for the Neur RING domain E3 ubiquitin ligase activity
(Deblandre et al., 2001; Lai et al., 2001; Le Borgne and Schweisguth, 2003b;
Pavlopoulos et al., 2001; Yeh et al., 2001).

Drosophila Mib interacts with and

endocytose both Delta and Jagged (Lai et al., 2005; Le Borgne et al., 2005), whereas
zebrafish Mib only interacts with and regulate the endocytosis of Delta (Chen and
Greenwald, 2004; Itoh et al., 2003). Importantly, Mib was required by the ligand signal
sending cell to activate Notch signaling during lateral inhibition through cell
transplantation procedures (Itoh et al., 2003). Furthermore, presence of a mono-ubiquitin
on the ligand ICD is required for ligand to activate Notch. Together, these findings
suggest a role for Neur and/or Mib mediated ubiquitylation in generating a competent
ligand and enhance signaling potential by promoting ligand endocytosis. Fly, mouse and
human genomes encode for two mib homologs, mib1 and mib2, suggesting conservation
of this E3 ubiquitin ligase throughout metazoans. Indeed, disruption of mib1 gene alone
but not neur1, neur2, and mib2 in developing mouse embryos produces the known Notch
like mutant phenotypes. Cells lacking Mib-1 and expressing Notch ligands do not
activate Notch reporters or target gene expression in mammalian co-culture assays
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(Hansson et al., 2010; Yamamoto et al., 2010). Neur1-dependent ubiquitylation directs
Jagged-1 for degradation, and this result in inhibition of Jagged-1-induced Notch
signaling in co-culture assays (Koutelou et al., 2008).
2.1.2. Distinct and redundant functions of Neur and Mib
There are numerous studies suggesting functional redundancy among Neur and
Mib. For example, Notch activation in the absence of Neur is due to the presence of
Mib-1, and in situations where both E3 ligases are expressed, simultaneous reduction of
both Mib-1 and Neur are essential to generate loss-of-Notch phenotypes (Lai et al., 2005;
Le Borgne et al., 2005; Wang and Struhl, 2005).

Despite numerous examples of

functional redundancy, Mib-1 was unable to rescue the Neur specific neurogenic
phenotype, identifying a unique requirement for Neur in this particular context (Le
Borgne et al., 2005). Drosophila Mib2 has been reported to maintain muscle integrity
and survival and neither Mib-1 nor Neur was able to rescue the muscle defects produced
by Mib2, suggesting an additional function of Mib2 in this context (Carrasco-Rando and
Ruiz-Gomez, 2008; Nguyen et al., 2007).

There are studies in mammalian cells

suggesting that Mib- and Neur-mediated ubiquitylation have distinct effects on Notch
ligands. For example, it has been proposed that Mib-1-mediated ubiquitylation of Delta
targets Delta for endocytosis, while ubiquitylation by Neur2 is needed for subsequent
trafficking of Delta through an endosomal pathway (Song et al., 2006). Another study
suggested a role for Neur2 in transcytosis of Delta ligand from the basolateral to apical
domain of the plasma membrane in polarized mammalian epithelial cells but has yet to be
linked to Notch signaling (Benhra et al., 2010). Additionally, whether Delta transcytosis
is unique to Neur and not mediated by Mib has not been reported.

In vertebrates,
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mindbomb, but not neutralized, is required for Notch-dependent morphological
phenotypes (Barsi et al., 2005; Koo et al., 2005).
2.1.3. Regulation of Neur and Mib activity
In Drosophila, a family of eight proteins called the Bearded (Brd) family binds
Neur, and thereby inhibits Neur from accessing and ubiquitylating Delta (Bardin and
Schweisguth, 2006; Chanet et al., 2009; De Renzis et al., 2006; Fontana and Posakony,
2009).

Brd proteins contain at least one NxxN motif that binds to the neutralized

homology repeats (NHRs) present in Neur. In Drosophila, Notch ligands Delta and
Serrate contain a NxxN motif, and NxxN motif of Delta has been shown to be necessary
for Neur binding and endocytosis of Delta (Fontana and Posakony, 2009). In addition,
Brd family proteins cannot bind Mib-1 since Mib proteins lack NHRs (Bardin and
Schweisguth, 2006). A recent study identified the cell polarity protein PAR-1 kinase
phosphorylating Mib1 which results in auto-ubiquitylation and subsequent degradation of
Mib-1 by the proteasome (Ossipova et al., 2009).
2.2. Epsin-dependent endocytosis in generating pulling forces
Endocytosis of ubiquitylated DSL ligand would generate pulling forces required
to destabilize bound Notch heterodimer and result in activating proteolysis for
downstream signaling. In Drosophila imaginal discs, Parks et al were the first to show
that the NECD co-localizes with Delta in endosomes in signal sending cells known to
activate Notch in signal receiving cells (Parks et al., 2000). Importantly, deficiencies in
ligand endocytosis prevent NECD trans-endocytosis by signal sending cells and this
correlates with Notch signaling defects in flies and mammalian cells (Nichols et al.,
2007; Parks et al., 2000). Signaling potential of a ligand most probably relies on early
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steps required for vesicle trafficking involving pulling force to bend the membrane, form
and release endocytic vesicles. In particular, ligands could employ mechanical force
intrinsic to endocytosis to pull on bound Notch and dissociate the preformed Notch
heterodimer. It is clear that epsin, a clathrin associated sorting protein, is required for
endocytosis of ubiquitylated ligand and functions downstream of ligand binding to Notch
to participate in the generation of pulling force during the endocytic process (D'Souza et
al., 2008; Nichols et al., 2007). Notch binding to ligand could induce ligand clustering,
which would assemble multiple ubiquitin-binding sites for epsin by means of its UIM.
Such an assembly of multiple UIM/monoubiquitin interactions will produce strong
epsin/ubiquitylated DSL interactions (Barriere et al., 2006; Hawryluk et al., 2006), which
may be necessary to overcome any resistance to DSL internalization when it is bound to
Notch (Figure 2). These data suggests that multiple ubiquitin binding sites are required
for ligand to activate Notch, possibly by providing stable interactions with epsin-positive
endocytic vesicles. Another important feature about epsin structure is that it is a multidomain protein known to interact with membrane phospholipids, clathrin, dynamin and
actin cytoskeleton all of which have been implicated in generating pulling force to bend
the plasma membrane during formation of endocytic vesicle (Liu et al., 2010; McMahon
and Gallop, 2005). Importantly, studies in flies, worms and mammalian cells have
indicated that these same endocytic components are required in signal sending cells to
activate Notch signaling in receptor expressing cells.

This may explain why

ubiquitylated DSL ligands internalized in cells deficient in epsin are not able to activate
Notch.
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2.3. Ligand recycling
Ligand endocytosis, trafficking through endosomes and recycling back to the cell
surface is required for Notch activation. However, it is still unclear how recycling
defects affect ligand activity. The following events could happen upon DSL ligand
recycling: Because clustering of cleaved DSL ligands is necessary for their activity, it is
possible that endocytosis aid in clustering of the ligand, which is then recycled back to
the plasma membrane (Hicks et al., 2002; Morrison et al., 2000). Recycling could also
allow posttranslational modification (monoubiquitylation) of DSL ligands in the sorting
or recycling compartments which may render the ligands more active (Wang and Struhl,
2004). In addition, recycling has also been proposed to generate an ‘active’ ligand by
sorting ligand to an intracellular endocytic compartment; however, the specific molecular
changes are not well defined (Wang and Struhl, 2004). The recycling model assumes that
newly translated ligand trafficked to the cell surface fails to activate Notch signaling.
Instead activation of Notch requires ligand endocytosis, trafficking through endosomes,
ligand activation or processing within the endosomes and recycling back to the cell
surface. Moreover, epsin has been shown to bind and target ubiquitylated Delta to a
specific endosomal pathway to become activated, and only the active form is recycled
back to the plasma membrane. However, to date no one has identified an activated or
proteolytically processed form of Notch ligand.

Nevertheless, the role for ligand

recycling in Notch activation was reinforced by two papers proposing that in sensory
organ development, the recycling proteins Sec15 and Rab11 may work in signal sending
cells to promote Delta recycling and thereby signaling. Losses in Sec15, which functions
with Rab11 in trafficking proteins from the recycling endosome to the plasma membrane,
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also produce cell fate transformations indicative of defects in Notch signaling (Emery et
al., 2005; Jafar-Nejad et al., 2005; Langevin et al., 2005; Wu et al., 2005); yet, it is still
unclear how recycling affects ligand activity and if it is required to generate an active
ligand. Interestingly, defects in Dll1 recycling in bone marrow stromal cells exhibits
Notch-independent phenotypic changes in lymphoid progenitors, suggesting that Notch
ligand recycling is required to generate an active ligand (Nichols et al., 2007). However,
direct evidence that Notch ligands actually recycle is lacking.

Conversely, a few

instances suggest that recycling is not the primary role of ligand endocytosis in Notch
signaling. Particularly, in the germline or in the developing eye, loss of Rab11 activity
was unable to affect Delta signaling (Banks et al., 2011; Windler and Bilder, 2010).
Further, Rab5, a prerequisite for entry into the Rab11 recycling pathway, is also not
necessary for Delta signaling in the germline or in the developing eye (Banks et al., 2011;
Windler and Bilder, 2010). Alternatively, recycling could direct ligand to a specific
plasma membrane microdomain or maintain optimal levels of DSL ligand at the plasma
membrane.

For example, Neur-dependent Delta transcytosis from the basolateral

membrane to an apical region of the plasma membrane juxtaposes Delta with Notch on
adjacent cells and thus enables it to engage and signal (Benhra et al., 2010; Rajan et al.,
2009). Finally, recycling of DSL ligand could generate strong signal sending cells
through asymmetric presentation of Neur that stimulates ligand activity by promoting
ubiquitin–epsin-dependent endocytosis and trafficking of Notch ligand. In addition, it has
been proposed that asymmetric localization of the recycling endosomes could regulate
Delta levels or activity. However, the reported accumulation of Dll1 to recycling
endosomes could decrease Dll1 at the cell surface, thereby accounting for the losses in
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Notch signaling. In this case, the need for Dll1 to pass through the recycling endosome
could reflect a mechanism to replenish cell surface ligand.
Conclusion
Breast cancer is a heterogenous and complex disease and great effort is made in
understanding the molecular biology and novel crosstalk mechanisms in breast cancer.
This will ultimately aid in identification of better prognostic makers to design customized
treatment strategies. We have identified a novel crosstalk mechanism between ErbB-2
and Notch pathways, where ErbB-2 is a negative regulator of Notch signaling in ErbB-2
positive breast cancer (Osipo et al., 2008). The evolutionary conserved Notch pathway is
used iteratively during development and adulthood to regulate cell fates (Fortini, 2009;
Kopan and Ilagan, 2009). Deregulation or loss of Notch signaling is associated with a
wide range of human disorders from developmental syndromes to cancer. In human
cancers, both Notch ligands and receptors are expressed on cancer cells and Notch
acitivity is robustly regulated in a spatio-temporal manner. Thus, activation of Notch in
cancer cells can transmit bidirectional signals to cancer cells, stroma, and endothelial
cells. Therefore, it is not surprising that Notch signaling can crosstalk with many other
oncogenic signaling pathways (Miele, 2006; Rizzo et al., 2008b). Notch and its crosstalk
with ErbB-2 plays an important role in ErbB-2 positive breast cancer cell growth,
survival, tumor recurrence, and drug resistance (Osipo et al., 2008; Pandya et al., 2011).
Thus, significant attention has been given in recent years to understand how Notch
activity is modulated in a spatio-temporal manner in presence of other active oncogenic
kinases and to develop a clinically useful inhibitor of Notch signaling. A decade ago
three seminal papers suggested a potential role for ubiquitylation, endocytosis and
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trafficking of ligands as a mechanism to regulate Notch signaling (Deblandre et al., 2001;
Lai et al., 2001; Pavlopoulos et al., 2001). Based on what was known then, what is
known now, we intend to extrapolate these finding in the context of ErbB-2 positive
breast cancer and try to understand the role of ligand ubiquitylation in ErbB-2 mediated
inhibition of Notch signaling.
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CHAPTER III
MATERIALS AND METHODS

1. Cell Culture
SKBr3 and BT474 breast cancer cells were purchased from American Type Culture
Collection (Manassas, VA). BT474 trastuzumab resistant (BT474 HR) breast cancer
cells were generated by treating BT474 trastuzumab sensitive (BT474 HS) cells with 10
g/mL trastuzumab (Genentech, San Francisco, CA) for 6 months in vitro. SKBr3 cells
were maintained in Iscove’s Minimal Essential Media (IMEM, Thermo Fischer
Scientific, Waltham, MA) supplemented with 100 μM non-essential amino acid
(Invitrogen, Carlsbad, CA), 1% L-glutamine (2 mM, Thermo Fischer Scientific,
Waltham, MA) and 10% fetal bovine serum (FBS, Gemini Bio-Products, West
Sacramento, CA). BT474 HS and HR cells were maintained in Dulbecco's Modified
Eagle Medium (DMEM, Thermo Fischer Scientific, Waltham, MA) supplemented with
100 µM non-essential amino acid, 1% L-glutamine (2 mM) and 10% FBS. Mouse
fibroblast LTK-parental and LTK-Jagged-1 cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 100 µM non-essential amino acid,
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1% L-glutamine (2 mM) and 10% FBS. All cells were incubated at 370C with 95% O2
and 5% CO2.

2. Drugs and Chemicals
Gamma-secretase inhibitors
The final proteolytic cleavage in the activation of Notch receptor is catalyzed by the
γ-secretase complex (Kopan and Ilagan, 2004, 2009). This final step can be targeted
using γ-secretase inhibitors (GSIs). The γ-secretase inhibitor LY 411,575, a reversible
competitive inhibitor, was kindly provided by Drs. Abdul Fauq and Todd Golde from the
Mayo Clinic in Jacksonville, FL. For xenograft studies, 5 mg/Kg LY 411,575 GSI was
used for 3 days on, 4 days off. MRK-003 GSI was kindly provided by Merck Oncology
& Co. (Whitehouse Station, NJ). MRK-003 GSI is small molecule inhibitor which binds
to the binding pocket of presenilin, the catalytic subunit of the γ-secretase complex. For
xenograft studies, 100 mg/Kg MRK-003 GSI dissolved in 0.2% methylcellulose was fed
to mice by oral gavage in a volume of 200 l per mouse for 3 days on, 4 days off.
Trastuzumab
Trastuzumab is a humanized monoclonal antibody targeted against the extracellular
portion of ErbB-2 (Carter et al., 1992). Trastuzumab was resuspended in sterile PBS to
obtain a stock concentration of 22 mg/mL. For xenograft studies, 10 mg/Kg trastuzumab
in a total volume of 100 l sterile PBS was intraperitoneally injected (i.p) into the mice
once a week. For cell culture treatments, the working concentration of 10 or 20 µg/mL
was used.
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Lapatinib
Lapatinib is a dual tyrosine kinase inhibitor of EGFR and ErbB-2. Lapatinib was
purchased from Selleck Chemicals, Houston, TX. For xenograft studies, 100 mg/Kg
lapatinib was fed by oral gavage, twice daily for 5 days. For cell culture treatments,
lapatinib was dissolved in the solvent dimethylsulfoxide (DMSO) to obtain a stock
concentration of 2 mM and was stored at -200C. The working concentration used for the
cell treatment was 2 µM.
N-Ethylmaleimide
N-Ethylmaleimide (NEM) was purchased from Sigma Aldrich (St. Louis, MO).
NEM is added fresh to lysis buffer at a concentration of 5 mM and allowed to rock for 20
minutes at 40C. NEM is an irreversible inhibitor of cysteine proteinases (deubiquitinases)
and is used to stabilize and detect ubiquitylation of proteins by western blot analysis.
3. Expression Vectors
pcMV10 and pcMV10-Flag-Ub expression vectors were kindly provided by Dr.
Adriano Marchese (Department of Pharmacology, Loyola University Medical Center,
Maywood, IL). A wild type Jagged-1 expression plasmid was kindly provided by Dr.
Urban Lendahl (Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden).
4. RNA Interference and Transfection Reagents
Jagged-1 siRNA was purchased from Ambion (Grand Island, NY). Mib-1 and DLL-1
ON-TARGETplus SMARTpool siRNA were purchased from Thermo Fischer Scientific
(Waltham, MA). Notch-1 and scrambled control siRNAs were purchased from Santa
Cruz Biotechnologies (Santa Cruz, CA). Transfection reagents, Lipofectamine 2000 and
Lipofectamine RNAi max, were purchased from Invitrogen (Grand Island, NY).
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Protocols were performed according to the manufacturer’s instructions. In a 6-well tissue
culture dish, Jagged-1 (5 µL, 100 µM), DLL-1 (5 µL, 10 µM), and Notch-1 (5 µL, 10
µM) siRNA transfections were performed using the Lipofectamine RNAi max reagent.
Transfections with Mib-1 (10 µL, 10 µM) siRNA alone or co-transfections with the FlagUb (1 µg) plasmid were performed using the Lipofectamine 2000 reagent. The siRNA
sequences are shown in Table 2.
siRNA
Jagged-1
Mib-1

Catalog#
AM16106
L-014033-00-0005

DLL-1
Notch-1

L-013302-00-0005
sc-36095

Scrambled control

sc-37007

Sequence
5’-GGUCCUAUACGUUGCUUGUtt-3’
5’-GACCUGAGCAUUCGAAAUA-3’
5’-GGUAUGCUCUGACAAGAAA-3’
5’-CAGCAUACCCAGAUUGUUA-3’
5’-CGACAGACACCACUUCAUA-3’
5’-CACCAGUUUGAAUGGUCAA-3’
5’-CCCAUGGUACCAAUCAUGA-3’
5’-CCAUGGUACCAAUCAUGAA-3’
5’-UUCUCCGAACGUGUCACGU-3’

Table 2: Sequences of siRNA(s).
5. Antibodies
Phosphorylated-AKT1 (Thr308, 244F9, 4056), total AKT1 (C67E7, 4691),
phosphorylated-p44/42 ERK1/2 (Thr202/Tyr204, 197G2, 4377), total p44/42 ERK1/2
(137F5, 4695), PTEN (138G6, 9559), Flag (M2, 2368) and Jagged-1 (28H8, 2620) were
purchased from Cell Signaling Technology (Cell Signaling Technology, Danvers, MA).
Notch-1 (C-20, sc-6014-R), Jagged-1 (C-20, sc-6011), Hes-1 (H-140, sc-25392), Ub
(P4D1, sc-8017) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).
Mib-1 (EPR2762(2), ab124929) was purchased from Abcam (Cambridge, MA).
Phosphorylated tyrosine-ErbB-2 (Y1248, 06-229) was purchased from Millipore,
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Billerica, MA and total ErbB-2 (e2-4001 + 3B5, AB-17) from Thermo Fisher Scientific,
Waltham, MA. PKCα (Y143, 1608-1) was purchased from Epitomics, Burlingame, CA.
Beta-Actin (AC-15, A5441) was purchased from Sigma Aldrich (St. Louis, MO). BetaActin was used as an endogenous control for all Western blots. Secondary antibodies
include donkey anti-mouse IgG-HRP (1:3000, sc-2314), donkey anti-rabbit IgG-HRP
(1:2000, sc-2313), and donkey anti-goat IgG-HRP (1:2000, sc-2020) and were purchased
from Santa cruz Biotechnologies (Santa cruz, CA).
6. Western Blot Analysis
Cultured cells
SKBr3 cells were plated in either a 6-well (5x105) or a 10 cm2 (5x106) tissue culture
treated dish. Twenty-four hours later, the cells were transfected with siRNA or plasmid
DNA, treated with 2 µM lapatinib or 10-20 µg/mL trastuzumab and maintained at 370C
with 95% O2 and 5% CO2. After 48 hours, medium was aspirated while on ice and the
cells were washed once with ice-cold PBS. Cells were then lysed using 300 µL per well
or 500 µL per 10 cm2 dish Triton X-100 lysis buffer (50 mM HEPES, 1% Triton X-100,
150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 1 mM o-vanadate, 10 mM NaF, 1 protease
cocktail tablet), scraped, and collected in labeled eppendorf tubes. The collected samples
were allowed to incubate on ice for 10 minutes. Following incubation, the lysates were
sonicated 10 seconds using the Sonic Dismembrator (Model 100, Thermo Fischer
Scientific, Waltham, MA). Lysates were then centrifuged at 4000 rpm for 15 minutes at
40C. The supernatant was isolated and used to determine protein concentration using the

62

BCA protein assay (Thermo Fisher Scientific, Waltham, MA). The plate was incubated
for 30 minutes at 370C and read on a 96-well plate FPR fluorescent plate reader. Samples
from protein lysates were made at 10 – 30 µg in 2x Laemmli buffer (161-0737, BioRad,
Hercules, CA) and beta-mercaptoethanol (BP-176-100, Thermo Fischer Scientific,
Waltham, MA).

Samples were then heated at 950C for 5 minutes.

Based on the

molecular weight and manufacturer’s instructions, detection of each protein by Western
blotting was performed as shown in Table 3. The denatured proteins were loaded into
each lanes of a SDS-PAGE gel. The gel was run at 150V for 1 hour for Tris acetate gel
or 200V for 1 hour for Bis-Tris gel. The separated proteins were transferred to PVDF
membranes at 40V for 2.5 hours in 1x Transfer Buffer (NuPAGE® 20x Transfer buffer
diluted to 1x in deionized water, 20% methanol) purchased from Invitrogen (Grand
Island, NY). Following transfer, the PVDF membrane was re-wetted briefly in methanol
followed by deionized water. The membrane was then blocked with 5% non-fat milk
(Bio-Rad, Hercules, CA) in TBST buffer (5 mM Tris-HCl, 5 mM Tris-base, 150 mM
NaCl, 0.05% Tween-20, and 0.2% NP-40 at pH 8.0) or 5% Roche blocking reagent
(Indianapolis, IN) in 1X TBS for one hour at room temperature while constantly shaking.
Primary antibodies were added for overnight incubation at 40C with constant shaking.
The following day, blots were washed three times in TBST at intervals of 10 minutes at
room temperature while shaking rigorously. Secondary antibodies conjugated to
horseradish peroxidase were added to 5% non-fat milk in TBST or 5% Roche blocking
reagent in 1X TBS for one hour at room temperature. Blots were then washed again three
times in TBST at intervals of 10 minutes at room temperature. Proteins were detected
with the enhanced chemiluminescence (ECL) Western blotting substrate (Pierce,
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Rockford, IL) or SuperSignal® West Dura (Thermo Fischer Scientific, Waltham, MA)
added in 1:1 volume, incubated for 1 or 5 minutes, respectively, at room temperature
while rocking, and stained bands were visualized by exposing the membrane to X-ray
film and developing in the dark room.
To re-probe Western blots, the membranes were rinsed briefly with TBST at room
temperature. Restore Plus Western Blot Stripping buffer (Thermo Fischer Scientific,
Waltham, MA) was added to cover the membrane and incubated for 15 minutes at room
temperature while rocking. The blots were then subjected to three quick rinses with
deionized water, and then washed in TBST 3 times at intervals of 10 minutes at room
temperature. Membranes were then blocked for 1 hour and Western blotting would
continue as described previously.
Frozen Tumor Samples
Frozen tumor samples from each treatment group were homogenized by grinding in
liquid nitrogen and lysed in lysis buffer (50 mM HEPES, 1% Triton X-100, 150 mM
NaCl, 5 mM EDTA, 10 g/ml pepstatin A, 10 g/ml leupeptin, 10 g/ml aprotinin, 25
g/ml PMSF, 10 g/ml TLCK, 10 g/ml TPCK, 1 mM o-vanadate, 10 mM NaF). The
tumor extract was sonicated, followed by centrifugation at 10,000 x g for 5 minutes. The
supernatant was collected and protein concentration was measured using the BCA protein
assay. Tumor lysates were then subjected to SDS-PAGE and Western blotting was
performed using the following antibodies: phosphorylated tyrosine (Y1248)-ErbB-2, total
ErbB-2, phosphorylated-ERK1/2, total ERK1/2, phosphorylated-AKT1, total AKT1,
PTEN, and β-actin as a loading control. Anti-mouse or anti-rabbit secondary antibodies
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conjugated to horseradish peroxidase were used to detect the primary antibody. The blot
was then developed using SuperSignal® West Dura and the stained bands were
visualized using the Fujifilm LAS-3000 imager.
Protein

% Gel

Blocking Reagent

Jag-1

7% Tris acetate

Mib-1
Hes-1

7% Tris acetate
10% Bis-Tris

Flag
Ub
PKCα
Pan-Tyrosine
ErbB-2
Phosphorylated
Tyr1248-ErbB-2
p-AKT
AKT
p-ERK1/2
ERK1/2
PTEN
β-actin

7% Bis-Tris
7% Bis-Tris
4-12% Bis-Tris
7% Tris acetate
7% Tris acetate
7% Tris acetate

5% Roche reagent
containing casein
5% milk
5% Roche reagent
containing casein
5% milk
5% milk
5% milk
5% milk
5% milk
5% milk

4-12% Bis-Tris
4-12% Bis-Tris
4-12% Bis-Tris
4-12% Bis-Tris
4-12% Bis-Tris

5% milk
5% milk
5% milk
5% milk
5% milk
5% milk

Primary Antibody
Dilution
1:500
1:1000
1:500
1:1000
1:1000
1:1000
1:1000
1:500
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:5000

Table 3: Western Blotting Specifications
7. Co-Immunoprecipitation (Co-IP)
SKBr3 cells (5x106) were plated in 10 cm2 cell culture dishes for 24 hours. The cells
were transfected with 6 μg of Flag-Ub and 60 µL of 10 μM solution of either scrambled
control siRNA (SCBi) or Mib-1 siRNA (Mib-1i) for 48 hours at 370C with 95% O2 and
5% CO2. Sixty microliters of Lipofectamine 2000 transfection reagent was used per
plate. The total volume in the plates was 11 mL (9 mL media and 2 mL Flag-Ub – siRNA
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– Lipofectamine 2000 mix). Before the completion of 48 hours incubation, cells were
treated with 2 µM solution of lapatinib for 30 minutes. Media was aspirated while on ice
and the cells were washed once with ice-cold PBS. Cells were then lysed using 500 µL
per plate Triton X-100 lysis buffer (50 mM HEPES, 1% Triton X-100, 150 mM NaCl, 5
mM EDTA, 1 mM PMSF, 1 mM o-vanadate, 10 mM NaF, 1 protease cocktail tablet),
scraped, and collected in respective 1.5 mL eppendorf tubes. The collected samples were
allowed to incubate on ice for 10 minutes. Following incubation, the lysates were
sonicated using the Sonic Dismembrator (Model 100, Thermo Fischer Scientific,
Waltham, MA). The lysates were then centrifuged at 4000 rpm at 40C for 15 minutes.
The lysate concentration was ascertained using the protein BCA protein assay, incubated
for 30 minutes at 370C, and measured using a 96-well plate FPR fluorescent plate reader.
Lysates at a concentration of 4 mg/mL were incubated with 4 μg of rabbit anti-human
Jagged-1 or rabbit isotype control IgG overnight with gentle rocking at 40C. Thirty
microliters of protein A-plus beads (sc-2002, Santa Cruz, CA) were added to the immune
complexes for 2 hours at 40C while gently rocking. Protein-antibody-bead complexes
were washed three times in Triton X-100 buffer. The pellet was resuspended in
previously boiled Laemmli sample buffer supplemented with beta-mercaptoethanol and
heated for 5 minutes at 950C while vigorously shaking. After boiling, the samples were
centrifuged at 5000 rpm at room temperature for 5 minutes. Western blotting was used
for detection of proteins in co-immunoprecipitated samples and total lysates as described
in the Western Blot section of these methods. Antibodies used for detection were: Ub,
Mib-1, PKCα Jagged-1, and β-actin.
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8. Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR)
Cultured cells
SKBr3 (5x105) cells were plated in a 6-well tissue culture treated dish. Twenty-four
hours later, the cells were transfected using appropriate reagents and maintained at 370C,
95% O2, and 5% CO2. Forty-eight hours later, cells were harvested. Total RNA was
extracted from the cells using the RiboPure Kit (Ambion, Grand Island, NY). Total RNA
recovered was then quantified using the NanoDrop Spectrophotometer (Thermo Fischer
Scientific, Waltham, MA). The cDNA was reverse transcribed (RT) from 1 μg total RNA
in a total 100 μL volume containing 1X RT buffer, 5.5 mM MgCl2, 500 μM dNTPs, 2.5
μM random hexamers, 0.4 U/μL RNase inhibitors, and 1.25 U/μL RT enzyme
(MultiScribe™ Reverse Transcriptase Kit, Applied Biosystems, Foster City, CA). The
parameters were as follows: 10 minutes at 250C, 30 minutes at 480C, 5 minutes at 950C,
60 minutes at 250C, and held at 40C until use. Real-time PCR was performed using
iTaq™ SYBR® Green Supermix with ROX (BioRad, Hercules, CA). In a 96-optical
PCR plate, 2.5 μL of cDNA was added to 22.5 μL of mastermix (2X Syber green
Universal Master Mix, and 50 μM forward and reverse primers). The quantitative PCR
parameters were as follows: the initial denature temperature was for 10 minutes at 950C;
PCR cycling for 40 cycles was carried out for 10 seconds at 950C, and for 45 seconds at
600C. A melt curve was added after completion of the 40 cycles set by the StepOnePlus
thermocycler manufacturer (Applied Biosystems, Foster City, CA). Cycle number at
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threshold (Ct) values was subsequently determined. For analysis, first, the Ct value were
normalized to human ribosomal protein L 13A (hRPL13A) or 18s, an endogenous
control. The values obtained from this normalization were used to calculate relative fold
induction or decrease compared to a control sample. The PCR primers that were used for
detection of specific transcripts are shown in Table 4.
Frozen Tumor Samples
Frozen tumor samples from each treatment group were homogenized by grinding in
liquid nitrogen and total RNA was extracted, reverse transcribed to total cDNA, and realtime PCR was performed as previously described. The PCR primers that were used for
detection of human specific transcripts are shown in Table 4.
Targets
Jagged-1

Forward primer
5’-GACTCATCAGCCGTGTCTCA-3’

Reverse primer
5’-TGGGGAACACTCACACTCAA-3’

Notch-1

5’-GTCAACGCCGTAGATGACC-3'

5'-TTGTTAGCCCCGTTCTTCAG-3'

Deltex-1
Hes-1
Hey-1

5’-CAGTTTCGCCAGGACACAG-3’
5’-CGGACATTCTGGAAATGACA-3’
5’-AGCTCCTCGGACAGCGAGCTG-3’

5’-GCAGATGTCCATATCGTAGGC-3’
5’-CATTGATCTGGGTCATGCAG-3’
5’-TACCAGCCTTCTCAGCTCAGACA-3’

hRPL13A

5’-CATAGGAAGCTGGGAGCAAG-3’

5’-ACAAGATAGGGCCCTCCAAT-3’

5’-ATGAACCAGGTTATGACCTTGAT-3’

5’-CCTGTTGACTGGTCATTACA-ATA-3’

18s

Table 4: Sequences of PCR primers
9. Cell Cycle Analysis
SKBr3 (3x105), BT474 HS (3X105), and BT474 HR (3X105) cells were seeded in a 6well plate. After 24 hours, the cells were transfected with 5 µL of 100 µM solution of
scrambled control siRNA (SCBi) or Jagged-1 siRNA (Jag-1i) using 5 µL of
Lipofectamine RNAi max transfection reagent. Six hours after transfection, the cells
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were treated with PBS or 10 µg/ml trastuzumab for 48 hours. After 48 hours, the media
was collected in a tube and mixed with the trypinized cells. Cells and media were
centrifuged at 40C, 1000 rpm for 5 minutes. The cell pellet was resuspended in 2 mL icecold PBS. From the 2 mL single cell suspension, cells were counted and 1x106 cells were
placed into FACS tubes. Cells were pelleted at 40C, 1200 rpm for 5 minutes. The
supernatant was removed by inverting and decanting and the pellet was washed by
adding 2 mL of ice cold 5% bovine calf serum (BCS) made in PBS. Cells were again
centrifuged at 40C, 1200 rpm for 5 minutes and the supernatant was removed by
decanting. Cells can be now fixed for later use by gently resuspending cells in 1 mL of
70% ethanol. The tubes can be stored at 40C for a week after this step. However, the
cells were resuspended in 100 µL of ice cold 5% BCS to which 600 µL of ice cold 100%
ethanol was added slowly. The tubes were incubated on ice for 30 minutes and then
washed twice by adding 2 mL of ice cold 5% BCS. Cells were then centrifuged at 4°C,
1200 rpm for 5 minutes and resuspended in 250 μL of 10 μg/mL RNase A. They were
incubated at 370C for 15 minutes followed by incubation at room temperature for 5
minutes. To the 250 μL volume, 250 μL of 100 μg/mL Propidium Iodide (P4170, Sigma
Aldrich, St. Louis, MO) was added, gently mixed, covered with foil and incubated at
room temperature for at least one hour in a dark area. The samples were measured by
flow cytometry (FACS Canto, BD Biosciences, San Jose, CA).
10. Annexin-V Apoptosis Assay
SKBr3 (3x105), BT474 HS (3X105), and BT474 HR (3X105) cells were seeded in a 6well plate. After 24 hours, the cells were transfected with 5 µL of 100 µM solution of
scrambled control siRNA (SCBi) or Jagged-1 siRNA (Jag-1i) using 5 µL of
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Lipofectamine RNAi max transfection reagent. Six hours after transfection, the cells
were treated with PBS or 10 µg/ml trastuzumab for 48 hours. After 48 hours, the media
was collected in a tube and mixed with the cells that were trypsinized, washed twice with
ice-cold PBS, and resuspended in a 1X Annexin-V binding buffer (556454, BD
biosciences, San Jose, CA). From that suspension, pipette 100 μL of the solution and
place it in a FACS tube. To the tube, 5 μL of 1 μg/mL FITC-Annexin-V stain (556420,
BD Biosciences, San Jose, CA) and 5 μL of 50 μg/mL propidium iodide (P4170, Sigma
Aldrich, St. Louis, MO) were added, covered with aluminium foil and incubated for 15
minutes at room temperature in a dark area. Then, 400 μL of 1X Annexin-V binding
buffer was added back and immediately within the hour the samples were measured by
flow cytometry (FACS Canto, BD Biosciences, San Jose, CA). The following control
tubes were used for compensation and background normalization: 1) a tube containing
100 µL of cells alone, 2) a tube containing 100 µL of cells plus FITC-conjugated
Annexin-V antibody, 3) a tube containing 100 µL of cells with Propidium Iodide, and 4)
a tube containing 100 µL cells, FITC-conjugated Annexin-V antibody, and Propidium
Iodide.
11. Co-culture Assay
Figure 6 shows the schematics of the co-culture technique. SKBr3 cells were plated at a
density of 3x106 cells per 10 cm2 plate. The next day, cells were transfected with 30 µL
of 100 µM scrambled control siRNA (SCBi) or Jagged-1 siRNA (Jag-1i) using 30 µL
Lipofectamine RNAi max. Thirty hours after transfection, mouse fibroblast (LTK) cells
expressing no ligand or rat Jagged-1 were added in equal parts (1:1) to plated, siRNA
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transfected SKBr3 cells. The cells were treated with PBS or 20 µg/ml trastuzumab at the
same time as adding the mouse fibroblast cells for 18 hours.

After 48 hours of

incubation, cells were washed with ice cold PBS, trypsinsed, and centrifuged at 40C,
1200 rpm for 5 minutes. Decant the supernatant and wash the cells with 1 mL of 1:50
diluted sterile filtered Fetal Bovine Serum (FBS). The cells were centrifuged again at
40C, 1200 rpm for 5 minutes. Then, 10 µL of PE-conjugated human-ErbB-2 antibody
(340552, Becton Dickinson, Franklin Lakes, NJ) was added to the pellet, incubated at
40C for 30 minutes, and washed twice with 1 mL of 1:50 diluted FBS. Samples were
then sorted for ErbB-2 expression at the cell surface by FACS. Sorted samples were
centrifuged at 40C, 1200 rpm for 5 minutes and total RNA was extracted, reverse
transcribed to total cDNA, and real-time PCR was performed as previously described in
the reverse transcription real-time polymerase chain reaction – Cultured cells section of
these methods. The PCR primers that were used for detection of specific transcripts are
Hes-1, Deltex-1, and hRPL13A and their sequences are shown in Table 4.
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Notch-1

Jag-1

Real-time PCR
Notch Target
Genes:
Hes-1 and Deltex-1

Jag-1
Mouse Fibroblast
Expressing Jag-1
(LTK-Jag-1)

SKBr3 Cells Expressing
Jag-1, Notch-1, and ErbB-2

Figure 6: Schematics of Co-culture Technique.

SKBr3 cells were plated at a density of 3.5x 106 in 10 cm2 plates. The following day,
SKBr3 cells were transfected with 5 µL of either scrambled siRNA (SCBi) or Jagged-1
siRNA. After 30 hours, the cells were co-cultured with mouse fibroblast LTK cells
expressing either no ligand (LTK-Parental) or ligand, Jag-1 (LTK-Jag-1). Concurrently,
the co-culture was treated with PBS or trastuzumab (20 µg/mL). Eiteen hours later, the
cells were trypsinized and stained using PE-conjugated human-ErbB-2 antibody. ErbB-2
positive cells were sorted by FACS and relative mRNA levels of Hes-1 and Deltex-1
were measured using Real-time PCR. Human RPL13A (hRPL13A) was measured as a
loading control and used for normalization.
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12. Development of BT474 Trastuzumab Sensitive, Ttrastuzumab Resistant, and
Lapatinib Sensitive Xenografts
BT474 HS, BT474 HR and BT474 LS (sensitive to lapatinib) breast cancer cells were
used to generate breast tumor xenografts. Five million cells were injected bilaterally into
mammary fat pads of ovariectomized, FoxN1nu/nu athymic nude mice (Harlan SpragueDawley, Madison, WI) followed by implantation of a 17-estradiol-containing silastic
capsule of 0.3cm in length with a constant release providing 83-100 pg/mL as described
previously (O'Regan et al., 1998). The identity of each mouse and tumor was tracked by
their ear tag. Once tumors grew to a mean cross sectional area (CRA) of 0.30-0.50 cm2,
mice were sacrificed; tumors were extracted, and re-transplanted into a set of 56 mice as
previously described (Osipo et al., 2005). Tumors were allowed to grow to a mean CRA
of 0.20-0.30 cm2 and mice were randomized to four treatment groups with each group
containing 14 mice: Vehicle control (0.2% methylcellulose in sterile PBS), trastuzumab
(10 mg/Kg in a total volume of 100 l sterile PBS, i.p. once a week) or lapatinib (100
mg/Kg; fed by oral gavage, twice daily for 5 days), LY 411,575 GSI(5 mg/Kg; 3 days on,
4 days off) or MRK-003(100 mg/Kg dissolved in 0.2% methylcellulose, 200 l fed by
oral gavage, 3 days on, 4 days off), or trastuzumab plus MRK-003 or LY 411,575 GSI or
lapatinib plus MRK-003 GSI. Tumor area (l x w) was measured weekly using Vernier
calipers and cross sectional area [(l x w))/4] was calculated and graphed. Tumor
recurrence was monitored after treatments with trastuzumab or trastuzumab plus GSI
were stopped.

Lack of tumor recurrence was confirmed by the Vevo 770 Ultrasound
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Imaging system. Tumor recurrence was monitored for approximately 100 days post
treatment. Protocols that were used to study breast tumor xenografts in mice were
approved by Loyola University’s Institutional Animal Care and Use Committee.
13. Immunohistochemistry
Tumor sections (4 m) were sliced from formalin-fixed, paraffin-embedded tumor
samples, incubated in 600C oven for 15 minutes, and cooled down to room temperature.
Tumor sections were then de-paraffinized and re-hydrated as follows: two washes of 5
minutes each with xylene, two washes of 4 minutes each with 100%, 95%, 80%, and 50%
ethanol, and finally with deionized water for 4 minutes. De-paraffinizing and rehydration
step, the slides containing tumor sections were put in coplin jars filled with 1x reveal
buffer to unmask the epitope using a decloaker. After cooling the coplin jars, rinse the
tumor sections 5-6 times with distilled water, once with PBS for 15 minutes, 3%
hydrogen peroxide for 15 minutes, and again 3 times with PBS for 5 minutes each.
Following washes incubate the tumor sections with 10% normal horse serum for 15
minutes. Tumor sections were stained by overnight incubation with an antibody against
the proliferation marker, Ki67 (1:100, DAKO, Carpinteria, CA), for all four treatment
groups. After 24 hours, biotinylated anti-mouse secondary antibody (VECTASTAIN
Elite ABC Kit, Vector laboratories, Burlingame, CA) was applied to the slides to detect
the primary antibody, followed by incubation with the avidin-horseradish peroxidase
complex reagent (VECTASTAIN Elite ABC kit, Vector laboratories, Burlingame, CA).
The three immunohistochemical staining steps described above were each followed by
three 5 minutes washes with PBS. The staining was developed in the diaminobenzidine
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chromogen substrate solution (Peroxidase Substrate Kit, Vector laboratories, Burlingame,
CA). Mayer’s haematoxylin was used as a counter-stain. Immunohistochemical analysis
of Ki67 was performed using at least 3-5 tumors per treatment group. The number of
Ki67 positive cells as shown on the Y-axis was determined by taking an average number
of Ki67 positive cells from 60 high power fields at 40x magnification per treatment
group. H & E was performed to ensure the presence of tumor cells in the tumor sections.
14. TUNEL Assay
Terminal

Deoxynucleotidyl

Transferase-Mediated

dUTP

Nick

End-Labeling

(TUNEL) assay with the TMR detection kit (Roche Diagnostic, Indianapolis, IN) was
used to detect 3’OH-associated DNA fragmentation resulting from apoptosis. Paraffinembedded BT474 trastuzumab and lapatinib sensitive tumors extracted from xenografts
were deparaffinized as follows: two times, 10 minutes each with citrisolve (Thermo
Fischer Scientific, Waltham, MA); two times, 10 minutes each with 100% ethanol; two
times, 5 minutes each with 95% ethanol; 5 minutes with 70% ethanol; 5 minutes with
50% ethanol, and 5 minutes with PBS at 250C. Tumor sections were then permeabilized
using 0.1% Triton X-100 and 0.1% sodium citrate prepared fresh for 8 minutes each at
250C, followed by 5 washes with PBS at 5 minutes each. TUNEL mix was prepared by
mixing the enzyme and label solution according to the manufacturer’s instructions and
the tumor sections for each treatment group were incubated with the prepared TUNEL
mix for 60 minutes at 370C. After incubation, the slides were washed three times with
PBS for 5 minutes each. One drop of vectashield mounting medium containing Dapi (H1200, Vector laboratories, Burlingame, CA) is added to TUNEL stained tumor sections in
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order to stain the nucleus. The TUNEL assay was performed using 3-5 tumors from each
treatment group. The number of TUNEL positive cells shown on the Y-axis was the
average number of TUNEL positive cells counted per 20 high power fields (HPF) per
tumor for a total of 60 HPFs at 40x magnification per treatment group.
15. Statistical Analysis
Karyn Richlyk, a statistician at Loyola University Medical Center assisted in
performing Power Analysis in order to determine the number of mice needed per
treatment group for the in vivo study. Based on experience, we hypothesized the
following average tumor size for the 4 groups in trastuzumab or lapatinib sensitive
xenograft studies at the end of the experiment (all measurements are in cross-sectional
2

area = cm ): 1. Vehicle = 2.0 (SD = 0.3); 2. Trastuzumab or Lapatinib = 0.4 (SD = 0.1);
3. GSI = 1.5 (SD = 0.1); and 4. GSI + Trastuzumab or Lapatinib < 0.1 (SD = 0.01). For
the trastuzumab resistant xenograft study, the average tumor size for Vehicle, GSI, and
GSI + Trastuzumab should remain the same as above.

However, since these are

trastuzumab resistant tumors we would expect the average tumor size for the trastuzumab
group as 1.5 cm2. Calculations were conducted using PASS 2002 software (Kaysville,
Utah, 2002). In a one-way ANOVA, sample sizes of 7, 7, 7, and 7, were obtained for the
4 groups whose means are to be compared, assuming 100% tumor take. The total sample
of 28 mice achieves 95% power to detect differences among the means versus the
alternative of equal means using an F test at a significance level of 0.05. The common
standard deviation within a group is assumed to be between 1 and 0.01. However,
experience suggests that tumor take will be 50-70%; therefore, in order to maximize the
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likelihood that 7 subjects per group will present with tumors, we must assume that a
sample of 7 represents 50-70% from a group of 14 mice, for a total of 56 mice per
experiment of four groups. Each mouse was identifiable with a numbered-tag. Each
tumor area on the left flank and right flank of the mouse was measured weekly with
Vernier calipers. At the end of the study, tumor CRA was calculated and linear regression
analysis was performed to determine the slope of the line for determination of the rate of
growth for each tumor. Slopes of lines were used only if the correlation coefficients were
greater than or equal to 0.85.

A one-way ANOVA with Bonferroni correction for

multiple comparisons and alpha = 0.05 was used to test statistical significance between
groups for tumor growth rates, mRNA expression levels, and IHC assays. A non-paired
Student’s T-test was used to test statistical significance between two groups.

CHAPTER IV
HYPOTHESIS AND SPECIFIC AIMS

The ErbB-2 gene is amplified and the resulting protein product overexpressed in 1530% of breast tumors, and associated with aggressive behavior and poor overall survival.
Trastuzumab, a humanized monoclonal antibody is directed against the extracellular
domain of ErbB-2. Unfortunately, trastuzumab resistance remains a major problem in
metastatic breast cancer. Our data suggested that gene amplification or overexpression of
ErbB-2 inhibits Notch-1 transcriptional activity and inhibition of ErbB-2 activity with
trastuzumab or a dual EGFR/ErbB-2 TKI such as lapatinib increased Notch-1
transcriptional activity (Osipo et al., 2008). Furthermore, Notch-1 is a novel target for the
treatment of trastuzumab resistant ErbB-2 positive breast cancer in vitro (Osipo et al.,
2008). The Notch-1 receptor is another potent breast oncogene (Stylianou et al., 2006)
that is overexpressed with its ligand Jagged-1 in breast cancers with the poorest overall
survival (Reedijk et al., 2005). Notch signaling is thought to be necessary for breast
tumor initiating cells (Grudzien et al., 2010; Harrison et al., 2010; Pannuti et al., 2010).
We showed that ErbB-2 inhibition activates Notch-1 which results in a compensatory
increase in Notch-1-mediated proliferation. However, we do not yet know the mechanism
by which ErbB-2 overexpression suppresses Notch-1 activity and whether inhibition of
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Notch-1 would reverse resistance to trastuzumab in vivo.

Preliminary results

demonstrated that trastuzumab or lapatinib treatment of SKBr3 cells increased the cell
surface protein expression of Jagged-1 by flow cytometry (Figure 7A). Cell surface
biotinylation assays showed that Jagged-1 was enriched on the cell surface in response to
trastuzumab treatment (Figure 7B). Moreover, confocal studies indicated that Jagged-1
exited early endosomal antigen-1 (EEA-1) positive vesicles when SKBr3 cells were
treated with trastuzumab (Figure 8). Taken together, these results suggest the following
hypothesis (Figure 9):
ErbB-2 inhibits Notch-1 by limiting the cell surface availability of Jagged-1.
Dual inhibition of Notch and ErbB-2 signaling will result in prevention and/or
reversal of trastuzumab resistance in vivo.
We will address this hypothesis with the following specific aims:
Specific Aim 1: Determine the role of ErbB-2 in Jagged-1-mediated regulation of
Notch activity.
Specific Aim 2: Establish the therapeutic efficacy of targeting Jagged-1 in vitro
or Notch signaling in vivo in ErbB-2 positive breast cancer.
Our studies will elucidate the mechanism by which ErbB-2 and Notch pathways crosstalk
in ErbB-2 positive breast cancer cells. ErbB-2 overexpressing breast cancer cells exhibit
low Notch-1 activity, which is then reversed when ErbB-2 activity is inhibited. However,
we do not know yet the molecular mechanism by which ErbB-2 inhibits Notch activity.
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Mechanisms underlying trans-activation and cis-inhibition of Notch by its ligand even
though not well characterized yet are critical processes regulating Notch activity. We
will demonstrate for the first time that Jagged-1 has a dual role in regulation of Notch
activity in ErbB-2 positive breast cancer: Jagged-1 inhibits Notch in cis and activates
Notch in trans. More interestingly, ErbB-2 prevents Jagged-1-mediated trans-activation
of Notch signaling by limiting the association of Jagged-1 and Mib-1 and subsequent
ubiquitylation of Jagged-1, a critical step in generating the pulling force required for
Notch activation. Moreover, Mib-1 is the E3 ubiquitin ligase required for lapatinibmediated ubiquitylation of Jagged-1 and induction of Notch activity.

Additionally,

ErbB-2 promotes an association between Jagged-1 and PKCα. Further, PKCα inhibits
Notch transcriptional activity.

These findings will provide a mechanism and functional

relevance of Jagged-1–Notch interactions in ErbB-2 positive breast cancer cells. These
studies will provide a mechanistic basis for the observation that activated Notch-1
promotes a survival advantage in response to ErbB-2 targeted therapies and contributes to
resistance.

Furthermore, these studies will identify Jagged-1 as a novel and better

therapeutic target for the treatment of ErbB-2 positive breast cancer. Finally, these
studies will provide a preclinical proof of concept for future clinical trials using
combination of trastuzumab or lapatinib and a Notch pathway inhibitor (GSI or Jagged-1
targeted therapy) for the treatment of ErbB-2 positive breast cancer.
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Figure 7: Cell Surface Localization of Jag-1, Notch-1, and ErbB-2.
(A.) SKBr3 breast cancer cells were plated at a density of 25x104 cells per well in a 6well plate. The following day, the adherent cells were treated with increasing
concentrations of trastuzumab (0 to 20 g/mL; upper panel) or lapatinib (0 to 5M;
bottom panel). Flow cytometry was performed 24 hours after treatment to specifically
measure cell surface protein expression of Jagge-1 (Jag-1). The panels showing flow
cytometry results are representative of at least three independent experiments. (B.)
SKBr3 cells were seeded in 10 cm2 plates at a density of 3x105 cells. After 24 hours,
SKBr3 cells were treated with either isotype control IgG (20 g/mL) or trastuzumab (20
g/mL) for 3 hours. The cell surface proteins were labelled with 2 mM biotinylation
reagent and immunoprecipitated using 30 µL Neutravidin Protein. 30 µL of the
precipitated protein was analysed by western blot using an antibody for Jag-1, Notch-1,
tyrosine phosphorylated ErbB-2, and total ErbB-2. No biotin negative control was
included to ensure specificity. The blots shown are representative of three independent
experiments.

81

ImmunoFluorescence
IgG

Jag-1 + EEA1

Trast

Figure 8: Co-localization of Jag-1 and EEA-1.
SKBr3 cells were grown on glass slides for 48 hours and treated with 20 g/mL IgG or
20 g/mL trastuzumab for 3 hours. At the end of the treatment, cells were rinsed twice in
PBS and fixed in cold methanol. Staining for Jagged-1 (Jag-1) was performed using 1
μg/mL of goat anti-human Jag-1 antibody and 20 μg/mL of AlexaFluor 488 labelled antigoat IgG. Staining for Early Endosomal Antigen-1 (EEA-1) was performed using 1
μg/mL of EEA-1 and 20 μg/mL of AlexaFluor 555 labelled anti-rabbit IgG. Confocal
immunofluorescence microscopy was used to detect Jag-1 (green) and EEA-1 (red). The
figure is a representative of three similar independent experiments.
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Figure 9: Hypothesis of the Investigation
ErbB-2 promotes PKCα and Jagged-1 (Jag-1) association while inhibiting Mib-1 and Jag1 association. This results in suppression of Jag-1 mediated trans-activation of Notch in
ErbB-2 positive breast cancer. Dual inhibition of ErbB-2 and Notch signaling will result
in prevention of tumor recurrence and partial reversal of trastuzumab resistance in vivo.

CHAPTER V
RESULTS

SPECIFIC AIM 1
Determine the role of ErbB-2 in Jagged-1-mediated regulation of Notch-1 activity.
The goal of specific aim 1 is to test the following hypotheses:
Aim 1A. ErbB-2 promotes Jagged-1-mediated cis-inhibition of Notch.
Aim 1B. ErbB-2 limits the expression and/or association of Jagged-1 with Mib-1
to inhibit trans-activation of Notch.
Aim 1C. ErbB-2 through PKCα inhibits Jagged-1 – Mib-1 association and
Notch activity.
Aim 1A. ErbB-2 Promotes Jagged-1-Mediated Cis-Inhibition of Notch.
Rationale
Our preliminary data demonstrated that trastuzumab or lapatinib treatment of SKBr3
cells increased the cell surface protein expression of Jagged-1 by flow cytometry (Figure
7A). Additionally, cell surface biotinylation assays showed that Jagged-1 and Notch-1
were enriched on the cell surface in response to trastuzumab treatment (Figure 7B).
Finally, our data showed that Jagged-1 co-localized with early endosome antigen-1
(EEA-1) to possibly sub-membraneous endosomes in ErbB-2 positive breast cancer cells
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as determined by confocal immunofluorescence (Figure 8). However, Jagged-1 exited
EEA-1 positive vesicles and localized to the cell surface in response to trastuzumab
(Figure 8). Together, these data suggest that ErbB-2 overexpressing breast cancer cells
trap Jagged-1 in sub-membraneous compartments such as early endosomes. However,
trastuzumab releases Jagged-1 to the cell surface, making Jagged-1 available to promote
trans-activation of Notch signaling via ligand-receptor interaction. The goal of aim 1A is
to determine if ErbB-2 promotes Jagged-1-mediated cis-inhibition of Notch.
1. Inhibition of ErbB-2 decreased Jagged-1 protein levels.
Our preliminary data from Figure 7A and 7B demonstrated that the cell surface level
of Jagged-1 was increased in response to trastuzumab. In order to determine whether this
effect was due to an increase in the total Jagged-1 mRNA or protein levels, we asked the
question: Does ErbB-2 decreases the total Jagged-1 mRNA or protein levels? To study
this question, we first measured the expression of Jagged-1 in SKBr3 cells in the absence
or presence of treatment with increasing concentrations of trastuzumab (0, 10, and 20
μg/mL) or lapatinib (0, 1, and 5 µM) by Real-time PCR and Western blot analysis. The
results showed that trastuzumab treatment (10 and 20 μg/mL) had no significant effect on
Jagged-1 mRNA expression compared to 0 μg/mL trastuzumab (Figure 10A; left panel).
However, 1 and 5 µM lapatinib significantly increased Jagged-1 mRNA expression by
3.5 and 4.5 fold, respectively compared to 0 µM lapatinib (Figure 10A; right panel). In
contrast, Jagged-1 and Notch-1TM protein was decreased in response to both trastuzumab
and lapatinib (Figure 10B). Therefore, it appeared that ErbB-2 inhibitors decreased
Jagged-1 protein levels, despite an up-regulation of Jagged-1 mRNA transcript levels.
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This suggested that ErbB-2 may stabilize, rather than inhibit, Jagged-1 protein. To
determine whether this decrease in Jagged-1 protein by anti-ErbB-2 inhibitors was
reproducible in other breast cancer cells, MCF-7 cells stably expressing either empty
vector (MCF-7/Neo), ErbB-2 (MCF-7/HER2), or heregulin-1 (MCF-7/HRG-1) were
treated with trastuzumab (20 μg/mL) for 24 hours and Jagged-1, PY-ErbB-2, and ErbB-2
proteins were detected by Western blot. HRG-1 is a growth factor that mediates its
effects through ErbB-3 receptor. Therefore, HRG-1 overexpressing cells served as a
negative control to observe ErbB-2 specific effects. The results showed that while
trastuzumab treatment decreased Jagged-1 protein in MCF-7/HER2 cells, the levels of
Jagged-1 remained unchanged in ErbB-2 non-overexpressing MCF-7/Neo and MCF7/HRG-1 cells (Figure 10C). These results taken together suggest that trastuzumab or
lapatinib-mediated decrease in Jagged-1 protein is most likely ErbB-2 specific. Indeed,
trastuzumab decreased the tyrosine phosphorylation of ErbB-2 with no change in total
ErbB-2 levels (Figure 10C).

These data suggest that ErbB-2 signaling could be

stabilizing Jagged-1 protein levels, thus providing ample ligand to inhibit Notch in cis
and restrict binding of Notch to the ligand expressed on adjacent cells.
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Figure 10: Expression of Notch Ligand, Jag-1, in Breast Cancer cells
SKBr3 breast cancer cells were plated at a density of 25x104 (A.) or 5x105 (B.) and MCF7 cells at a density of 5x105 (C.) cells per well in a 6-well plate. (A.) The following day,
the cells were treated with increasing concentrations of trastuzumab (0 to 20 g/mL; left
panel) or lapatinib (0 to 5 M; right panel). Relative mRNA levels of Jagged-1 (Jag-1)
were measured 24 hours after each treatment using Real-time PCR. 18s rRNA was
measured as a loading control and used for nomalization. Real-time PCR results show
means of fold differences between treatments compared to vehicle control plus or minus
standard deviations of three independent experiments. *denotes statistically significant
differences between lapatinib and vehicle control. Statistical significance was calculated
using a two-sided, non-paired Student’s T-test. (B. and C.) After 24 hours, the cells
were treated with trastuzumab (10 µg/mL) or lapatinib (2 µM) for 6 hours and total
protein levels of Jag-1, Notch-1, PY-ErbB-2, ErbB-2, were measured by Western
blotting. 30 µg of total protein lysate was loaded onto each lane of gel as described in the
materials and methods. β-actin was measured as an endogenous control.
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2. Jagged-1 inhibits Notch activity via cis-inhibition.
Notch is regulated in at least two ways by Notch ligands: 1. trans-activation of Notch
by neighboring signal sending cells (Figure 11; top panel), and cis-inhibition of Notch
within its own cell (Figure 11; bottom panel). This level of tightly controlled activation
is critical for cell fate determination during development and differentiation of adult stem
cells. However, little is known about how Notch activation is regulated in breast cancer.
If ligand and receptor are expressed on the same cell, then the ligand-receptor interaction
results in cis-inhibition of Notch activity in that same cell. If ligand and receptor are
expressed on adjacent cells, then the ligand-receptor interaction results in trans-activation
of Notch signaling in the Notch receptor expressing cell. As shown in figures 7, 8, and
10, ErbB-2 hyperactivity resulted in an increase in total Jagged-1 protein that also
coincided with enhanced co-localization of Jagged-1 and EEA-1 and a decrease in cell
surface Jagged-1 expression and Notch activity.

To further investigate the role of

Jagged-1 on Notch activity, we asked the question: Can Jagged-1 mediate cis-inhibition
of Notch in ErbB-2 overexpressing breast cancer cells? To address this question, we
used a co-culture technique which has been used widely to understand cis and trans
functions of Notch ligands and Notch receptors.

Figure 12 demonstrates Jagged-1

protein levels in LTK-Parental and LTK-Jagged-1 cells and down-regulation of Jagged-1
protein by RNA interference in SKBr3 cells.

88

Breast Cancer Cells
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Signal Receiving Cell

Jag-1
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NICD
Jag-1
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Figure 11: Trans-Activation vs Cis-Inhibition of Notch via its Ligand Jag-1.
Notch ligand and receptor expressed on the adjacent cells results in trans-activation of
Notch signaling in signal receiving cell (Top panel). Whereas, Notch ligand and receptor
expressed on the same cell results in cis-inhibition of Notch signaling in signal sending
cell (Bottom panel).
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β-actin

Figure 12: Expression of Jag-1 in LTK-P, LTK-Jag-1, and SKBr3 cells.
LTK-Parental (LTK-P) and LTK-Jagged-1 (LTK-Jag-1) fibroblast cells were harvested
and protein levels of Jagged-1 (Jag-1) were detected by Western blot analysis (left panel).
SKBr3 cells were transfected with 5 µL of either scrambled control siRNA (SCBi) or
Jag-1 siRNA (Jag-1i). Protein levels of Jag-1 were detected by Western blot analysis after
48 hours (right panel). β-actin was used as an endogenous control.
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To examine if Jagged-1 is cis-inhibiting Notch, we co-cultured mouse fibroblast cells
expressing no ligand (LTK-Parental) with SKBr3 cells transfected with a scrambled
siRNA (SCBi) or Jagged-1 siRNA (Jag-1i) (Figure 13A). Knockdown of Jagged-1 by
Jag-1i up-regulated mRNA levels of canonical Notch target genes, Hes-1 by 4-fold and
Deltex-1 by 13-fold compared to SCBi suggesting that Jagged-1 may be inhibiting Notch
activation through a cis mechanism in ErbB-2 positive breast cancer cells (Figure 14).
Nevertheless, the up-regulation of Hes-1 and Deltex-1 mRNA may be in part due to
compensatory up-regulation of other Notch ligands upon Jagged-1 down-regulation.
3. Jagged-1 restores Notch activity via trans-activation.
Notch ligands including Jagged-1 have the ability to activate Notch in trans.
Therefore, we examined what happens to Notch activity when we force trans-activation
in the co-culture experiment. SKBr3 cells transfected with SCBi or Jag-1i were cocultured with mouse fibroblast cells overexpressing Jagged-1 (LTK-Jag-1).

Notch

activity was measured in SKBr3 cells after sorting for ErbB-2 positive breast cancer cells
(Figure 13B) and performing Real-time PCR to measure Hes-1 and Deltex1 transcripts.
Providing SKBr3 cells with abundant Jagged-1 in trans demonstrated an increase in
mRNA levels of Hes-1 by 3-fold (Figure 14A) but had no change in Deltex-1 mRNA
levels (Figure 14B). Moreover, Jag-1i did not further induce Hes-1 mRNA levels (Figure
14A) but relieved cis-inhibition of Deltex-1 and increased its mRNA levels by 16-fold
(Figure 14B). These results indicate that Hes-1 is down-regulated by Jagged-1 mediated
cis-inhibition of Notch which can be rescued by providing Jagged-1 in trans, suggesting
that Jagged-1 is regulating Hes-1 gene expression.
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Figure 13: Schematics of Co-culture Experiment.
(A.) Mouse fibroblast cells expressing no ligand (LTK-Parental or P) were co-cultured
with SKBr3 cells transfected with a scrambled siRNA (SCBi) or Jagged-1 siRNA (Jag1i). (B.) SKBr3 cells transfected with SCBi or Jag-1i were co-cultured with mouse
fibroblast cells expressing Jagged-1 (LTK-Jag-1). Notch activity in sorted ErbB-2
positive breast cancer cells was measured using Real-time PCR.
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Figure 14: Jag-1 Cis-Inhibits and Trans-Activates Notch.
SKBr3 cells were plated at a density of 3.5x106 in 10 cm2 plates. The following day,
SKBr3 cells were transfected with 5 µL of either scrambled siRNA (SCBi) or Jagged-1
siRNA (Jag-1i). After 30 hours, the cells were co-cultured with mouse fibroblast LTK
cells expressing either no ligand (LTK-Parental) or Notch ligand, Jagged-1 (LTK-Jag-1).
Eiteen hours later, the cells were trypsinized and ErbB-2 positive cells were sorted by
FACS and relative mRNA levels of Hes-1 (A.) and Deltex-1 (B.) were measured using
Real-time PCR. Human RPL13A (hRPL13A) was measured as a loading control and
used for normalization. Real-time PCR results show means of fold changes between Jag1i/PBS and SCBi/PBS in LTK-Parental and LTK-Jag-1 cells. Statistical significance was
calculated using ANOVA for multiple comparisons using Prism Pad. * denotes
statistically significant differences between SCBi/PBS treated LTK-Parental vs LTK-Jag1. ** denotes statistically significant differences between Jag-1i/PBS vs SCBi/PBS in
LTK-Parental cells. *** denotes statistically significant differences between Jag-1i/PBS
vs SCBi/PBS in LTK-Jag-1 cells.
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However, Deltex-1 is strongly cis-inhibited by Jagged-1 which was relieved only with
Jag-1i, suggesting that Deltex-1 gene expression is not induced by Jagged-1. Finally, the
results so far suggest that Jagged-1 is a cis-inhibitor of Notch activity.
4. Trastuzumab promotes Jagged-1-mediated trans-activation of Notch.
The previous results suggest that Jagged-1 cis-inhibits Notch in ErbB-2 positive
breast cancer cells (Figure 14). To address the hypothesis that ErbB-2 inhibits Notch
activity by promoting Jagged-1-mediated cis-inhibition of Notch, we treated the cocultured cells with trastuzumab and asked whether inhibiting ErbB-2 reverses Jagged-1mediated Notch inhibition. In the presence of LTK-Parental cells, trastuzumab treatment
alone induced Notch activity as demonstrated by an increase in mRNA levels of Hes-1 by
4-fold and Deltex-1 by 13-fold compared to SCBi/PBS control. Furthermore, Jagged-1
knockdown had little effect on trastuzumab-mediated increase in Hes-1 or Deltex1
(Figure 15). These results indicate that ErbB-2 is potentially limiting trans-activation of
Notch.
To specifically address the question that ErbB-2 is promoting Jagged-1 mediated cisinhibition, SKBr3 cells were co-cultured with LTK-Jagged-1 cells and treated with
trastuzumab. If ErbB-2 is specifically promoting Jagged-1-mediated cis-inhibition of
Notch, then inhibiting ErbB-2 should activate Notch targets to the same degree as
Jagged-1 knockdown. However, the results do not support that hypothesis.
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Figure 15: Role of ErbB-2 in Jag-1 Mediated Cis-Inhibition of Notch.
SKBr3 cells were plated at a density of 3.5x106 in 10 cm2 plates. The following day,
SKBr3 cells were transfected with 5 µL of either scrambled siRNA (SCBi) or Jagged-1
siRNA (Jag-1i). After 30 hours, the cells were co-cultured with mouse fibroblast LTK
cells expressing either no ligand (LTK-Parental) or Jagged-1 (LTK-Jag-1). Concurrently,
the co-culture was treated with PBS or trastuzumab (20 µg/mL). Eiteen hours later, the
cells were trypsinized and stained using PE-conjugated human-ErbB-2 antibody. ErbB-2
positive cells were sorted by FACS and relative mRNA levels of Hes-1 (A.) and Deltex-1
(B.) was measured using Real-time PCR. Human RPL13A (hRPL13A) was measured as
a loading control and used for normalization. Real-time PCR results show means of fold
changes between treatments compared to SCBi/PBS control in LTK-Parental and LTKJag-1 cells. Statistical significance was calculated using ANOVA for multiple
comparisons using Prism Pad. # denotes statistically significant differences between
SCBi/Trast vs SCBi/PBS in LTK-Parental and LTK-Jag-1 cells.
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Regardless of whether ErbB-2 is inhibited or not, Jagged-1 knock down was sufficient to
relieve the cis-inhibitory signal on Hes-1 and more significantly on Deltex-1 mRNA
levels by 8-fold when co-cultured with LTK-Jagged-1 cells (Figure 15). These data
together imply that Jagged-1 is a potent cis-inhibitor of Notch activity in ErbB-2 positive
breast cancer. However, ErbB-2’s role in Jagged-1-mediated cis-inhibition of Notch is
not clear. More importantly, the results do support the conclusion that ErbB-2 most
probably inhibits Jagged-1–Notch trans-activation.
5. Cis-inhibition of Notch by Jagged-1 might be a general mechanism in breast
cancer cells.
Findings from figure 14 showed for the first time that Jagged-1 could be a cisinhibitor of Notch-1 in ErbB-2 positive breast cancer cells, SKBr3. To determine whether
Jagged-1-mediated cis-inhibition of Notch activity is a common mechanism in other
subtypes of breast cancer cells. MCF-7 (Luminal A), SKBr3 (ErbB-2+), BT474 HS
(Luminal B), BT474 HR (Luminal B), and MDA-MB-231 (triple-negative) cells were
lysed and Jagged-1, Notch-1, and its target gene, Hes-1, protein levels were measured by
Western blot. MDA-MB-231 cells express the highest Jagged-1 protein levels followed
by MCF-7, SKBr3, BT474 HS and then BT474 HR cells (Figure 16). More importantly,
the data indicated an inverse correlation between levels of Jagged-1 protein and Notch
activity as measured by Hes-1 protein levels. For example, MDA-MB-231, MCF-7, and
SKBr3 cells expressing the highest levels of Jagged-1 protein had the lowest Hes-1
protein levels (Figure 16). Whereas, BT474 HS and HR cells expressing low levels of
Jagged-1 protein showed the highest Hes-1 protein levels (Figure 16). This result showed
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that the inverse correlation between Jagged-1 and Hes-1 was not limited to breast cancer
cell lines harboring a gene amplification for ErbB-2 (Figure 16).
Taken together, these results suggest that ErbB-2 inhibits Jagged-1-mediated transactivation of Notch in SKBr3 cells. However, Jagged-1-mediated cis-inhibition of Notch
activity could be ErbB-2 independent.

MDA-MB-231

BT474 HR

BT474 HS

SKBr3

MCF-7

97

Jag-1
Hes-1
β-actin
Notch-1
β-actin

Figure 16: Protein Levels of Jag-1 in Breast Cancer Subtypes.
MCF-7, SKBr3, BT474 HS, BT474 HR and MDA-MB-231 cells were plated and total
protein levels of Jagged-1 (Jag-1) was detected by Western blot analysis. 30 µg of total
protein lysate was loaded onto each lane of gel as described in the materials and methods.
β-actin was measured as an endogenous control.
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Aim 1B. ErbB-2 Limits the Expression and/or Association of Jagged-1 with Mib-1 to
Inhibit Trans-Activation of Notch.
Our results showed that Jagged-1 and Notch-1 co-localized in ErbB-2 positive breast
cancer cells (Figure 17). However, upon trastuzumab treatment, Notch-1 and Jagged-1
were completely separated with Notch-1 localized throughout the cell and Jagged-1
concentrated near cell-cell junctions (Figure 17). Together, these data suggest that ErbB2 overexpressing breast cancer cells trap both Jagged-1 and Notch-1 in sub-membraneous
compartments such as early endosomes. However, trastuzumab releases Jagged-1 to the
cell surface, making Jagged-1 available for trans-activation of Notch signaling via ligandreceptor interaction and possibly in the correct orientation to pull the NEC into the ligand
expressing cell. Osipo et al and data from Figure 15 demonstrated an increase in Notch
activity in response to trastuzumab (Osipo et al., 2008) and Notch could be activated in
trans. Two E3 ubiquitin ligases, Mindbomb-1 (Mib-1) and Neuralized-1 (Neur), have
been shown to be essential for ligand-mediated trans-activation of Notch as discussed in
chapter II. In order for Jagged-1 to be endocytosed, Mib-1 mono-ubiquitylates the Cterminal tail of Jagged-1 which then generates the pulling force necessary for endocytosis
of ligand - NEC into the signal sending cell (De Renzis et al., 2006; Deblandre et al.,
2001; Lai et al., 2001; Le Borgne and Schweisguth, 2003a; Pavlopoulos et al., 2001).
Knockout studies in vertebrates revealed that, deficiency of Mib-1, but not Neur,
abrogates Notch signaling (Barsi et al., 2005; Koo et al., 2005). Thus, the goal of aim 1B
is to determine if ErbB-2 by regulating expression and/or association of Mib-1 with
Jagged-1 inhibits Notch activity.
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Figure 17: Localization of Notch-1 and Jag-1 protein.
SKBr3 cells were grown on glass slides for 48 hours and treated with 20 µg/mL IgG or
trastuzumab for 3 hours. At the end of the treatment, cells were rinsed twice in PBS and
fixed in cold methanol. Staining for Notch-1 was performed using 1 μg/mL of the rabbit
anti-human Notch-1 antibody and 20 μg/mL of AlexaFluor 555 labelled anti-rabbit IgG.
Staining for Jagged-1 (Jag-1) was performed using 1 μg/mL of goat anti-human Jag-1
antibody and 20 μg/mL of AlexaFluor 488 labelled anti-goat IgG. Confocal
immunofluorescence microscopy was performed to detect Jag-1 (green) and Notch-1
(red). The figure is a representative of three similar independent experiments.
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1. ErbB-2 does not regulate total Mib-1 protein levels.
If Mib-1 is critical for Jagged-1 mediated trans-activation of Notch-1, then ErbB-2 by
decreasing Mib-1 protein levels could be inhibiting Notch. Thus, we asked the question:
Does ErbB-2 decrease Mib-1 protein levels? To address this question, SKBr3 cells were
treated with trastuzumab or lapatinib and MCF-7/Neo, MCF-7/HER-2, and MCF-7/HRG1 cells with trastuzumab for 6 hours and Mib-1 protein levels were measured by Western
blotting. Our results showed that expression levels of Mib-1 protein was relatively
unaffected by ErbB-2 inhibitors (Figure 18). Further, Mib-1 is expressed in breast cancer
cells, MCF-7 (Luminal A), SKBr3 (ErbB-2+), BT474 HS (Luminal B), BT474 HR
(Luminal

B),

and

MDA-MB-231

(triple-negative)

(Figure

19).

Therefore,

downregulation of Mib-1 is not a mechanism by which ErbB-2 inhibits Notch activation.
2. ErbB-2 limits the association of Mib-1 with Jagged-1.
While our data demonstrated that ErbB-2 does not regulate Mib-1 protein, it was
important to determine whether ErbB-2 might be limiting the association of Mib-1 with
Jagged-1 to prevent endocytosis of Jagged-1. Therefore, we asked the question: Does
ErbB-2 restrict the interaction of Mib-1 with Jagged-1? To address this question, Jagged1 was immunoprecipitated from SKBr3 cells treated with trastuzumab or lapatinib and
Western blotting was performed to detect Jagged-1 and Mib-1 proteins.

Co-

immunoprecipitation demonstrated that Jagged-1 was in complex with Mib-1 upon
inhibition of ErbB-2 by either trastuzumab or lapatinib (Figure 20). From these results,
we can conclude that ErbB-2 restricts a critical interaction between Jagged-1 and Mib-1.
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Figure 18: Expression of E3 Ubiquitin Ligase, Mib-1, in Breast Cancer Cells.
SKBr3 (A.) and MCF-7 (B.) breast cancer cells were plated at a density of 5x105 per well
of a 6-well plate. (A.) The following day, the cells were treated with trastuzumab (10
µg/mL in A. or 20 µg/mL in B.) or lapatinib (2 µM in A.) for 6 hours and total protein
levels of Mib-1 was measured by Western blotting. 30 µg of total protein lysate was
loaded onto each lane of gel. β-actin was measured as an endogenous control.
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Figure 19: Protein Levels of Mib-1 Among Breast Cancer Subtypes.
MCF-7, SKBr3, BT474 HS, BT474 HR and MDA-MB-231 cells were plated and total
protein levels of Mib-1 was detected by Western blot analysis. 30 µg of total protein
lysate was loaded onto each lane of gel as described in the materials and methods. βactin was measured as an endogenous control.
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Figure 20: Co-Immunoprecipitation of Endogenous Jag-1.
SKBr3 cells were treated with PBS, trastuzumab (10 µg/mL; trast), DMSO or lapatinib (1
µm; Lap) for 6 hours. Lysates were subjected to immunoprecipitation using Jagged-1
(Jag-1) or its isotype IgG control. Subsequent Western blot analysis was performed and
Jag-1 and Mib-1 protein levels were detected. The figure shows three similar
independent experiments.
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3. ErbB-2 by limiting an association between Mib-1 and Jagged-1 decreases Jagged-1
ubiquitylation.
Jagged-1 is a substrate for Mib-1’s ubiquitin ligase activity. To determine if the
increased association between Jagged-1 and Mib-1 in response to ErbB-2 inhibitors
resulted in an increase in Jagged-1 ubiquitylation, SKBr3 cells were transfected with a
Flag-Ub expression construct and treated with DMSO or lapatinib for 30 minutes. A
Jagged-1 IP to detect its ubiquitylation was performed. The data showed that Jagged-1 is
ubiquitylated upon treatment with lapatinib (Figure 21).
4. Mib-1 is the E3 ubiquitin ligase that ubiquitylates Jagged-1.
Because Mib-1 is in complex with Jagged-1 and Jagged-1 is ubiquitylated upon
inhibition of ErbB-2, we asked the question: Is Mib-1 the E3 ligase that ubiquitylates
Jagged-1? To answer this question, SKBr3 cells were co-transfected with scrambled
control siRNA (SCBi) or Mib-1 siRNA (Mib-1i) and the Flag-Ub expression construct
for a total of 48 hours.

Cells were then treated with DMSO or lapatinib for 30 minutes

and Jagged-1 was immunoprecipitated and Western blotting was performed to detect
Jagged-1, Ubiquitin, and Mib-1 proteins. Co-immunoprecipitation confirmed that Mib-1
is in complex with Jagged-1 and that Jagged-1 is ubiquitylated in response to lapatinib.
More importantly, Mib-1i decreased lapatinib-induced ubiquitylation of Jagged-1 (Figure
22).
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Figure 21: Co-Immunoprecipitation of Endogenous Jag-1 and Associated Ub.
SKBr3 cells were treated with DMSO or lapatinib (1 µm; Lap) for 15, 30, or 60 minutes.
Lysates were subjected to immunoprecipitation using Jagged-1 (Jag-1) or its isotype IgG
control. Subsequent Western blot analysis detected immunoprecipitated Jag-1 and Ub
levels. Total Jag-1 and Ub levels in protein lysates were also detected by Western blot
analysis. β-actin was measured as an endogenous control. Figure 22A shows two similar
independent experiments.
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Figure 22: Mib-1 is the E3 Ubiquitin Ligase for Jag-1.
SKBr3 cells were transfected with Flag-Ub and either scrambled siRNA (SCBi) or Mib-1
siRNA (Mib-1i). At the completion of 48 hours, cells were treated with DMSO or
lapatinib (1 µm; Lap) for 30 minutes. Lysates were subjected to immunoprecipitation
using Jagged-1 (Jag-1) or its isotype IgG control. Subsequent Western blot analysis
detected immunoprecipitated Jag-1, Mib-1, and Ub levels. Total Jag-1, Mib-1, Flag levels
in protein lysates were also detected by Western blot analysis. β-actin was measured as an
endogenous control.
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5. Mib-1 knockdown abrogates lapatinib-induced increase in Notch activity.
If lapatinib promotes trans-activation of Notch and Mib-1 is critical for Jagged-1
mediated trans-activation of Notch, then Mib-1 should be required for lapatinib induced
activation of Notch. Hence, we asked the question: Is Mib-1 necessary for trastuzumab
or lapatinib-induced activation of Notch? In order to investigate the role of Mib-1 on
Notch activity, the effect of Mib-1 siRNA on the expression of Hes-1 protein levels was
measured. SKBr3 cells were transfected with either scrambled control siRNA (SCBi) or
Mib-1 siRNA (Mib-1i) and treated with DMSO or lapatinib for 6 hours. As measured by
Western blot analysis, Mib-1 protein levels were decreased upon Mib-1 knocked down
(Figure 23). Either trastuzumab or lapatinib treatment increased Hes-1 protein (Figure
23). More importantly, Mib-1i decreased the trastuzumab or lapatinib-induced increase
in Hes-1 protein (Figure 23), suggesting that Mib-1 is necessary for Notch activation
when ErbB-2 is inhibited.
Taken together, these results indicate that ErbB-2 limits Mib-1’s association and
subsequent ubiquitylation of Jagged-1 and fails to generate a competent ligand required
for trans-activation of Notch.
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Figure 23: Mib-1 Abrogates Trast or Lap Mediated Activation of Notch.
SKBr3 cells were transfected with either scrambled siRNA (SCBi) or Mib-1 siRNA
(Mib-1i). At the completion of 48 hours, cells were treated with DMSO or lapatinib (1
µm) for 6 hours. Total protein levels of Mib-1 and Hes-1 were detected by Western blot
analysis. 30 µg of total protein lysate was loaded onto each lane of gel as described in
the materials and methods. β-actin was measured as an endogenous control.
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Aim 1C. Identify the Downstream Factors of ErbB-2 Signaling that Regulates Jagged1 Activity.
ErbB-2 is a receptor tyrosine kinase which when active initiates a series of
downstream phosphorylation events that regulate cell proliferation and survival (Figure
2). To determine the mechanism by which ErbB-2 regulates the Jagged-1 and Mib-1
association, the protein sequences of Jagged-1 and Mib-1 were scanned using Prosite and
several putative PKCα binding sites (Figure 24) were identified. Moreover, it has been
demonstrated that ErbB-2 up-regulates c-Src which in turn activates PKCα (Tan et al.,
2006). Additionally, PKCα is necessary for ErbB-2 driven cancer cell invasion (Tan et
al., 2006). The goal of this aim 1C is to elucidate whether ErbB-2 through PKCα inhibits
Jagged-1 or Mib-1 to restrict the association and Notch activation (Figure 25).
1. ErbB-2 promotes an association between PKCα with Jagged-1.
PKCα is a critical downstream mediator of ErbB-2.

In order to determine the

mechanism by which ErbB-2 limits Jagged-1 and Mib-1 association, we asked the
question: Does ErbB-2 promote an association of PKCα and Jagged-1? SKBr3 cells
were treated with DMSO or lapatinib for 30 minutes and Jagged-1 was
immunoprecipitated and Western blotting was performed to detect PKCα, Ubiquitin,
Mib-1, and Jagged-1 proteins. Co-immunoprecipitation demonstrated that Jagged-1 was
in complex with PKCα when ErbB-2 was active (Figure 26). The results confirmed that
upon lapatinib treatment, Mib-1 is in complex with Jagged-1 which leads to Jagged-1
ubiquitylation (Figure 26).
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Figure 25: Hypothesis of Specific Aim 1C.
ErbB-2 up-regulates c-Src which in turn activates PKCα. ErbB-2 limits association of
Jagged-1 (Jag-1) and Mib-1 and inhibits Notch activity. Therefore, we hypothesize that
ErbB-2 through PKCα inhibits Jag-1 or Mib-1 to restrict their association and Notch
activation.
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Figure 26: ErbB-2 Promotes Association of PKCα and Jag-1.
SKBr3 cells were treated with DMSO or lapatinib (1 µm; Lap) for 30 minutes. Lysates
were subjected to immunoprecipitation using Jagged-1 (Jag-1) or its isotype IgG control.
Subsequent Western blot analysis was performed and Ub, PKCα, Mib-1, and Jag-1
protein levels were detected. Heavy chain IgG was detected as an endogenous loading
control for immunoprecipitation. A., B., and C. represent Western blot images from three
independent but similar experiments.
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2. PKCα is required for inhibition of Notch activity.
ErbB-2 promotes an association of PKCα with Jagged-1 and PKCα is necessary for
ErbB-2 driven malignancies, thus, we asked the question: Is PKCα required for ErbB-2mediated inhibition of Notch activity? To investigate the role of PKCα on Notch activity,
the effect of PKCα siRNA on the expression of canonical Notch target genes such as
Hes-1 and Hey-1 was examined. SKBr3 cells were transfected with either scrambled
control siRNA (SCBi) or PKCα siRNA (PKCαi) for 48 hours. As measured by Real-time
PCR and Western blot analysis, PKCα mRNA (Figure 27A) and protein (Figure 27B)
levels were decreased upon PKCα knockdown. With the decrease in PKCα transcript and
protein, the data showed an increase in transcript (Figure 27A) and protein (Figure 27B)
levels of Hes-1, respectively. In addition, another Notch target, Hey-1 protein levels
were increased upon PKCα knockdown (Figure 27B).
Taken together, these results indicate that ErbB-2 facilitates a PKCα-Jagged-1
association to limit Mib-1-mediated ubiquitylation of Jagged-1 and subsequent transactivation of Notch.
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Figure 27: Knockdown of PKCα Activates Notch-1 Target Genes.
SKBr3 cells were transfected with either scrambled siRNA (SCBi) or PKCα siRNA
(PKCαi) for 72 hours. (A.) Relative mRNA levels of Hes-1 and PKCα were measured
using Real-time PCR. Human RPL13A (hRPL13A) was measured as a loading control
and used for nomalization. (B.) Protein levels of PKCα, Hes-1, and Hey-1 were
detected by Western blot analysis after 48 hours. β-actin was used as an endogenous
control.
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SPECIFIC AIM 2
Establish the therapeutic efficacy of targeting Jagged-1 in vitro and Notch signaling in
vivo in ErbB-2 positive breast cancer.

Rationale
Notch signaling is critical for cell fate determination (Politi et al., 2004) and ErbB-2
is critical for proliferation and survival (Citri et al., 2003). Notch and ErbB-2 pathways
when deregulated independently can lead to breast cancer and poor survival (Slamon et
al., 1987; Slamon et al., 1989; Stylianou et al., 2006). We have identified a novel
crosstalk between ErbB-2 and the Notch pathway, where ErbB-2 inhibits Notch activity,
and trastuzumab increases Notch activity.

Moreover, preliminary data from our lab

showed that either Notch-1 siRNA or a pan-Notch inhibitor, GSI, enhanced sensitivity to
trastuzumab in sensitive cells or reversed trastuzumab resistance in vitro (Osipo et al.,
2008).

In addition, results from specific aim 1 suggested that ErbB-2 mediates its

inhibitory effects on Notch activity by limiting Jagged-1 and Mib-1 association. Thus,
targeting of Notch receptors by a GSI or Jagged-1 by siRNA could provide a novel
therapeutic strategy to enhance the efficacy of anti-ErbB-2 therapy or possibly reverse
trastuzumab resistance.

The goal of specific aim 2 is to address the following

hypotheses:
Aim 2A. Establish whether targeting Jagged-1 by siRNA increases the efficacy
of trastuzumab in SKBr3 and BT474 cells.
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Aim 2B. Establish whether a combination of GSI plus trastuzumab prevents
tumor growth.
Aim 2C. Establish whether a GSI in combination with trastuzumab reverses
drug resistance.
Aim 2A. Establish whether targeting Jagged-1 by siRNA increase the efficacy of
trastuzumab in inhibiting the growth of SKBr3 and BT474 trastuzumab sensitive cells
and restored sensitivity to trastuzumab in BT474 trastuzumab resistant cells.
To understand the biological significance of the crosstalk between ErbB-2 and Notch
signaling on growth of ErbB-2 positive breast cancer cells, we asked the question: Does
knockdown of Jagged-1 enhances the growth inhibitory effects of trastuzumab on SKBr3,
BT474 HS, and BT474 HR cells? Cell cycle analysis using Propidium Iodide was
performed to determine where in the cell cycle the combination of trastuzumab plus a
Jagged-1 siRNA inhibits growth of SKBr3 and BT474 cells.
1. Dual blockade of Jagged-1 and ErbB-2 induces a growth arrest in SKBr3 cells.
Trastuzumab treatment alone showed a 17% increase in the number of SKBr3 cells
in the G1 phase of the cell cycle compared to IgG control. Consequently, trastuzumab
decreased the number of cells in S phase by 33% (Figure 28). This result demonstrates
that trastuzumab is functioning as expected to inhibit growth of ErbB-2 positive SKBr3
cells. Interestingly, Jagged-1 knockdown alone showed a similar increase in the G1 phase
and a decrease in the S phase of the cell cycle compared to trastuzumab (Figure 28).
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Figure 28: Trastuzumab plus Jagged-1 siRNA Induces a Growth Arrest.
SKBr3 cells were transfected with scrambled control siRNA (SCBi) or Jagged-1 siRNA
(Jag-1i) alone or were treated with IgG control or Trastuzumab (Trast) for 48 hours. Cell
cycle analysis using Propidium Iodide was performed by flow cytometry. Mean
percentage of cells in each experiment were plotted. Statistical significance was
determined by performing ANOVA analysis. The error bars represent standard
deviations of the mean for three independent experiments. * denotes statistically
significant differences between trastuzumab alone and trastuzumab plus Jagged-1 siRNA.
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However, the combination of Jagged-1 knockdown and trastuzumab treatment resulted
in a 29% increase in the G1 phase and 50% reduction in the S phase of the cell cycle
compared to trastuzumab alone (Figure 28). These results indicate that both Jagged-1
and ErbB-2 are critical for the proliferation of SKBr3 cells.
2. Blockade of Jagged-1 enhances sensitivity to trastuzumab or reverses trastuzumab
resistance.
To address the question whether Jagged-1 siRNA increases sensitivity to
trastuzumab, we chose BT474 HS (sensitive to trastuzumab) cells.

Trastuzumab

treatment alone showed a 75% increase in the number of BT474 HS cells in the G1 phase
of the cell cycle compared to IgG control. Consequently, trastuzumab decreased the
number of cells in S phase by 50% (Figure 29A). Interestingly, Jagged-1 knockdown
alone showed a 50% increase in the G1 phase and a 38% decrease in the S phase of the
cell cycle compared to IgG control (Figure 29A). However, the combination of Jagged-1
knockdown and trastuzumab treatment resulted in a 29% increase in the G1 phase and
65% reduction in the S phase of the cell cycle compared to trastuzumab alone (Figure
29A). These results indicate that Jagged-1 knockdown further sensitized BT474 HS cells
to trastuzumab.
To address the question whether Jagged-1 siRNA reverses trastuzumab resistance,
BT474 HR (resistant to trastuzumab) were used. Trastuzumab did not change the cell
cycle distribution of resistant cells (Figure 29B). As demonstrated previously, BT474
HR cells are resistant to trastuzumab.
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Figure 29: Jagged-1 siRNA Sensitize BT474 HS Cells to Trastuzumab and
Restore Sensitivity of BT474 HR Cells to Trastuzumab.

BT474 HS (A.) and BT474 HR (B.) cells were transfected with scrambled control siRNA
(SCBi) or Jagged-1 siRNA (Jag-1i) alone or were treated with IgG control or
Trastuzumab (Trast) for 48 hours. Cell cycle analysis using Propidium Iodide was
performed by flow cytometry. Mean percentage of cells in each experiment were plotted.
Statistical significance was determined by performing ANOVA for multiple comparisons.
The error bars represent standard deviations of the mean for three independent
experiments. * denotes statistically significant differences between trastuzumab alone
and trastuzumab plus Jagged-1 siRNA. ** denotes statistically significant differences
between trastuzumab alone and SCBi/IgG. *** denotes statistically significant
differences between Jagged-1 siRNA alone and SCBi/IgG.
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Interestingly, Jagged-1 knockdown alone showed a 50% increase in the G1 phase and a
33% decrease in the S phase of the cell cycle compared to IgG control (Figure 29B).
However, the combination of Jagged-1 knockdown and trastuzumab treatment resulted in
a 56% increase in the G1 phase and 50% reduction in the S phase of the cell cycle
compared to trastuzumab alone (Figure 29B).

These results indicate that Jagged-1

knockdown reverses resistance of BT474 HR cells to trastuzumab.
3. Dual inhibition of Jagged-1 and ErbB-2 induces apoptosis of SKBr3 and BT474
breast cancer cells.
Does dual inhibition using both Jagged-1 knockdown and trastuzumab induce
apoptosis in SKBR3, BT474 HS, and BT474 HR cells? To address this question, flow
cytometry using Annexin-V/Propidium Iodide dye was performed to detect early
apoptotic cells.
In SKBr3 cells, trastuzumab treatment alone significantly increased the number of
Annexin-V positive cells by 110% compared to SCBi/IgG (Figure 30). Jagged-1 siRNA
alone increased the number of Annexin-V positive cells by 265% compared to SCBi/IgG
(Figure 30). Importantly, the combination of Jagged-1 knockdown and trastuzumab
treatment increased the number of Annexin-V positive cells by 133% compared to
trastuzumab (Figure 30). These results, taken together with the cell cycle data, suggest
that both Jagged-1 and ErbB-2 activities are critical for cell proliferation and survival of
SKBr3 breast cancer cells.
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Figure 30: Trastuzumab plus a Jagged-1 siRNA Induced Apoptosis in SKBr3
Cells.
SKBr3 cells were transfected with scrambled control siRNA (SCBi) or Jagged-1 siRNA
(Jag-1i) alone or were treated with IgG or trastuzumab (Trast) for 48 hours. Annexin-V
staining was performed by using flow cytometry. The mean percentage and standard
deviation of cells in each experiment were plotted. Statistical significance was
determined by performing ANOVA for multiple comparisons. The error bars represent
standard deviations of the mean for three independent experiments.. ** denotes
statistically significant differences between trastuzumab alone and SCBi/IgG. ***
denotes statistically significant differences between Jagged-1 siRNA alone and
SCBi/IgG. **** denotes statistically significant differences between trastuzumab plus
Jagged-1 siRNA and SCBi/IgG.
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In BT474 HS cells, trastuzumab treatment alone increased the number of Annexin-V
positive cells by 150% compared to SCBi/IgG (Figure 31A). Jagged-1 siRNA alone
increased the number of Annexin-V positive cells by 175% compared to SCBi/IgG
(Figure 31A). Importantly, the combination of Jagged-1 knockdown and trastuzumab
treatment increased the number of Annexin-V positive cells by 40% compared to
trastuzumab treatment alone (Figure 31A). These results, taken together with the cell
cycle data, suggest that Jagged-1 decreases efficacy of trastuzumab and confers a
protection from apoptosis in BT474 HS cells.
In BT474 HR cells, trastuzumab treatment alone showed a similar increase in the
number of Annexin-V positive cells compared to SCBi/IgG (Figure 31B). This result
further confirmed that BT474 HR cells are resistant to trastuzumab. A Jagged-1 siRNA
alone was sufficient to increase apoptosis by 125% compared to SCBi/IgG (Figure 31B).
Importantly, the combination of Jagged-1 knockdown and trastuzumab treatment
increased the number of Annexin-V positive cells by 140% compared to trastuzumab
control (Figure 31B).
These results, taken together suggested that inhibiting Jagged-1 could increase the
sensitivity of ErbB-2 positive breast cancer cells to trastuzumab and reverse resistance.
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Figure 31: Trastuzumab plus a Jagged-1 siRNA Induced Apoptosis in BT474 HS
and HR Cells.

BT474 HS (A.) and BT474 HR (B.) cells were transfected with scrambled control siRNA
(SCBi) or Jagged-1 siRNA (Jag-1i) alone or were treated with IgG or trastuzumab (Trast)
for 48 hours. Annexin-V staining was performed by using flow cytometry. The mean
percentage and standard deviation of cells in each experiment were plotted. Statistical
significance was determined by performing ANOVA for multiple comparisons. The error
bars represent standard deviations of the mean for three independent experiments. *
denotes statistically significant differences between trastuzumab alone and trastuzumab
plus Jagged-1 siRNA. *** denotes statistically significant differences between Jagged-1
siRNA alone and SCBi/IgG.
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Aim 2B. Establish whether a combination of GSI plus trastuzumab prevents tumor
growth in vivo.
The data from cell cycle and Annexin-V analyses suggested that Jagged-1 might play
a novel role in resistance to trastuzumab, which could be prevented or reversed by
inhibiting Jagged-1. Because of the lack of a pharmacological means to inhibit Jagged-1
in vivo, we inhibited Notch using γ-secretase inhibitors (GSIs) which block the final
cleavage step of Notch preventing release of NICD. BT474 breast cancer cells contain an
ErbB-2 gene amplification and are sensitive to trastuzumab. Osipo et al showed that
ErbB-2 overexpression suppresses Notch-1 activity, thus BT474, which has an
amplification and overexpression of ErbB-2, exhibit low Notch-1 activity (Osipo et al.,
2008).
1. Trastuzumab plus a γ-secretase inhibitor (GSI) prevents or reduces tumor
recurrence.
Breast tumor xenografts were generated using BT474 trastuzumab sensitive cells
using athymic, nude mice. Growth of tumors was measured in response to Vehicle,
trastuzumab, LY 411,575 or MRK-003 GSI, or trastuzumab plus GSI. The results from
two independent studies showed that trastuzumab treatment almost completely inhibited
the tumor growth of BT474 breast tumor xenografts with approximately 90-100% of
tumors regressing to undetectable levels (Figure 32A and 32B). GSI treatment of tumors
alone using LY 411,575 (Figure 32A) or MRK-003 (Figure 32B) had no statistically
significant effect on tumor growth during the treatment phase of the study compared to
Vehicle control. Moreover, GSI treatment of tumors using LY 411,575 (Figure 32A) or
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MRK-003 (Figure 32B) in combination with trastuzumab had no significant effect on
tumor growth compared to trastuzumab alone.
There is significant evidence of enhanced Notch signaling in tumor initiating or
putative breast cancer stem cells (Grudzien et al., 2010; Harrison et al., 2010; Pannuti et
al., 2010). As these cells are suggested to be responsible for tumor recurrence, we
discontinued treatment and measured tumor recurrence in mice where tumors were no
longer detectable using the Vevo 770 Ultrasound Imager. During the recurrence phase of
the study, we detected significant tumor re-growth at week 14 (Figure 32A) and 25
(Figure 32B) for the previously trastuzumab-treated mice only. In contrast, mice
previously treated with the combination of trastuzumab plus LY 411,575 GSI did not
display tumor re-growth until week 25 and their tumors were significantly smaller (0.12
cm2 versus 0.87 cm2 for the trastuzumab alone arm, p<.001) (Figure 32A). Furthermore,
no recurrent tumors were detectable in mice previously treated with the combination of
trastuzumab plus MRK-003 GSI (p<.0001) (Figure 32B). Figure 33 is a Kaplan-Meier
analysis of log-rank (Mantel-Cox) test for the rate of tumor recurrence post-treatment. In
both studies, approximately 40% of mice previously-treated with trastuzumab alone
displayed tumor recurrence at 40 weeks. In contrast, only 10% of mice displayed tumor
recurrence in the trastuzumab plus LY 411,575 GSI group and 0% of mice displayed
tumor recurrence in the trastuzumab plus MRK-003 group (Figure 33). All mice were
sacrificed at the end of 40 weeks and it was confirmed via surgery that tumors were
completely absent in the trastuzumab plus MRK-003 group.
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Figure 32: Trastuzumab plus a -Secretase Inhibitor Prevents or Reduces Tumor
Recurrence.
Fifty six ovariectomized, athymic nude mice were injected with 5 x 106 ErbB-2 gene
amplified BT474 cells into both mammary fat pads. Once tumors grew to a mean tumor
cross sectional area of 0.20 cm2, mice were randomized and treated with vehicle (100L
sterile PBS injected i.p. 1 day/week and 200L 2% carboxymethylcellulose), 10mg/Kg
trastuzumab in 100L PBS injected i.p. once weekly, 5mg/Kg LY 411,575 GSI (A) or
100mg/Kg MRK-003 GSI (B) in 200L 2% carboxymethylcellulose, fed by oral gavage;
three days on, 4 days off, or trastuzumab plus LY 411,575 GSI or MRK-003 GSI. Tumor
area was measured weekly for up to 12 or 19 weeks using Vernier calipers. After the
treatments were stopped, tumor recurrence was monitored up to 105 days or 98 days in
mice that specifically showed complete tumor regression (A and B). The graphs from A
and B show mean tumor cross sectional area [(area x )/4] on the Y-axis and time in

127

weeks on the X-axis. Error bars are standard deviations of the mean for 12 and 8 micebearing tumors in the response phase and in the recurrent phase of the study, respectively.
*denotes statistically significant differences between mean slopes of the curve for
trastuzumab plus GSI versus GSI alone. **denotes statistically significant differences
between mean slopes of the curve for trastuzumab versus trastuzumab plus GSI in
recurrent tumors. Linear regression analyses were performed for tumor growth curves in
panels A and B.
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These data suggest that the main benefit of using a GSI (MRK-003) in trastuzumab
sensitive, ErbB-2 positive breast tumors is prevention of tumor recurrence.
Tumors from Figure 33 were excised at week 10, which is prior to trastuzumab
induced regression, to perform H/E staining, Ki67 staining, TUNEL assay, and Western
blotting.
2. Lack or Delay of Tumor Recurrence was due to Prevention of Trastuzumab
Induced Increase in Notch.
Real-time RT-PCR was performed to detect canonical Notch target gene transcripts
which include Hey-1 and Deltex-1 (Kopan and Ilagan, 2009) as measures of Notch
signaling and efficacy of the LY 411,575 (Figure 34A) or MRK-003 GSI (Figure 34B) on
the Notch pathway. Figure 34A and 34B demonstrated that LY 411,575 or MRK-003
GSI alone significantly inhibited Hey-1 and Deltex-1 transcripts compared to Vehicle
control. Trastuzumab treatment alone significantly increased Hey-1 by 2-4 fold and
Deltex-1 by 20 fold compared to Vehicle control (Figure 34A and 34B). LY 411,575 or
MRK-003 GSI significantly decreased the trastuzumab-induced increase in Hey-1 and
Deltex-1 (Figures 34A and 34B).

In addition, recurrent tumors that grew post-

trastuzumab treatment showed increased baseline expression of Hey-1 by 2 fold and
Deltex-1 by 4 fold as compared to trastuzumab treated tumors (Figure 34A). In contrast,
recurrent tumors post-trastuzumab plus LY 411,575 GSI treatment showed decreased
expression of Hey-1 and Deltex-1 transcripts compared to trastuzumab treated recurrent
tumors (Figure 34A). These results would indicate that the lack or delay of breast tumor
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recurrence observed for the combination of trastuzumab plus GSI treatment could be due
to prevention of trastuzumab-induced increase in Notch signaling.
3. BT474 xenograft histology and signaling pathways.
Haematoxylin and eosin (H/E) staining was used to confirm the presence of tumors.
H/E staining of tumors from Figure 35B showed that tumors treated with Vehicle,
trastuzumab, or MRK-003 GSI alone appeared similar in histology (Figure 35A, upper
panel). However, tumors treated with trastuzumab plus MRK-003 GSI contained vast
numbers of pyknotic nuclei, a possible indication of cell death (Figure 35A, upper panel).
Ki67 staining of tumors was used to detect proliferation. The Vehicle control,
trastuzumab, or MRK-003 GSI alone treatments had similar numbers of Ki67 positive
nuclei (200) (Figure 35A, middle panel) which was quantified using at least 3-5 tumors
and 60 high powered fields (Figure 35B). In contrast, Ki67 staining was almost
undetectable in trastuzumab plus MRK-003 GSI treated tumors (Figure 35A, middle
panel and 35B). Furthermore, TUNEL assay was performed to detect early apoptotic
cells.

TUNEL assay showed a 10 fold increase in TUNEL positive cells from

trastuzumab plus MRK-003 GSI treated tumors compared with vehicle, consistent with
nuclear pyknosis observed by H/E (Figure 35A, lower panel and 35B). These results
indicate that the lack of tumor recurrence from trastuzumab plus MRK-003 GSI treatment
is probably due to simultaneous induction of apoptosis and down-regulation of
proliferation.
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*p=0.01
**p=0.03

Figure 33: Kaplan-Meier Curve.
Kaplan-Meier curve of percentage tumor-free mice generated from BT474 breast cancer
cells among Trast1, Trast1+MRK-003 GSI, Trast2, and Trast2+LY 411,575 GSI
treatment groups using a log rank (Mantel-Cox) test. *denotes statistically significant
differences between Trast1 and Trast1 + MRK-003 GSI. **denotes statistically
significant differences between Trast2 and Trast2 + LY 411,575 GSI.
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Figure 34 Notch-1 Gene Target Expression in BT474 Tumors.
(A and B) In a separate experiment, 1mg of snap-frozen tumors were homogenized,
lysed in TRI reagent solution, total RNA was extracted, and reverse transcribed to total
cDNA as described in the methods section. Real-time PCR was performed using humanspecific primers to detect transcripts from Notch target genes: human HEY1 and human
Deltex1. Human-specific 18s rRNA was detected for normalization. Results are mean
relative transcripts levels compared to Vehicle (Control) after normalization to 18s
rRNA. Error bars are standard deviations of the mean for five independent tumor
samples. *denotes statistically significant differences between MRK-003 or LY 411,575
GSI and Vehicle (control). **denotes statistically significant differences between
trastuzumab (Trast) and Vehicle (control). *** denotes statistically significant differences
between GSI + Trast and Trast alone. # denotes statistically significant differences
between Trast-treated tumors and recurrent tumors previously treated with Trast. ##
denotes statistically significant differences between GSI + Trast and Trast alone in
recurrent tumors.
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Figure 35 Histological Staining and Signaling Pathways of BT474 Tumors.
Five Mice were euthanized and tumors excised at week 12 as shown in Figure 32B. One
half of the tumors were immediately fixed in formalin and the remaining half snap-frozen
in liquid nitrogen for future study. (A) Fixed tumors were paraffin-embedded and
sectioned for H/E staining (upper panel), Ki67 (middle panel), and TUNEL (lower panel)
assays. All sections were photographed at 40X magnification using a light microscope.
Four panels are shown: BT474 tumors-treated with Vehicle, trastuzumab (Trast), MRK003 GSI, or Trast plus GSI. Shown are representative photographs based on at least 3
tumors. (B) Quantification of Ki67 and TUNEL positive cells of 3 tumors using 60 high
powered fields (HPF) at 40X magnification. The Y-axis represents number of Ki67 or
TUNEL positive cells for 60 HPF. The bar graphs are means plus or minus standard
deviations. *denotes statistical significance between trastuzumab and trastuzumab plus
MRK-003 GSI (Trast + MRK-003). **denotes statistical significance between MRK-003
GSI and Trast + MRK-003 GSI. (C) Expression of ErbB-2 and downstream signaling
pathways in BT474 tumors. Bits of tumors (1mg) that were snap-frozen in liquid
nitrogen were homogenized and lysed in RIPA buffer containing protease and
phosphatase inhibitors. Cellular debris was removed by centrifugation at 1000g for 5
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minutes at 4oC. Supernatants were collected and 25g of total protein loaded onto a 7%
SDS-PAGE gel followed by Western blotting to detect tyrosine phosphorylated ErbB-2
or HER2 (PY1248-HER2), total HER2, P-ERK1/2, total ERK1/2, P-AKT1, total AKT1,
PTEN, and actin proteins. The Western blot shown is a representative of 3 independent
tumor samples with similar results. Density of bands corresponding to PY-HER2 and
total HER2 for each treatment groups was quantified by the use of Image J program and
expressed as a PY-HER2/HER2 ratio of area of the peak.
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The ERK and AKT pathway are activated downstream of overexpressed ErbB-2
(Yarden, 2001; Yarden and Sliwkowski, 2001). Thus, we asked the question: What is the
status of ERK and AKT activation in treated tumors? BT474 tumors excised at week 12
from Figure 33B were analyzed by Western blotting to detect tyrosine-phosphorylated
ErbB-2 (PY1248), total ErbB-2, phosphorylated ERK1/2, total ERK1/2, phosphorylated
AKT1, total AKT1, and PTEN proteins. Figure 35C demonstrated that MRK-003 GSI
treatment of BT474 tumors increased PY-ErbB-2 protein compared to Vehicle control.
Trastuzumab alone showed 80% decrease in PY-ErbB-2 protein versus Vehicle control
(Figure 35C). Interestingly, PY-ErbB-2 protein was reduced by 60% with trastuzumab
plus MRK-003 GSI compared to Vehicle control (Figure 35C). Furthermore, while either
MRK-003 GSI or trastuzumab alone decreased P-ERK1/2 and P-AKT1 compared to
Vehicle, only trastuzumab plus MRK-003 GSI decreased both P-ERK1/2 and P-AKT1 to
almost undetectable levels (Figure 35C). This decrease in P-AKT1 was associated with
increased PTEN protein levels (Figure 35C). These results would suggest that downregulation of proliferation and induction of apoptosis by trastuzumab plus MRK-003 GSI
could be due at least in part to synergistic or additive inhibition of ERK1/2 and AKT1
activities, which are critical signaling pathways for proliferation and anti-apoptosis,
respectively.
4. Lapatinib plus MRK-003 GSI reduces tumor growth, proliferation, and ERK1/2
and AKT1 activity and induces apoptosis.
Lapatinib is a more potent drug in vitro compared to trastuzumab. Therefore, we
chose BT474 lapatinib sensitive cells and generated breast tumor xenografts in athymic
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nude mice. Growth of tumors was measured in response to Vehicle, lapatinib, MRK-003
GSI, or lapatinib plus GSI. The results showed that lapatinib treatment decreased tumor
growth by only 40% compared to Vehicle control (Figure 36A). Treatment of tumors
using MRK-003 GSI alone had no statistically significant effect on tumor growth
compared to Vehicle control (Figure 36A).

However, lapatinib plus GSI showed

significant reduction in tumor growth at week 13 compared to GSI alone, lapatinib alone,
or Vehicle (Figure 36A). The study was stopped at week 13 due to onset of diarrhea in
lapatinib-treated mice.

Haematoxylin and eosin (H/E) staining showed that tumors

treated with Vehicle, lapatinib, MRK-003 GSI or lapatinib plus GSI appeared similar in
histology and confirmed the presence of tumor in the samples excised (Figure 36B, upper
panel). Ki67 staining of tumors from lapatinib, MRK-003 GSI, or lapatinib plus GSI
treatments demonstrated 75-90% reduction in the Ki67 positive nuclei compared to the
vehicle control (Figure 36B, middle panel and 36C). Furthermore, apoptosis as measured
by TUNEL assay showed a 10 fold increase in TUNEL positive cells from lapatinib plus
MRK-003 GSI treated tumors compared to Vehicle (Figure 36B, third panel, and 36C).
These results indicate that induction of tumor regression from lapatinib plus MRK-003
GSI treatment is probably also due to simultaneous induction of apoptosis and downregulation of proliferation. Moreover, Western blotting was performed to detect tyrosine
phosphorylated ErbB-2 (PY1248), total ErbB-2, phosphorylated ERK1/2, total ERK1/2,
phosphorylated AKT1 and total AKT1 proteins. Figure 36D demonstrates that lapatinib
or MRK-003 GSI treatment alone decreased PY-ErbB-2 protein by 40% compared to
Vehicle control. Interestingly, lapatinib plus GSI treatment, unlike trastuzumab, had little
effect on PY-ErbB-2 protein.

However, both phosphorylated ERK-1/2 and AKT1

137

proteins were reduced in tumors treated with lapatinib plus GSI compared to all other
treatments (Figure 36D). These results indicate that induction of tumor regression by
lapatinib plus MRK-003 GSI could also be due to simultaneous inhibition of both
ERK1/2 and AKT1 activities.
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Figure 36: Lapatinib plus MRK-003 GSI Reduces Tumor Growth.
(A) ErbB-2 overexpressing BT474 xenografts were generated in 40 ovariectomized,
athymic nude mice by injecting 5 x 106 cells into both mammary fat pads. Once tumors
reached a mean tumor cross sectional area of 0.25 cm2, mice were randomized and
treated with Vehicle, lapatinib (LAP), MRK-003 GSI, or LAP plus GSI. Tumor area
(length X width) was measured weekly using Vernier calipers. The measurements were
performed up to 13 weeks. Results show mean tumor cross sectional area [(area x )/4]
on the Y-axis and time in weeks on the X-axis. Error bars are standard deviations of the
mean for 10 mice-bearing tumors. (B) Fixed tumors were paraffin-embedded and
sectioned for H/E staining (upper panel), Ki67 (middle panel), and TUNEL (lower panel)
assays. All sections were photographed at 40X using a light microscope. Four panels are
shown: BT474 tumor-treated with Vehicle, lapatinib (LAP), MRK-003 GSI, and LAP +
GSI. The photographs of a single tumor sample are representative of 3 tumor with similar
results. (C) Quantification of Ki67 and TUNEL positive cells of 3 tumors using 60 high
powered fields (HPF) at 40X magnification. The Y-axis represents number of Ki67 or
TUNEL positive cells per 60 HPF. The bar graphs are means plus or minus standard
deviations. *denotes statistical differences compared to Vehicle control. **denotes
statistical differences between LAP and LAP + GSI. ***denotes statistical difference
between MRK-003 GSI and LAP + GSI. Statistical analysis was performed using a twosided, non-paired Student’s T-test. (D) Bits of tumors (1mg) that were snap-frozen in

141

liquid nitrogen were homogenized and lysed in RIPA buffer containing protease and
phosphatase inhibitors. Cellular debris was removed by centrifugation at 1000g for 5
minutes at 4oC. Supernatants were collected and 25g of total protein loaded onto a 7%
SDS-PAGE gel followed by Western blotting to detect tyrosine phosphorylated ErbB-2
or HER2 (PY1248-HER2), total HER2, P-ERK1/2, total ERK1/2, P-AKT1, total AKT1,
and actin proteins. Densitometry was performed on PY-HER2 and total HER2 bands for
each treatment groups using Image J program and expressed as a PY-HER2/HER2 ratio
of area of the peak. Western blotting was performed on at least 3 independent tumor
samples. Representative Western blots are shown with similar results. *denotes
statistically significant differences between mean slopes of the curve for LAP plus GSI
and GSI alone. **denotes statistically significant differences between mean slopes of the
curve for LAP and Vehicle control. ***denotes statistically significant differences
between mean slopes of the curve for LAP plus GSI and LAP alone. Linear regression
analyses were performed for tumor growth curve.
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Aim 2C. Establish whether a GSI in combination with trastuzumab reverses resistance
in vivo.
1. GSI paritally restores trastuzumab sensitivity in resistant tumors.
Trastuzumab resistant, ErbB-2 positive, BT474 breast cancer cells were generated by
treating cells with 10 g/mL trastuzumab for 6 months in vitro as described previously
(Osipo et al., 2008). These resistant cells were injected into athymic, nude mice to
generate trastuzumab resistant breast tumor xenografts in vivo. Figure 37A and 37B show
that xenograft tumors generated from trastuzumab resistant cells were resistant to
trastuzumab in two independent studies. Treatment with LY 411,575 (Figure 37A) or
MRK-003 (Figure 37B) GSI alone did not inhibit tumor growth when compared to
Vehicle or trastuzumab alone (Figure 37A and 37B). However, trastuzumab plus LY
411,575 or MRK-003 GSI decreased the rate of tumor growth by almost 50% compared
to GSI or trastuzumab alone (Figure 37A and 37B). While the reduction of tumor growth
by trastuzumab plus LY 411,575 GSI reached significance, the reduced tumor growth for
trastuzumab plus MRK-003 GSI did not reach statistical significance.
These data taken together suggest that the benefit of using a combination of
trastuzumab plus GSI is prevention of tumor recurrence. However, once trastuzumab
resistance occurs, a GSI can only partially restore trastuzumab sensitivity.
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Figure 37: GSI Partially Restores Trastuzumab Sensitivity in Resistant Tumors.
(A and B) The exact same protocol as described in Figure 1 was used to generate
trastuzumab resistant tumors in athymic, nude mice using BT474 trastuzumab resistant
cells. (A) LY 411,575 GSI was used. (B) MRK-003 GSI was used. Tumor area (length X
width) was measured weekly using Vernier calipers. The measurements were performed
up to 15 or 10 weeks, respectively. Results show mean tumor cross sectional area [(area x
)/4] on the Y-axis and time in weeks on the X-axis. Error bars are standard deviations
of the mean for 10 mice-bearing tumors. *denotes statistically significant differences
between GSI and Trast + GSI. **denotes statistically significant differences between
Trast and Trast + GSI.

CHAPTER VI
DISCUSSION

ErbB-2 positive breast cancer is currently treated with therapeutic agents,
trastuzumab (Carter et al., 1992) or lapatinib (Nahta et al., 2007). Although trastuzumab
or lapatinib plus chemotherapy have been successful in the treatment of ErbB-2 positive
breast cancer, some patients will not respond to these drugs and, among responders, 1525% will have disease recurrence and ultimately progression (Cobleigh et al., 1999;
Vogel et al., 2002). Thus, anti-ErbB-2 therapy-associated resistance remains a serious
clinical problem. One possible reason for this problem could be alterations in signaling
pathways that are downstream or parallel to ErbB-2 upon chronic trastuzumab or
lapatinib treatment. We showed that ErbB-2 inhibition activates Notch-1 which results in
a compensatory increase in Notch-1-mediated proliferation (Osipo et al., 2008). Notch-1,
a breast oncogene, is a modulator of cell-fate decisions (Politi et al., 2004). Notch-1 and
Notch-4 has been implicated in the self-renewal and survival of tumor-initiating cells
(Harrison et al., 2010; Magnifico et al., 2009). Overexpression of constitutively active
forms of Notch-1, Notch-3, and Notch-4 develop spontaneous murine mammary tumors
in vivo (Callahan and Raafat, 2001). In addition, Notch-1 has been recently suggested as
a novel marker of trastuzumab resistance from human breast cancer tissue (Huober et al,
2010). We have identified Notch-1 as a novel target in trastuzumab-resistant breast
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cancer in vitro (Osipo et al., 2008).

Flow cytometry (Figure 7A) and biotinylation

assays (Figure 7B) showed an increase in Jagged-1 cell surface expression. In addition,
preliminary results demonstrated that Jagged-1 and Notch-1 co-expressed in SKBr3 cells,
by confocal microscopy studies (Figure 17). However, Notch-1 and Jagged-1 were
completely separated at the sub-cellular level: Notch-1 localized throughout the cell and
Jagged-1 was concentrated at the cell surface near cell-cell contacts, when SKBr3 cells
were treated with trastuzumab (Figure 17). Together, these data suggest that ErbB-2
overexpressing breast cancer cells trap Jagged-1 and Notch-1 in sub-membranous
compartments such as early endosomes. However, trastuzumab released Jagged-1 to the
cell surface, making Jagged-1 available to interact with and trans-activate Notch
signaling. These results, taken together suggest a dual role for ErbB-2 in inhibition of
Notch activity: 1, ErbB-2 promotes Jagged-1 mediated cis-inhibition of Notch and 2,
ErbB-2 inhibits Jagged-1 mediated trans-activation of Notch.
Our studies have provide insight into a mechanism by which ErbB-2 and Notch

pathways crosstalk in ErbB-2 positive breast cancer cells. Results from specific aim 1
show that ErbB-2 might stabilize total Jagged-1 protein (Figure 10). More interestingly,
ErbB-2 via PKCα possibly limits the interaction between Jagged-1 and Mib-1 and
subsequent ubiquitylation of Jagged-1 (Figures 20, 21, and 26). Moreover, Mib-1 is the
E3 ubiquitin ligase required for lapatinib-mediated ubiquitylation of Jagged-1 (Figure 22)
and induction of Notch activity (Figure 23). Furthermore, PKCα, possibly downstream
of ErbB-2, inhibits Notch transcriptional activity (Figure 27).

These results, taken

together imply that overexpression of ErbB-2 restricts the critical association between
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Jagged-1 and Mib-1 to inhibit Notch activity and to drive breast tumor proliferation,
survival which consequently decreases the efficacy of anti-ErBb-2 targeted agents.
Results from specific aim 2 identified Jagged-1 as a novel target in ErbB-2 positive breast
cancer and more importantly in trastuzumab resistance (Figures 28, 29, 30, and 31).
Moreover, our data provide, to our knowledge, the first preclinical proof of concept in
mice for future clinical trials of combination regimens including trastuzumab and a Notch
inhibitor, MRK-003 GSI, for the prevention of tumor recurrence (Figure 32) and possibly
reversal of trastuzumab resistance (Figure 37) in ErbB-2 positive breast cancer.
Based on the confocal immunofluorescence microscopy results, we hypothesized that
ErbB-2 overexpressing breast cancer cells express Jagged-1 to inhibit Notch in cis.
Results from the co-culture studies revealed that Jagged-1 could be a potent cis-inhibitor
of Notch activity in ErbB-2 positive breast cancer cells (Figure 14) and possibly other
breast cancer cell subtypes (Figure 16). However, the results did not demonstrate that
ErbB-2 overexpression specifically promoted Jagged-1 mediated cis-inhibition of Notch
(Figure 15). What the co-culture data revealed are that trastuzumab most likely promotes
trans-activation of Notch by increasing the cell surface expression of Jagged-1. As shown
in Figure 10, ErbB-2 seems to be important in stabilizing the Jagged-1 protein and this
result coincided with inhibition of Notch activity. One idea is that the E3 ligase Neur
ubiquitylates and degrades the cis-inhibiting ligand to allow Notch to bind another or the
same ligand in trans on adjacent cells, leading to receptor activation (Glittenberg et al.,
2006).

Although, Mib-1 plays a critical role in ubiquitylation and generation of a

signaling competent ligand, it has never been shown so far to play a role in regulation of
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levels of the cis-inhibiting ligand for Notch activation (Deblandre et al., 2001; Lai et al.,
2001). Because the function of Mib-1 and its role in the mammalian system, and more
importantly in cancer, is beginning to be revealed, we aim to explore in the near future a
role for Mib-1 in regulating Jagged-1 protein stability in the presence or absence of ErbB2. It is possible that ErbB-2 by limiting Mib-1 binding to Jagged-1 confers a protection
on Jagged-1 from Mib-1 or another E3 ligase dependent degradative pathway.
Jagged-1 knockdown showed an up-regulation of Notch target genes (Figure 14),
suggesting the possible role for other Notch ligands or receptors in the transcriptional
induction of Hes-1 and Deltex-1 mRNAs. Preliminary data suggested that Jagged-1 is a
positive regulator of DLL-1, DLL-4, and Notch-2, and hence these components of the
Notch pathway might not be responsible for the Jagged-1 siRNA mediated increase in
Notch activity. We could not detect Jagged-2, DLL-3, and Notch-3 due to lack of
availability of good antibodies. Alternatively, it could be the dosage of Jagged-1 that is
critical to regulate Notch activation by cis or trans mechanisms. Sprinzak et al used a
titration based approach to demonstrate how levels of cis and trans Delta are integrated
by the Notch pathway (Sprinzak et al., 2010). Notch activity gradually increased with
increasing concentrations of Delta in trans, independent of Delta levels in cis (Sprinzak et
al., 2010). Moreover, upon decreasing the concentration of Delta in cis, a Notch response
to Delta in trans was observed (Sprinzak et al., 2010). Most importantly, the threshold
level of Delta in cis below which Notch is activated, was independent of Delta levels in
trans (Sprinzak et al., 2010). Whether the same molecule can simultaneously interact in
cis and/or in trans with Notch is not known. As shown in Figure 10, ErbB-2 clearly
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regulates the amount of Jagged-1 protein. Therefore, ErbB-2 may play a role in Jagged-1
mediated cis-inhibition of Notch by stabilizing Jagged-1 levels in cis.
Our data for the first time identified ErbB-2 as a negative regulator of Jagged-1mediated trans-activation of Notch (Figure 15). As shown in Figures 20 and 21, ErbB-2
limits Mib-1 association and subsequent ubiquitylation of Jagged-1.

However, the

mechanism regulating the critical association between Mib-1 and Jagged-1 is unknown.
ErbB-2 is a RTK which activates a variety of kinases and related downstream
phosphorylation events. Therefore, downstream kinase expression and/or activity could
play a role in regulation of the Jagged-1 and Mib-1 association in ErbB-2 positive breast
cancer. Using a proteomic approach, we can identify kinase(s) downstream of ErbB-2
whose expression and/or activity changes with anti-ErbB-2 therapy. It has been shown in
the literature that ErbB-2 via Src positively regulates PKCα expression and activity (Tan
et al., 2006). Therefore, using a candidate approach, we further identified PKCα as a
downstream effector of ErbB-2. Our data demonstrate that high ErbB-2 activity promotes
the formation of PKCα-Jagged-1 complex but limits Mib-1-Jagged-1 association (Figure
26).

However, trastuzumab or lapatinib treatment decreases the PKCα-Jagged-1

interaction and conversely promotes the Mib-1 association with Jagged-1 (Figure 26).
These results indicate that ErbB-2 by activating PKCα protein is facilitating its
interaction with, and possibly phosphorylation, of Jagged-1. In contrast, anti-ErbB-2
therapy decreases PKCα protein and phosphorylation, and favors Mib-1 association with
Jagged-1, generating a signaling competent ligand leading to Notch activation.
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A single phosphorylation signal may directly alter the function and activity of
proteins, e.g., by promoting a conformational change, protein-protein interactions, protein
degradation, protein stability, and protein localization.

PKCα is a kinase that

phosphorylates many substrates. Scanning for putative PKC binding sites using the
NCBI Prosite website in both Jagged-1 and Mib-1 proteins revealed several putative
PKCα binding sites (Figure 24). In addition, four putative phosphorylation sites (T1197,
S1207, S1210, and Y1216) along with a PDZ protein-protein interaction motif were
identified in the intracellular domain of Jagged-1 (Popovic et al., 2011). This could
indicate that PKCα, downstream of ErbB-2, is phosphorylating and modulating either
Mib-1 or Jagged-1 to modulate their functions.
PKCα could physically bind and phosphorylate the C-terminal Jagged-1 tail.
Phosphorylation of Jagged-1 may change its conformation, retain Jagged-1 in a cisinhibitory endocytic compartment or regulate the amount of Jagged-1 protein expression.
This could then disrupt Mib-1 binding and prevent generation of a competent ligand
needed to activate Notch.
In addition to the PKCα’s ability to regulate Jagged-1, it may also regulate Mib-1’s
function. Ossipova et al has demonstrated that PAR-1 kinase-mediated phosphorylation
of Mib-1 targets Mib-1 for degradation by the proteasome. Because Mib-1 protein levels
are regulated by phosphorylation events and PKCα is a kinase, ErbB-2 via PKCα could
be phosphorylating Mib-1 and targeting it for degradation. However, Figure 19 showed
that Mib-1 protein levels remain relatively unaffected upon trastuzumab or lapatinib
treatment. Therefore, PKCα demonstrates no regulation on Mib-1 stability.
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Overexpression of ErbB-2 drives proliferation and growth of ErbB-2 positive breast
cancer cells. This was further confirmed when trastuzumab treatment reduced growth
and induced apoptosis in 40% of SKBr3 cells (Figure 28 and 30).

Jagged-1 siRNA

reduced proliferation and increased apoptosis in 70% of SKBr3 cells (Figure 28 and 30)
and that coincided with an aberrant increase in Notch activity (Figure 14). The enhanced
apoptosis of ErbB-2 positive breast cancer cells in the presence of Jagged-1 siRNA could
be a result of an increase in the differentiation signal in a context of ErbB-2 driven
proliferation. Interestingly, it was demonstrated that dual inhibition of Jagged-1 and
ErbB-2, further reduced proliferation (Figure 28) and increased apoptosis in 90% (Figure
30) of SKBr3 cells. Notch signaling is critical for cell fate determination and ErbB-2 is
critical for proliferation and survival.

Therefore, the combination inhibiting the

proliferation signal and promoting the differentiation signal in a cancer cell further
sensitized ErbB-2 positive breast cancer cells to trastuzumab and lead to catastrophic cell
death.

Similar results were obtained in other cell lines, BT474 HS (trastuzumab

sensitive) and HR (trastuzumab resistant) cells (Figures 29A, 29B, 31A, and 31B). These
data suggested that inhibiting Jagged-1 could increase the sensitivity of ErbB-2 positive
breast cancer cells to trastuzumab and reverse resistance. To confirm that this is not an
off target effect of Jagged-1 siRNA, similar experiments should be performed targeting
Jagged-1 using the same siRNA and re-expressing either full length Jagged-1 or an
interaction dead Jagged-1 mutant to investigate whether Jagged-1 expression rescued the
cell death-mediated by Jagged-1 siRNA. In addition, to demonstrate that the Jagged-1Mib-1-Notch-1-Hes-1 axis was critical for survival of ErbB-2 positive breast cancer cells,
each component would need to be knocked down and apoptosis studies performed. This
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would further test if the Jagged-1 siRNA mediated induction of apoptosis is due to the
modulation of the canonical Jagged-1–Mib-1-Notch-1–Hes-1 pathway.
Co-overexpression of Jagged-1 and Notch-1 predicts for the poorest outcome in
women with breast cancer. We observed that when Jagged-1 is abundant it acts as an
inhibitor of Notch activity whereas when limiting it can orient itself in trans and now
bind and activate Notch.

Therefore, it is possible that a cell exhibiting increased

expression of Jagged-1 sends a cis-inhibitory signal to limit aberrant activation of Notch
which induced cell death in ErbB-2 positive breast cancer cells as shown. Thus, ErbB-2
promoting cis-inhibition of Notch is selected because it generates a stable cellular state
driving growth and survival of ErbB-2 positive breast cancer cells. Although, inhibition
of ErbB-2 decreases the total Jagged-1 protein, the remaining Jagged-1 may be sufficient
to trans-activate Notch receptors. At a multicellular level, this low line level of activated
Notch can amplify and provide a survival advantage to ErbB-2 positive breast cancer
cells and could potentially cause resistance to anti-ErbB-2 treatment.
One of the major problems with anti-ErbB-2 treatments is resistance, particularly in
metastatic disease. To circumvent these problems, we designed and evaluated for the
first time a combination therapeutic strategy that can prevent and/or reverse trastuzumab
resistance in vivo. Our findings, along with evidence from the literature, indicate that
Notch could be an important target in trastuzumab-resistant, ErbB-2 positive breast
cancer (Osipo et al., 2008). One class of compounds that are being used to inhibit the
Notch pathway are GSIs that are currently in clinical trials for the treatment of breast
cancer and other solid tumors (Pannuti et al, 2010). Recently, it was reported that MRK003 GSI treatment of Balb/c-neuT female mice reduced tumor onset, tumor burden, and
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AKT1/mTOR activities associated with ErbB-2 positive, murine breast tumors (Efferson
et al, 2010).

Our results demonstrate that although trastuzumab treatment caused

virtually complete tumor regression (Figure 32A and 32B), which mimics what is
observed in the clinic, it could not prevent tumor recurrence in 40% of the mice (Figure
32A and 32B, and 33).

However, adding a GSI to trastuzumab treatment either

completely abolished (MRK-003) or significantly reduced (LY 411,575) tumor
recurrence (Figure 32A and 32B, and 33). Interestingly, recurrent tumors posttrastuzumab plus the LY 411,575 GSI treatment showed a significant decrease in Notch
transcriptional activity compared with trastuzumab treatment alone (Figure 34),
suggesting that Notch signaling could be responsible for ErbB-2 positive breast tumor
recurrence post-trastuzumab treatment. Consistent with the literature, our data

also

suggest that Notch plays a critical role in the survival of tumor-initiating cells as
demonstrated by the lack of tumor recurrence when Notch was inhibited in combination
with ErbB-2 inhibition.
Treatment with the combination of trastuzumab plus MRK-003 GSI simultaneously
decreased proliferation and induced tumor cell death (Figure 35A and 35B). These
antitumor effects of the combination therapy may be because of near-complete blockade
of two critical signaling pathways downstream of ErbB-2: ERK1/2 and AKT1 (Figure
35C). Thus, a combination of trastuzumab plus MRK-003 GSI could benefit those
women with recurrent, or possibly resistant, ErbB-2-positive breast cancer ultimately to
reduce or eliminate disease progression and deaths by simultaneously inactivating two
critical prosurvival and antiapoptotic pathways such as ERK1/2 and AKT1.
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Lapatinib is a very potent inhibitor of ErbB-2 activity in vitro; however, lapatinib
alone reduced tumor growth by only 40% in our BT474 model of ErbB-2 positive breast
cancer (Figure 36A). A combination of lapatinib plus MRK-003 GSI showed significant
reduction in the tumor growth (Figure 36A). This is likely because of inhibition of
ERK1/2 and AKT1 activities (Figure 36D) that resulted in increased apoptosis and
decreased proliferation (Figure 36B and 36C). However, the onset of diarrhea-associated
toxicity with lapatinib or lapatinib plus GSI treatment at week 13 caused the study to end
prematurely and, therefore, complete tumor regression was not reached.
Our results also showed that a GSI could partially restore sensitivity to trastuzumab in
resistant tumors (Figure 37). The mechanism by which a GSI only partially reverses
trastuzumab resistance in vivo is being actively studied. It is possible that targeting all
four Notch receptors with a pan-Notch inhibitor such as a GSI might not effectively
target Notch-1, which we have shown to be necessary for trastuzumab resistance in vitro
(Osipo et al, 2008). Moreover, Notch-2 has been implicated as a tumor suppressor. Thus,
targeting all four Notch receptors using a GSI may inhibit a tumor suppressor which is
why we observed only a partial reversal of resistance. Work from Han et al, however,
suggested that GSI induced cytotoxic effects on the xenograft tumors and was due to
inhibition of proteasome function (Han et al., 2009). Therefore, a more specific Notch-1
or possibly other Notch signaling pathway inhibitors could prove to be more effective
and potent.
Our in vitro data identified Jagged-1 as a novel target for the treatment of ErbB-2
positive breast cancer.

Jagged-1 inhibition using siRNA induced aberrant Notch

activation which in turn leads to cell death in ErbB-2 positive breast cancer cells. Thus,
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targeting Jagged-1 specifically in combination with current therapies (trastuzumab or
lapatinib) would increase Notch activity and induce apoptosis in vivo. Differential effect
of Notch has been observed between tissues and within a tissue between normal and
disease states and is influenced by the number of receptors activated. Our data for the
first time demonstrated the role of increased Notch activity in inducing apoptosis in
SKBr3 and BT474 cells. On one hand, targeting Jagged-1 seems to be promising as it
induced cell death in cancer cells but that coincided with aberrant increase in Notch
activity. Since the dosage dependent effects of Notch activity on the proliferation and
survival of the cancer cell are unclear, targeting Jagged-1 specifically seems to be a dicey
approach to target Notch pathway. Until more light is shed on the dosage dependent
functions of Notch activity, the best approach to target Notch pathway would be to inhibit
trans interactions between Jagged-1 and Notch.

This way we will inhibit Notch

activation completely.
Over recent years many approaches have been taken to inhibit the Notch pathway.
The first Notch pathway inhibitors, used both experimentally and clinically, were GSIs
which prevent cleavage of NEXT and therefore the release of NICD from the plasma
membrane.

Agents that compete with MAML for binding to the RBPjk/NICD

transcriptional activator complex have also been generated. These agents include
SAHM1 and TR4 (Moellering et al., 2009). However, GSIs, SAHM1 and TR4 can
disrupt signaling by all four Notch receptors. More recently, monoclonal antibodies
directed against the EGF repeats 11 – 15 within Notch receptors that prevent
ligand/receptor interaction have been generated. In addition, monoclonal antibodies that
prevent the conformational change within the extracellular domain required to expose the
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S2 cleavage site have been generated. Monoclonal antibodies that recognize specific
ligands (Dll4) (Hoey et al., 2009) or receptors (Notch1-3) (Aste-Amezaga et al., 2010;
Wu et al., 2010) have been developed. Pan-inhibition of Notch signaling with GSIs has
been associated with goblet cell dysplasia in the gut (Pannuti et al., 2010; Wu et al.,
2010). Not only that but long-term treatment with Notch pathway inhibitors is associated
with development of vascular tumours (Liu et al., 2011b). Thus,targeting individual
Notch pathway receptors and ligands would be more effective and potent.
Furthermore, the Notch pathway is complicated in tumors because of multiple modes
of action. For example, it is known that Delta-like 4 (DLL-4) on endothelial cells engages
and activates the Notch-1 receptor on cancer epithelial cells to promote angiogenesis
(Yan et al, 2010). In addition, Notch signaling has been recently implicated to play a role
in survival and differentiation of tumor stroma (Orr et al, 2009). The level of complexity
for the role of Notch signaling in the tumor microenvironment requires a thorough
investigation of the Notch pathway in breast cancer, and most notably in anti-ErbB-2targeted drug resistance, with the goal of identifying novel and specific targets to treat or
reverse resistance.
1. Conclusion
We demonstrated for the first time that high levels of Jagged-1 could possibly act as
potent cis-inhibitor of Notch transcriptional activity. ErbB-2 prevents Jagged-1-mediated
trans-activation of Notch. Jagged-1 is a novel and potentially better therapeutic target for
the treatment of ErbB-2 positive breast cancer and trastuzumab resistance. Our findings
suggest for the first time that the benefit of using a combination of trastuzumab plus a
GSI is prevention of ErbB-2 positive breast tumor recurrence. Because Notch is a breast
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oncogene that is critical for survival and proliferation of breast cancer cells, our findings
strongly suggest that combined treatment with a Notch inhibitor could be an effective
therapeutic strategy to prevent tumor recurrence and possibly disease progression and
death in ErbB-2 positive breast cancer. The combination of trastuzumab plus MRK-003
GSI could benefit women with recurrent, or possibly resistant, ErbB-2-positive breast
cancer to prevent disease progression, increasing percent disease free survival.
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2. Model
ErbB-2 is hyperactive
When ErbB-2 is hyperactive, there is no signal sending or receiving cell. ErbB-2
positive breast cancer cells express equal number of Notch receptors and ligands. When
ErbB-2 is active, Jagged-1 and Notch-1 co-localize to EEA-1 positive vesicles and there
is a decrease in the cell surface expression of Jagged-1 levels. Moreover, PKCα is in
complex with Jagged-1 and Jagged-1 protein is stabilized by ErbB-2’s activity. These
events result in cis-inhibition of Notch activity.

EEA-1 positive vesicle
P

Notch ligand
Notch receptor

P P P PP P

ErbB-2

ErbB-2

Notch receptor
Notch ligand

EEA-1 positive vesicle
Signal Receiving Cell

ErbB-2 Hyperactive
(No signal sending or receiving cell)
“Cis-Inhibition”
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ErbB-2 is Inactive
When ErbB-2 is inactive, there occurs a small stoichiometric change in the expression
of Notch receptors and ligands resulting in two distinct cell types signal sending cell
(High Jagged-1, low Notch) or signal receiving cell (High Notch, low Jagged-1). Upon
anti-ErbB-2 therapy, we observed a decrease in total Jagged-1 protein and an increase in
cell surface expression of Jagged-1. Notch-1 was distributed throughout the cell.
Jagged-1 at the plasma membrane could engage with Notch expressed on adjacent cell.
The pulling force required to pull ligand-NEC and trans-activate Notch could be provided
by an increase in Mib-1 binding and ubiquitylation of Jagged-1. These events ultimately
result in trans-activation of Notch in signal receiving cell.
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Lapatinib

P P P PP P
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3. Future Investigations
Our studies demonstrated that ErbB-2 inhibitors decreased total Jagged-1 protein
levels and that coincided with an increase in the cell surface levels of Jagged-1 and Notch
activity. It would be important to investigate whether ErbB-2 activity regulates the
amount of total and cell surface Jagged-1 to determine a dosage dependent effect of
Jagged-1 on Notch activity. A time course of lapatinib treatment on SKBr3 cells could
be performed to sort for cells exhibiting high levels of Jagged-1 at the cell surface. Cells
expressing low-levels of Jagged-1 at the cell surface will be sorted from vehicle treatment
group. The sorted cells could be analyzed using Jagged-1 and Hes-1 antibody by Western
blot to determine the total amount of Jagged-1 and how the levels and localization of
Jagged-1 regulates Notch activity in two distinct populations of cells.
Identification of the molecular mechanism underlying this regulation of Jagged-1
dose by ErbB-2 would be an important future study. ErbB-2 is a receptor tyrosine kinase
which regulates a series of downstream phosphorylation events. Future studies will be
aimed at identifying a kinase(s) whose expression and/or activity is regulated by ErbB-2
using a proteomic approach. Our data demonstrated that when ErbB-2 is active, PKCα is
in complex with Jagged-1 (Figure 26). As described previously, phosphorylation of
Jagged-1 may change its conformation, regulate trafficking or regulate the amount of
Jagged-1. Any one of these events could disrupt Mib-1 binding to Jagged-1 to prevent
generation of a competent ligand needed to activate Notch.

Therefore, a thorough

investigation of the phosphorylation status of Jagged-1 and whether it plays a role in
regulating total and cell surface Jagged-1 levels, Jagged-1 trafficking, and limiting the
association between Mib-1 and Jagged-1 would be important future studies.
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ErbB-2 inhibition decreased Jagged-1 protein levels, which in turn activated Notch in
trans. To examine the role of Jagged-1 stability in ErbB-2-mediated regulation of Notch
activity, inhibition of lysosomal entry using siRNA against Rab7, a protein localized in
late endosome, or internalization to the lysosomal lumen using siRNA to LAMP,
lysosomal-associated membrane glycoprotein, in SKBr3 cells in presence or absence of
anti-ErbB-2 therapy could be performed. Notch activity will be measured by Real-time
PCR. Inhibiting the Jagged-1 lysosomal degradation route will direct Jagged-1 protein to
the recycling route and stabilize the Jagged-1 protein. Stabilizing Jagged-1 protein levels
using siRNA against either Rab7 or LAMP should block the anti-ErbB-2 inhibitormediated decrease in Jagged-1 protein levels and possibly Notch activation.
To test the hypothesis that the kinase activity of ErbB-2 is required for Jagged-1mediated regulation of Notch activity COS cells will be used. COS is a fibroblast-like
cell line derived from monkey kidney tissue and lacks expression of ErbB-2, Jagged-1,
and Notch-1. We will overexpress ErbB-2 wild type and its kinase dead mutant, as well
as Jagged-1 and Notch-1 in COS cells. We will also transfect the cells with a Notch
luciferase reporter construct to measure Notch activity. If ErbB-2 has a direct role in
regulating Notch activity via Jagged-1, then using a kinase dead mutant of ErbB-2 should
decrease protein levels of Jagged-1 and activate Notch as measured by an increase in
luciferase activity.
Confocal microscopy studies showed that Jagged-1 co-localized with early endosome
antigen-1 (EEA-1) to possibly submembraneous endosomes in ErbB-2 positive breast
cancer cells (Figure 8). Jagged-1 exited EEA-1 positive vesicles and localized to the cell
membrane in response to trastuzumab (Figure 8). We could examine the possibility that
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ErbB-2 decreases Jagged-1 cell surface availability by either increasing the rate of
endocytosis and/or decreasing the rate of recycling to the plasma membrane. To identify
the role of endocytosis, down-regulation via siRNA of AP-2 (clathrin-mediated
endocytosis), Dynamin (Dynamin mediated endocytosis) or caveolin (lipin raft mediated
endocytosis) in SKBr3 cells in presence or absence of anti-ErbB-2 therapy could be
performed.

Jagged-1 distribution will be monitored with respect to markers (AP-2,

Dynamin, and caveolin) that represent various types of endocytosis by confocal
immunofluorescence.

We could overexpress Rab11A/Rab4 in the presence or absence

of trastuzumab or lapatinib to determine if Jagged-1 recycling to the plasma membrane is
restored regardless of whether ErbB-2 is inhibited or not.
Our data showed that PKCα down-regulation via siRNA increases Notch activity
(Figure 26). If PKCα is downstream of ErbB-2 and ErbB-2 inhibits Notch activity, it
would be important to investigate whether PKCα or an unidentified kinase can abrogate
lapatinib- or trastuzumab-mediated increase in Notch activity.
Additionally, Jagged-1 siRNA has been shown to up-regulate Notch activity. A
thorough investigation of whether other Notch ligands or receptors regulate Notch
activity in presence of Jagged-1 siRNA is thus an important future study. Inhibition of
other Notch pathway components independently and in combination with Jagged-1 could
explain the increase in Notch activity observed upon Jagged-1 down-regulation.
What these studies implied was that Jagged-1 mediated cis-inhibition of Notch could
be dosage dependent and a general mechanism among different subtypes of breast cancer
(Figure 16). After having a better understanding of the mechanism of this complex
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regulation, we could determine the mechanism of Jagged-1 mediated cis-inhibition and
trans-activation of Notch in other subtypes of breast cancer.
The effects of Jagged-1 down-regulation alone or in combination with trastuzumab on
apoptosis were dramatic. To determine if the effects observed on cellular proliferation
and apoptosis upon Jagged-1 knockdown were Jagged-1 mediated, we could perform a
rescue experiment. If it is Jagged-1 mediated, then overexpression of wild type Jagged-1,
but not JNdr mutant should rescue the effects of Jagged-1 siRNA and confer protection
against apoptosis. If the results demonstrate Jagged-1 specific effect, then we could
investigate if it is through the canonical Jagged-1–Mib-1-Notch-1–Hes-1 pathway. We
could perform the exact same experiment but using siRNA to individual components and
observe if it can recapitulate the Jagged-1 siRNA effects.
With the catastrophic effects observed on cell proliferation and apoptosis upon dual
inhibition of Jagged-1 and ErbB-2 in ErbB-2 positive breast cancer cells, an in vivo study
using a doxycycline inducible Jagged-1 shRNA system could be designed. Xenografts of
BT474 transfected with Jagged-1 shRNA whose expression is under the control of
doxycycline could be injected into the mammary fat pads of nude mice. After the tumors
grow, we would administer doxycycline and trastuzumab. Tumor burden and size could
be measured to determine if dual inhibition has the same effects on tumor proliferation in
vivo.
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